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Es ist hier nicht der Ort, alle die Ursachen zu erörtern, die es zuwege bringen, 
dass das Studium der Malaria, dieser merkwürdigsten unter allen Krankheiten, 
bei uns so sehr [ist] vernachlässigt worden.
Wenigstens sind uns Franzosen und Italiener auf dem Wege der 
Erforschung der Krankheit weit vorangeeilt.
Dmitri LeoniDovitch romanowsky, 
Zur Frage der Parasitologie und Therapie der Malaria. 






Squeezing through the bottlenecks
Lizards may not be the first animals that one associates with malaria. Being a 
poikilothermic animal it is challenging to measure “fever” in this reptile but 
malaria has nonetheless a physiological impact on it, because red blood cells 
are bursting with parasites [1]. Plasmodium parasites are very abundant. Their 
subgenera infect red blood cells in various groups of vertebrates: birds, reptiles, 
and many mammals including rodents and primates. All of the Plasmodium species 
have in common that their life cycle depends on two hosts, alternating between 
vertebrates and blood-feeding insects. Humans are usually infected with one 
of four parasite species, Plasmodium vivax, Plasmodium malariae, Plasmodium 
ovale and Plasmodium falciparum, all transmitted by Anopheles mosquitoes. This 
thesis focuses on P. falciparum, dominant in sub-Saharan Africa, and the most 
malignant of the four, causing an estimated 220 million malaria cases and more 
than 400,000 malaria deaths annually [2]. The following introduction summarizes 
the foundation of my research into aspects of transmission of Falciparum malaria 
– and the efficiency of the parasites in squeezing through important and narrow 
bottlenecks on their way from one host to the other.
Discovery I – The causative agent of “tertian fevers” – Oscillaria malariae
The first documented report on malaria parasites is in fact also the first description 
of gametocytes, the sexual stadium of Plasmodium. 
When the French physician Laveran was examining a blood smear from a seriously 
ill soldier in Algeria in 1880, he spotted something that did not belong there 
[3]. Through his very basic microscope he noticed rare blood cells with pigment 
while other blood cells were being disturbed by moving filaments. Laveran was 
quick to make the connection to the pigmented cells that had been observed in 
the spleens of deceased patients and to define the moving organisms “oscillaria 
malariae” as the cause of the disease. He carefully portrayed all parasitic forms he 
could see (Fig 1). We now know that he saw male gametocytes that showed their 
normal behavior when temperature drops. A similar activation can be observed 
after ingestion by the mosquito during a blood meal. In nature, the entire sexual 
reproduction of malaria parasites happens in the mosquito midgut (Fig 2A). Male 
gametocytes rapidly form up to eight motile microgametes that have flagella 
for movement (a process called exflagellation) and compete to fertilize the 
macrogamete (Fig 2A-1).
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MacCallum added a more detailed description using his studies of gametocytes in 
bird and human malaria in 1897 [4]. He drew the right conclusions in calling what 
he witnessed in a drop of blood “a sexual process”. His observations included an 
“in vitro” fertilization event – he recognized that there are two different types of 
parasites involved – later identified as male and female gametes, or micro- and 
macrogametes, respectively. 
The flagella of male gametes make them motile and enable them to reach the 
female gametes for fertilization. The post-fertilization stages are also motile: zygote 
and eventually the ookinete that crosses the mosquito’s midgut epithelium. It 
establishes an infection by expanding into an oocyst where sporozoites form (Fig 
2A-2). Eventually, sporozoites colonize the insect’s salivary gland and are injected 
with the mosquito saliva during a bloodmeal (Fig 2A-3). After a liver stage (Fig 
2A-4), the parasites start replicating in red blood cells. With regular bursts, they 
multiply and initiate typical fevers (blood stage, Fig 2A-5). A few parasites stop 
replicating, commit to sexual development and keep circulating as female and 
male gametocytes (Fig 2A-6).
Microscopy was undoubtedly the most powerful technique that early malaria 
Figure 1. Alphonse Laveran’s drawing of malaria parasites in 1880 [3]. Fig. 1-2: infected 
and pigmented red blood cells. Fig. 3-5: Mature gametocytes Fig. 6: Female gamete, when a 
female gametocyte is activated, it rounds off and sheds the red blood cell membrane, awaiting 
fertilization. Fig. 7-8: exflagellating male gametocytes, four flagella of potentially eight are visible, 
the male gametocyte undergoes quick DNA replication and cell division to generate a maximum 
of eight microgametes. Fig 9: single microgamete, motile and ready to fertilize a macrogamete 
(today’s interpretations).
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Figure 2. Life cycle of P. falciparum, adapted from Bousema & Drakeley [7]. (A) Life cycle 
in human and mosquito host. 1) Sexual reproduction of P. falciparum upon uptake of gametocytes 
by the Anopheline mosquito. A microgamete fertilizes a macrogamete, and an ookinete is 
formed. 2) The ookinete breaks through the epithelium of the midgut and establishes an oocyst 
where sporozoites develop. A week later, sporozoites migrate to the salivary glands, and the 
now infectious mosquito can deposit sporozoites in the human skin during the next bloodmeal. 
4) Sporozoites seek blood vessels and travel to the liver where they infect hepatocytes. After a 
week, each infected hepatocyte releases thousands of merozoites, and blood stage parasitemia 
begins. 5) Merozoites infect erythrocytes, replicate, and release ~16 new merozoites two days 
later, destroying increasing numbers of red blood cells. 6) Some parasites do not replicate but 
differentiate into either male or female gametocytes. (B) Developmental stages of gametocytes. 
Immature gametocytes (stage I to IV) are developing in the bone marrow. Mature gametocytes 
(stage V) are found in circulation.
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scientists had at hand, soon aided by the newly developed staining technique by 
Romanowsky [5]. This methylene blue/eosin staining is still in use today, mostly 
with the modifications brought forward by Nocht and Giemsa [6]. The parasite’s 
cytoplasm will stain blue and their nuclei and granules red to purple (Fig 2B shows 
developing gametocytes in Giemsa). While the detection of malaria parasites in 
a blood smear can be of great importance to a patient searching relief from 
febrile episodes, it does not suffice to look through a microscope to unravel the 
parasite’s exciting molecular secrets. Instead, malaria researchers – including me 
– greatly benefited from the revolutions in biochemistry and bioinformatics in the 
twentieth century.
Discovery II – Mosquito transmission of malaria
How do people contract malaria? A very ancient idea of disease as a result of 
inhaling bad air forms the base of the miasma theory [8]. In the light of experience 
of increased malaria risk around swamps and Laveran’s discovery of microscopic, 
potentially free-living organisms, disease transmission by water was also a possible 
explanation. Ronald Ross, who worked on human and bird malaria, proofed that 
malaria is not transmitted by either air or water.
Only mosquitoes of the Anopheles genus are able to transmit Plasmodium to 
humans, and in 1897 Ross managed to let some of these grow from collected 
eggs and feed on a febrile patient carrying “crescents” (later termed gametocytes) 
[9]. Ross called them “new, brown” mosquitoes, as he was not familiar with 
the species he found in his working environment in India. Two of the eight 
mosquitoes showed pigmented cysts on the midgut after a few days, which for 
him resembled the features of the malarial haemamoeba and for us the oocyst 
stage. Right after this breakthrough, Ross was transferred to a malaria-free area 
in Rajputana and later Calcutta. To his own great frustration, Ross then continued 
working on bird, not human malaria, and could show the parasite in the salivary 
glands of Culex mosquitoes as well as malaria transmission by mosquito bite from 
an infected bird to healthy sparrows and weaver birds [10].
Around the same time in Italy, researchers including Amico Bignami and 
Giovanni Battista Grassi showed the full life cycle of human malaria parasites [11]. 
They infected single healthy volunteers under controlled conditions to refine their 
suspicions about which mosquitoes transmit the disease [12]. Their argument of 
mosquito transmission was supported by dividing a large group of people (more 
than 200) that went into the marshy malarious areas around Rome – with or 
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without protection from mosquito bites [13]. This is an elegant early combination 
of thorough observations of disease patterns and making predictions for a 
validating experiment to demonstrate causality.
The deliberate infection of healthy individuals with malaria was a logical and 
necessary step that researchers took without (reporting) ethical considerations. 
Of note, many studies today, also at the Radboud University Medical Center, use 
volunteers that are well informed about potential risks and harms and give their 
consent to be infected with malaria for the purpose of research. Nowadays, the 
wellbeing of the studied individuals and their absolute voluntary participation are 
the ethical foundation of these studies, as agreed upon by the World Medical 
Association in 1964 (Declaration of Helsinki, with its latest version from 2013) 
[14].
In the early twentieth century, many physicians tried to cure neurosyphilis with 
the bursts of fever that vivax or falciparum malaria parasites elicit during blood 
stage (Figure 2A-5). Every 48 hours, infected red blood cells rupture to release 
a new wave of parasites, and cause the characteristic (tertian) fever. Exploiting 
malarial fevers to fight the (not even identified) bacteria started with the attempts 
of Wagner-Jauregg in Vienna [15,16]. As there was no other treatment option 
for neurosyphilis, then termed general paresis of the insane, it was considered to 
infect the patient with another fever-provoking disease, first injecting tuberculin 
(bacterial extract) or typhus, and eventually malaria. Wagner-Jauregg injected 
blood from an infected patient subcutaneously at the back of the patient. After 
a number of fever attacks, quinine was used to treat malaria [15]. Later, to avoid 
fatal falciparum infections, the benign vivax malaria was administered almost 
exclusively, and patients with malaria were used to infect batches of mosquitoes. 
At Horton Mental Hospital in Epsom, England, mosquitoes were prepared for 
treatment of neurosyphilis in 69 hospitals instead of blood inoculation [17]. The 
infamous syphilis treatments were used for research into malaria then and also 
post-hoc. The well documented disease progression and other parameters of 
hundreds of patients were reviewed in the decades after the treatments and the 
data are still used today. In 1937, an early report appeared on efforts to quantify 
parasite dynamics and gametocyte mass that is needed to infect mosquitoes [18]. 
The “historical” patient data were included by McKenzie and others to model 
gametocyte production and optimal conditions for transmission [19]. The high 
efficiency of transmission despite the low numbers of parasites involved that he 
observed remains intriguing (Fig 3). It was noticed that gametocytes are detected 
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much later than the first fever in P. falciparum malaria [20]. Falciparum gametocytes 
undergo a sophisticated development: maturation takes seven days, and during 
this time the immature gametocytes (stage I-IV, Fig 2B) sequester in the bone 
marrow and are thus absent from circulation [21]. Fully matured gametocytes are 
re-entering the blood stream for their weeks of circulation silently awaiting the 
final passage into the mosquito.
Advances in P. vivax biology by analyzing the data from the reported malario-
therapy attempts were reviewed by Snounou and Pérignon in 2013 [22]. 
Discovery III – DNA as inherited information and sequencing of nucleic 
acids
Many differences were observed between the different Plasmodium species, P. 
falciparum causing the more severe “malaria tropica” and P. vivax causing a milder 
form of “malaria tertiana”. Researchers were wondering if they could distinguish 
more types or “races” of parasites [reviewed in 19]. Whilst expert microscopy 
allows differentiation of parasite species, a pre-requisite for detailed studies was 
their continuous culture. In vitro culturing enables malaria researchers to elucidate 
differences between parasite strains and study molecular mechanisms without 
the need for human sources. In 1976, Trager and Jensen reported culturing 
success with P. falciparum [24], using RPMI medium with human red blood cells 
and human serum. Many laboratories culture P. falciparum today under almost 
identical conditions, while we still fail to keep P. vivax in culture for longer than 
eight replication cycles [25]. Culturing P. vivax is more challenging due to the 
parasite’s preference for reticulocytes, young red blood cells [26].
With constantly replicating parasites cultured in vitro, there was ample 
material for molecular analyses. Additionally, major advances in biochemistry, the 
knowledge about DNA [27–29] and since 1975 the possibility to sequence [30] 
the “code” that is made of adenine, thymine, cytosine and guanine were a leap 
forward for many fields in biology, including malaria research.
Together, DNA sequencing and routine parasite culture, lead to the current 
annotation of P. falciparum’s genome. In the respective database (PlasmoDB 
version 46), it comprises 5,129-5,683 protein coding genes (depending on the 
strain) on fourteen chromosomes [31]. Progress in sequencing initially was slow: 
Some of the most studied genes that will also be discussed in this thesis, like 
circumsporozoite protein (CSP) and the sexual stage surface protein Pfs25 were 
sequenced individually in the 1980’s [32,33]. An international consortium, the 
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Malaria Genome Sequencing Project, was initiated to facilitate the sequencing and 
annotation of the P. falciparum genome in 1996 [34]. After whole chromosome 
sequences for chromosomes 2 and 3 [35,36], in 2002 the complete genome of P. 
falciparum was published [37], followed by the P. vivax genome in 2008 [38]. In 
the following years, different laboratory strains and field isolates were sequenced 
at increasing rate, and Pf3k, a new international effort was concerted in 2014 
to gain insight into natural variation by sequencing 3,000 P. falciparum isolates 
[https://www.malariagen.net/pf3k].
While the genomic DNA for a given parasite is relatively constant over the 
course of an infection, the gene expression varies considerably among the 
life stages. To capture these differences in mRNA expression, comprehensive 
microarrays were designed, soon after the whole genome of P. falciparum was 
known. With these hybridization assays, gene expression differences between 
blood stage parasites and gametocytes were measured [39]. With synchronized 
cultures, a finer resolution of parasite development was obtained, e.g. sampled 
every hour [40]. The advent of RNA sequencing made microarrays obsolete, and 
it is currently possible to obtain transcriptional profiles from single cells by single 
cell RNA sequencing [41–43]. Single cell RNA sequencing data is generally noisier 
and shallower than data from bulk RNA sequencing, but can reveal biologically 
relevant differences between individual cells. New human immune cell types have 
been identified in what was previously thought to be homogenous populations 
[44] and for P. falciparum, a distinct gene profile for sexually committed parasites 
was discovered by sequencing mRNA of single cells [41]. 
Discovery IV – The proteome: insights into functionality and temporal 
dynamics
Insights into genomic DNA and mRNA expression are important pieces of a cell’s 
puzzle, but significant knowledge gaps remain. The functionality of a cell relies 
on the timed synthesis and degradation of proteins, for which the nucleic acids 
provide templates.
In P. falciparum, extensive regulatory mechanisms have been identified, mainly 
storing mRNA for later translation into proteins upon transition to the next 
life stage. Both sporozoites and gametocytes employ this strategy, using Puf2-
mediated storage of transcripts – among others [45,46]. These two stages are 
particularly interesting as they share some features that set them apart from asexual 
blood stage parasites: i) Endurance: sporozoites and gametocytes can wait for 
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prolonged periods without replication. The sporozoites stand by in the mosquito 
salivary gland and the gametocytes circulating in the blood stream. ii) Reactivity: 
they “wake up” rapidly and trigger cascades of morphological, metabolic and 
behavioral changes as a reaction to the dramatic change in environment upon 
host-switch. iii) Efficiency: very few gametocytes or sporozoites need to ensure 
the infection of the mosquito or human, respectively (Fig 3).
To study the underlying mechanisms, knowledge of protein composition is 
key. The first amino acid (asparagine) was discovered in 1806 [47] and in the 
early 1900s the peptide bonds were proposed independently by two chemists, 
Hofmeister and Fischer [48]. The simple beauty of linear chains of amino acids 
forming complex proteins, enables biochemists to go “backwards” and analyze 
parts of the chains. Degrading large proteins into smaller peptides forms the 
basis of proteome analysis. A uniquely detectable peptide is sufficient evidence 
for the presence of the whole protein that it maps to. Proteomics, the large-
scale analysis of all proteins for certain cells or organisms, often uses mass 
spectrometry, a technique to measure mass-to-charge ratio of ions. It was 
Figure 3. Parasite volume across different life stages and the host switches of P. falciparum.
Illustration of parasite mass in the human and mosquito host. When a malaria infection reaches 
2% parasitemia, a great number of erythrocytes are infected. These red blood cells will eventually 
burst, resulting in fever, anemia and other characteristic symptoms. Gametocytes are formed at 
5-10% of asexual parasitemia. A mosquito blood meal has a volume of 1-5 mL, thus containing 
relatively small numbers of gametocytes. After successful fertilization, few zygotes establish an 
infection in the mosquito. In one oocyst, about 3,000 sporozoites will mature, of which a fraction 
will colonize the salivary glands. The bottlenecks of malaria transmission are the host switches, 
characterized by small numbers of sexual stage parasites in the mosquito, and the low numbers 
of sporozoites injected into a human. During both switches, the environment and tasks for the 
parasite change dramatically (red boxes, tasks in italics).
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adapted to macromolecules like proteins that need extensive preparation before 
the experiment. The resulting spectra rely on computational processing – the 
proteome of a single sample produces 10-20 GB of raw data [49]. To assign 
peptides and proteins to the observed peaks in a mass spectrometer is not trivial 
and subject to algorithm development until today [reviewed in 41].
Discovery V - Bioinformatics in malaria research
Large amounts of sequencing, gene expression and omics data have been acquired 
for P. falciparum and need to be analyzed. Computation itself has become 
indispensable, and not only to the analysis of mass spectrometry data. Initially in 
1970, Paulien Hogeweg and her colleague Ben Hesper wanted to “study informatic 
processes in biotic systems” and coined the term “bioinformatics”. They later 
realized that “bioinformatics” actually evolved to describe a new discipline that 
was data-driven comparative research [51]. The -omics suite of today includes 
genomics, transcriptomics, proteomics, metabolomics, epigenomics, lipidomics 
and glycomics, of which the first three are central to this thesis. The analysis of 
large amounts of data is a challenge which amplifies when multiple studies on the 
same or similar objects are considered to answer new questions. We advocate the 
idea that new experiments are not always required. Instead, we may be able to 
maximize the information obtained by independent studies. With differences in 
focus and methodology of previously published work, this requires a framework 
to integrate the outcomes. One powerful approach is to define assumptions 
based on prior knowledge and benchmark all input studies. This Bayesian data 
integration method has been applied previously to discover genes involved in 
anti-viral defenses [52] or components of the cilium [53], an organelle found 
on many epithelial cells. In this thesis, I hope to deploy a similar approach to 
answer urgent questions related to malaria transmission where a wealth of data 
is already available. This vast amount of transcriptional and protein data may be 
integrated with new experiments to better understand the biology of life stages 
relevant for transmission between human and mosquito hosts. In addition to 
better understanding biological processes, insights may allow the development of 
molecular or serological diagnostics and better design interventions and predict 
possible vulnerabilities of interventions such as genetic variation. 
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Chapter overview
Chapter 2: Predicting the transcripts and proteins specific to the 
gametocyte life stage
The importance of gametocytes for transmission of malaria from humans to 
mosquitoes asks for measures directed against this stage. Unlike blood stage 
parasites, gametocytes do not replicate and circulate in the blood for several 
weeks, even after successful antimalarial treatment. It might seem paradox, as 
gametocytes form a bottleneck for the transmission of malaria from a single 
individual, but generally gametocytes are very abundant, produced during every 
malaria infection, unaffected by standard treatment and often present at sub-
microscopic densities [7]. In order to define potential targets that might help 
detect and clear gametocytes in potential carriers, we integrated multiple data 
sources. Transcriptome data (RNAseq and microarray) and proteome data were 
analyzed separately to define transcripts and proteins that are specific to the 
gametocyte life stage. Published data from 18 studies in P. falciparum, P. berghei 
and P. vivax were integrated using Bayesian statistics and a gold standard of 
known gametocyte genes.
Chapter 3: Detection and quantification of female and male gametocytes 
in blood samples
How can we identify gametocyte carriers? Which gametocyte features can be 
exploited to aid molecular diagnostics? Using one of the predicted gametocyte-
specific transcripts from the work described in Chapter 2, we developed a 
novel multiplex PCR targeting a male- and a female-specific target. The multi-
exon structure of the genes and their high specificity to either sex allowed 
for development of a quick medium-throughput assay that can be applied to 
screening blood or culture samples. The wide range over which quantification is 
possible and high sensitivity facilitate monitoring of interventions.
Chapter 4: Examining the importance of gametocyte sex ratio for 
malaria transmission
The transition from humans to mosquitoes poses a bottleneck for the parasite 
that is not only defined by the density but also the sex ratio among gametocytes. 
A permissive number of both sexes needs to be present in a blood meal to allow 
transmission to occur. A medium-throughput assay to measure the gametocyte 
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sex ratio in a blood or culture sample is described in Chapter 3. However, little 
is known about “the decision” process and the triggers to make a gametocyte 
of either sex. We reviewed what has been described about development and 
longevity of gametocytes. Further, we dissected a number of factors known to 
influence sex ratio and ultimately transmission success.
Chapter 5: Monoclonal antibodies can block transmission of cultured and 
field-isolated gametocytes to mosquitos
Malaria interventions that aim to induce or passively transfer immunity may 
encounter antigenic diversity among parasites. We tested the potential of three 
monoclonal antibodies (mAbs) that aim to take advantage of the transmission 
bottleneck in mosquitoes and target pre- or post-fertilization antigens of 
Plasmodium to prevent infection of the mosquito. For three candidates (Pfs25, 
Pfs48/45 and Pfs230) we compared the reduction of infected mosquitoes using 
cultured gametocytes and naturally acquired gametocytes in natural donors. The 
study aim was to assess whether, compared to cultured gametocytes, naturally 
occurring parasites in Burkina Faso and Cameroon can be equally well blocked 
when mAbs are added to the mosquito’s blood meal. If differences are observed, 
we aim to unravel possible reasons.
Chapter 6: Sporozoite-specificity scoring reveals high variability in 
sporozoite genes and offers insights into sporozoite biology
The last two chapters look at the mosquito-to-human transmission of malaria. 
Sporozoites are injected into the skin with mosquito saliva. This second bottleneck 
of transmission provides an attractive target for protective interventions as 
sporozoites are small in number and very exposed, even if for a short period 
before they infect a hepatocyte. 
A better understanding the biology of the life stages relevant to transmission 
can arise from thorough analysis of transcripts and proteins present specifically 
at these time points. With the same approach described in Chapter 2, we set 
out to define genes that are specific to another life stage of Plasmodium, the 
sporozoite. Again, using published data and a “gold standard” of sporozoite 
genes to weight the input of each of 26 studies, we provided a new resource 
for sporozoite research. Homology-based annotation of formerly unknown genes 
might give cues to the “dormancy” the sporozoites are in while waiting in the 
salivary gland of the mosquito.
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Chapter 7: Modest heterologous protection after malaria immunization 
under chloroquine prophylaxis
Similar to Chapter 5, active immunization strategies have to counteract parasite 
evasions strategies. The only licensed malaria vaccine to date targets a sporozoite 
protein, but has limited efficacy [55]. The lack of efficacy may partially be attributed 
to variations of the target protein CSP. In this chapter, we aimed to assess whether 
an immunization strategy with whole parasites instead of a single protein target 
is equally vulnerable to differences among parasite strains.
This clinical study tested the immunity of healthy volunteers after an 
immunization scheme with one frequently used P. falciparum strain, NF54. When 
challenged with the same strain, participants are usually protected from malaria, 
but when we challenged them with different strains, NF135 and NF166, very 
few participants were protected. In this chapter, I examined variability of these 
strains on the basis of whole-genome sequencing data. Most of the antigens that 
are implied in humoral immune responses are variable among the three parasite 
strains, which can contribute to the limited heterologous protection.
Lastly, in Chapter 8, I provide a comprehensive discussion of our findings. We 
defined some of the intriguing features of the parasite stages that squeeze through 
(quantitative) bottlenecks. Their relevance and future implications are discussed 
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Abstract
Plasmodium gametocytes are the sexual forms of the malaria parasite essential for 
transmission to mosquitoes. To better understand how gametocytes differ from 
asexual blood-stage parasites, we performed a systematic analysis of available 
‘omics data for P. falciparum and other Plasmodium species. 18 transcriptomic 
and proteomic data sets were evaluated for the presence of curated “gold 
standards” of 41 gametocyte-specific versus 46 non-gametocyte genes and 
integrated using Bayesian probabilities, resulting in gametocyte-specificity scores 
for all P. falciparum genes.
To illustrate the utility of the gametocyte score, we explored newly predicted 
gametocyte-specific genes as potential biomarkers of gametocyte carriage and 
exposure. We analyzed the humoral immune response in field samples against 
30 novel gametocyte-specific antigens and found five antigens to be differentially 
recognized by gametocyte carriers as compared to malaria-infected individuals 
without detectable gametocytes. We also validated the gametocyte-specificity of 
15 identified gametocyte transcripts on culture material and samples from naturally 
infected individuals, resulting in eight transcripts that were >1000-fold higher 
expressed in gametocytes compared to asexual parasites and whose transcript 
abundance allowed gametocyte detection in naturally infected individuals.
Our integrated genome-wide gametocyte-specificity scores provide a compre-
hensive resource to identify targets and monitor P. falciparum gametocytemia.
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Introduction
Despite a decrease in malaria incidence and mortality over the past two decades, 
malaria remains a major global health challenge [1,2]. Furthermore, the emergence 
and spread of insecticide resistance in mosquitoes [3] and artemisinin resistance 
in Plasmodium falciparum (Pf) [4–6] threaten recent gains in malaria control. The 
decline in malaria burden and the necessity to contain artemisinin-resistance 
have increased interest in malaria elimination that may require interventions that 
specifically aim to prevent malaria transmission. Malaria transmission depends on 
male and female gametocytes, the sexually reproducing forms of the Plasmodium 
parasite that are ingested by blood-feeding Anopheles mosquitoes. In the mosquito 
gut, gametocytes may complete the parasite’s reproductive cycle and, following 
sporogonic development, render the mosquito infectious. Factors that govern 
gametocyte production and infectivity remain poorly understood. Whilst recent 
studies have shed light on the processes controlling gametocyte commitment [7,8], 
commitment and maturation of gametocytes may differ between infections and 
over the course of infections, under influence of environmental and host factors 
[9,10]. A better understanding of gametocyte dynamics during infections, as well 
as the development of tools to monitor or target gametocytes, may be informed 
by high-throughput protein and transcriptome studies [11,12]. In the past 15 
years, a number of large-scale studies on Plasmodium gametocytes have been 
reported: the proteome of Pf and the rodent malaria parasite Plasmodium berghei 
(Pb) have been examined by mass spectrometry [13–21], and the transcriptome 
of both species by microarray and RNA sequencing [15,20,22–28]. These studies 
differed in their focus and resolution in examining (sexual) developmental stages 
and each faced challenges in detecting low abundance proteins [29] and by 
the purity of parasite populations [13,14]. The use of fluorescent parasites and 
fluorescence-assisted sorting of staged parasites have recently permitted a better 
discrimination of proteins in either male or female gametocytes [16,17,20] and 
have allowed more detailed comparisons of Plasmodium life-stages. However, 
individual studies are still vulnerable to imperfect sample purity, and other sources 
of uncertainty such as correct gene identification for accurate peptide assignment. 
These technical and methodological challenges lead to discrepancies between 
individual studies and hamper firm conclusions about gametocyte-specificity of 
proteins and transcripts. 
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We utilized the numerous published proteomics and transcriptomics Plasmodium 
data sets in a comprehensive data integration framework to obtain a consensus 
of gametocyte-specific transcripts and proteins. Our data integration approach is 
an adaptation of the naïve Bayesian classifiers that have previously been applied 
in the prediction of protein interactions and components of cellular systems 
[30,31]. The framework calculates probabilities that any given transcript or 
protein is gametocyte-specific given the evidence presented across the total of 
transcriptomics and proteomics data. A key aspect of the methodology is that it 
takes into account the predictive power of each contributing data set: it assigns 
weights to data sets based on their ability to distinguish gold standard lists of 
gametocyte and asexual proteins. These we have constructed using existing 
literature where life-stage specificity was confirmed using classical “non-omics” 
approaches (e.g. protein detection in immunofluorescence-assays, functional/
genetic studies), followed by expert curation. The most informative data (from 
datasets with the highest discriminative power against the gold-standard lists) 
will thus contribute most to the predictions, while less informative data are 
down-weighted. This allows for (i) the resolution of conflicting evidence without 
disregarding data, and (ii) the construction of a transparent scoring system in 
which the relative contribution of each data set is directly visible.
Using this approach, we propose a robust gametocyte-specificity score for all 
Pf genes that allows a consensus list of gametocyte-specific genes at protein 
and transcript level. We illustrate the utility of our findings by examining 
naturally acquired responses to newly identified gametocyte-specific proteins 
in gametocyte-carriers and non-carriers by protein microarray. In addition, we 
confirmed gametocyte-specificity for a selection of gametocyte-specific transcripts 
using culture material from geographically distinct Pf strains and samples from 
naturally infected malaria patients.
Results
Weighted integration of proteomics and gene expression data
Using Bayesian statistics, we integrated Plasmodium mass spectrometry and 
transcript datasets from 18 different studies (Table 1) on P. falciparum (Pf; 
n=14), P. berghei (Pb; n=3) and P. vivax (Pv; n=1). Since gametocyte biology 
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Figure 1. Clustered data sets used in this study with genes ranked according to their 
protein or transcript expression. Level of expression as detected in the respective samples with 
unique peptide counts for MS data and percentiles for transcriptomics. The studies are clustered 
using complete linkage according to their overall gene expression similarities (Euclidean distance). 
See Table 1 for study keys. Distribution of asexual(a)/gametocyte(g) samples (red/blue) is shown in 
top bar, proteomics (P) and transcriptomics (T) (dark/light grey) in lower bar.
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differs between Plasmodium species, scores were calculated for the total set 
of Plasmodium studies and for Pf only. Unsupervised clustering of genes based 
on peptide counts or mRNA expression resulted in grouping according to data 
acquisition method rather than parasite stage (Fig 1), illustrating the necessity 
of a supervised approach to discriminate between gametocyte-specific and 
non-gametocyte genes. To objectively assess the value of individual data sets 
and allow their assembly into a gametocyte-specificity score, we created a 
gold standard that served as a benchmark for every sample. This gold standard 
was collected from literature review and comprises two lists; one of asexually 
expressed proteins, mainly blood stage but also sporozoite and liver stage, and 
one of known gametocyte proteins (Supplementary Table S1). A gametocyte-
specificity score was then derived for each gene by comparing its expression in all 
studies to the relative expression of the gametocyte and asexual gold standards 
in those samples (Supplementary Fig S1-2). Proteins or RNAs detected in a study 
with high discriminative power for gametocyte and asexual gold standard genes 
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(ratio of gametocyte to asexual gold standard genes) received higher gametocyte-
specificity scores than those detected in a study with lower discriminative power. 
The individual log-transformed scores per gene were combined for proteomics 
and transcriptomics data separately. Scores for Pf -only studies (Supplementary 
Table S2) and all combined data sets were highly correlated (Fig 2D; Pearson’s 
r=0.9867 and r=0.9514 for proteomics and transcriptomics, respectively) and the 
latter were used in the remainder of the manuscript.
The distribution of scores for proteins and transcripts are presented for the 
Figure 2. Gametocyte-specificity scores for P. falciparum genes derived from proteomics 
(P) and transcriptomics (T) data sets. (A) Boxplot for integrated scores for the two gold standard 
sets and all other Pf genes, derived from proteomics, transcriptomics or all data sets (combined). 
(B) Density of P and T gametocyte scores, individual gold standard genes and their scores are 
indicated at the bottom (red, asexual, blue gametocyte). (C) 100 highest ranking proteins and 
transcripts, gametocyte gold standard in blue. (D) Correlation of the gametocyte-specificity scores 
derived from all integrated MS studies and Pf MS studies only.
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two sets of genes of the gold standard as well as for all other genes (Fig 2A). As 
expected, the gametocyte and asexual gold standard set of genes are perfectly 
separated by their respective proteomics-derived scores and show only little 
overlap in their transcriptomics-derived scores (Fig 2B). The shift in the density 
peak of the proteomics compared to transcriptomics is due to an inherent 
property of the method that gives a negative score for gametocyte-specificity 
to all proteins that were not detected in the proteomics studies (n=1583). The 
highest scoring 100 genes for proteomics and transcriptomics contained 26 
(63.4 %) and 15 (36.6 %) of the 41 gold standard gametocyte genes, respectively 
(Fig 2C), indicating both the respective discriminating power of the gold standard 
and that many other genes are as specific for gametocytes as the highest gold 
standard representatives. Translationally repressed genes are common in late 
stage female gametocytes [32,33] and are detectable by high transcriptomics and 
low proteomics score. In our analysis 461 genes have this profile (Supplementary 
Table S3), including genes that are known to be translationally repressed like 
Pfs28 [32,34] and 186 genes with a previously reported bias towards expression 
in female gametocytes [20].
Cross-validation illustrates the improved predictive power of the 
integrated data
Ten-fold cross-validation was performed using random subsamples of the gold 
standard lists to predict the ranks of left-out genes. The resulting proteomics 
ranking shows near perfect sensitivity, with all but two gold standard gametocyte 
genes ranking higher than the gold standard asexual genes (Fig 3). The added value 
of our integrated approach is illustrated by the receiver operating characteristic 
curve where the integration of data sets gave higher sensitivity and areas under 
the curve for both proteomics and transcriptomics than any individual study (Fig 3). 
Using the Bayesian integration based on the complete gold standards, we ranked 
all Pf proteins by giving them a gametocyte-specificity score (Supplementary Table 
S2). All proteins with a score >5 (n=602) were considered gametocyte-specific. 
Most of these have not consistently been described as “specific” or “enriched” 
in gametocytes in the original data sets (Fig 4A and Supplementary Table S4). 
Previous studies defined 315 [13] to 1725 [20] proteins as gametocyte-specific for 
Pf. Not only did our integrated approach lead to a better recovery of gold standard 
listed known gametocyte proteins, we also identified 178 genes with undescribed 
function as gametocyte-specific (Supplementary Table S2). We further identify a 
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number of proteins as gametocyte-specific even though they had been reported 
as asexual by previous studies (Fig 4B).
A recent proteomics study of male and female Pf gametocytes [35], not 
included in our original analysis, was used to test the robustness of our scores. 
When we included this data set in our final Bayesian proteomics scores, both 
gametocyte scores and gene ranks before and after addition of this data set were 
highly correlated (Pearson’s r=0.997 and Spearman’s rho=0.995, respectively). 
Furthermore, the top 100 gametocyte proteins did not change and the top 602 
proteins were 96% identical (578 of 602). Taken together, cross-validation and 
independent data suggest that the integrated gametocyte-specificity score is 
robust and contains potential novel gametocyte markers.
Figure 3. Validation of Bayesian gametocyte scoring with area under the curve (AUC) 
values. Integrated data and individual data sets are compared by 10-fold cross-validation 
(subsampling of gametocyte and asexual gold standard sets). Integrated proteomics (P) and 
transcriptomics (T) scores in bold lines. P. berghei data sets in shades of red, individual proteomics 
and transcriptomics studies with short and long dashes, respectively. See Table 1 for study keys.
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Predicted gametocyte-specific proteins are recognized by gametocyte-
carriers
As an illustration of the utility of gametocyte-specific proteins as markers of 
gametocyte exposure, we utilized protein microarray data from a study that 
aimed to characterize the immune profile associated with transmission-reducing 
immunity in naturally infected gametocyte carriers [36]. For the current study, 
we compared responses to our gold standard gametocyte genes (n=40) and 
novel gametocyte genes from our 100 highest scoring proteins that were on 
the array (n=30). Antibody prevalence for these genes was compared between 
Figure 4. Comparison of reported gametocyte-specific proteins in mass spectrometry 
studies. (A) Proteins reported as gametocyte-specific by six individual studies, agreements on 
gametocyte-specificity are summarized in the table. Bayesian: gametocyte-specific proteins 
(n=602) that have a score > 5 after data integration. The overlap with previously published data 
sets is shown, but not to scale. Overlap between the individual studies is not shown for better 
visibility. Note that the Lasonder 2002 study includes proteins that were found in gametocytes or 
gametocytes and gametes. (B) Proteins that were reported as non-gametocytic and are (partially) 
included after data integration
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Gambian gametocyte carriers and Gambians who carried asexual parasites 
but not gametocytes as determined by microscopy. Antibody responses to the 
predicted gametocyte-specific proteins were significantly higher in gametocyte 
carriers (p=0.005), while for the gold standard antigens this difference was 
less significant (p=0.058) (Fig 5A, Mann-Whitney U test). When antigens were 
analysed individually, a significantly higher antibody prevalence in gametocyte 
carriers was detected for five novel gametocyte antigens (Fig 5B, p<0.05 in 
Fisher’s exact, corrected for multiple testing, Supplementary Table S5, Supple-
mentary Fig S3). Only two of these five have an assigned function – a DNA 
ligase, and Gamete egress and sporozoite-traversal protein (GEST). For two of 
the three remaining Plasmodium proteins, we were able to predict a function 
based on homology, using the sensitive homology detection tool HHpred [37]. 
PF3D7_1251000 is homologous to the co-chaperone HSP20 heat shock protein 
and PF3D7_1439600 is homologous to the MLRQ subunit of complex IV of the 
oxidative phosphorylation, underlining the enrichment in mitochondrial proteins 
Figure 5. Seroprevalence in two cohorts of parasite carriers in The Gambia. (A+B) Antibodies 
against the highest scoring gametocyte-specific proteins were measured on protein microarrays. 
Comparison of positivity (mixture-model cutoff) in gametocyte carriers (n=164) and non-carriers 
(n=63). Gametocyte presence determined by microscopy. All individuals were positive for asexual 
parasites.  (A) Prevalence of antigens from the gold standard (n=40) and predicted gametocyte-
specific proteins (n=30), Mann-Whitney U test (B) Antigens of five predicted gametocyte-specific 
proteins are preferentially recognized by gametocyte carriers. Error bars indicate the upper limit 
of the 95% confidence interval around the proportion.  p<0.05 Fisher’s exact test, corrected for 
multiple testing of a total of 70 antigens (Benjamini-Hochberg)
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as discussed below (Supplementary Table S6 includes homology predictions for all 
conserved, highly gametocyte-specific Plasmodium proteins). 
Gametocyte-specific RNA transcripts detect (submicroscopic) gametocyte 
carriage 
Of the 100 highest-scoring transcripts, 15 non-gold standard candidates were 
selected for qRT-PCR validation based on their gametocyte scores in a prelimi-
nary analysis (Table 2). Mature gametocytes of four Pf strains from different geo-
graphical origins were compared to asexual blood stage parasites. The minimum 




) ranged from 4.76 to 14.95 
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Figure 6. Validation of gametocyte-specific targets in qRT-PCR. Targets are sorted for 
decreasing gametocyte-specificity in all panels, see Table 2. (A) Minimum transcript abundance 
in blood stage versus gametocytes in different Pf strains. 1000-fold enrichment of transcript in 
gametocytes over asexuals was assumed when delta-Ct was 10 or higher (dashed line), considering 
the lowest Ct value detected in any asexual concentration-matched sample. This threshold was 
not met by the transcripts with gene IDs in grey. (B) Detection limit of eight validated targets 
alongside Pfs25 in serial dilutions of Pf NF54 asexual stage parasites (ring stage parasites 10-20 
hours post invasion). (C) Detection limit of the most sensitive targets in serial dilutions of stage 
V gametocytes. (A-C) For Pf NF54, all n=3, other strains n=2 biological replicates (error bars: 
standard error of the mean), all measurements in triplicates. (D) Sensitivity of eight validated 
targets in Kenyan blood samples of varying gametocyte densities. 
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(Fig 6A and Supplementary Table S7 qPCR & primers), reflecting 27.1 to 31,500-
fold higher transcript numbers in gametocytes compared to asexual parasites and 
confirming pronounced upregulation of all selected targets in gametocytes. With 
a very conservative threshold of 1,000-fold enrichment in three of the four strains 
tested (Fig 6A), eight of the 15 tested transcripts were highly specific to game-
tocytes. Transcript abundance in ring-stage parasites was assessed and compared 
to Pfs25 mRNA, an established and highly abundant yet intron-less female game-
tocyte specific transcript [11,38]. Five out of eight gametocyte specific transcripts 
were undetectable in asexual ring stages at ≤105 parasites/mL, similar in specificity 
to Pfs25 (Fig 6B); the five most sensitive gametocyte markers detected game-
tocytes across the range of 102 – 106 gametocytes/mL (Fig 6C). In RNA samples 
from a previously reported clinical trial conducted in Kenya [39], all eight game-
tocyte markers detected gametocytes at densities below 103/mL (Fig 6D). 
Gametocyte-specific proteins are enriched for cytoskeletal movement 
and metabolism functions
To uncover novel characteristics underlying gametocyte function, we analyzed 
over-represented gene ontology (GO) terms in our integrated consensus game-
tocyte proteins. The 100 highest ranked proteins were examined for enrichment 
of GO terms that reflect specific biological functions. Microtubule based 
movement, metabolism of carboxylic acids and metabolism of nucleic acids were 
highly enriched among gametocyte proteins (Supplementary Fig S4). Four out 
of the six putative Pf dynein heavy chain proteins are found back among the 
100 most gametocyte-specific proteins, alongside a tubulin gamma chain and a 
tubulin chaperone. The importance of DNA elongation and ligation processes is 
reflected in GO term associations as well as in antibody response to a DNA ligase 
(Fig 5B). The “classic” GO term enrichment calculation was complemented by a 
rank-based gene set enrichment analysis (GSEA). GSEA uses all Pf genes and their 
respective (proteomics derived) gametocyte-specificity score and thus does not 
include an arbitrary cutoff of the proteins that are or are not gametocyte-specific. 
It confirmed the above-mentioned results, and in addition to those the terms 
“mitochondrial protein complex“ (GO:0098798) and “TCA” (GO:0006099) were 
enriched, stressing both mitochondrial location and processes.
Although male gametocytes carry pre-synthesized proteins to rapidly form eight 
motile gametes upon activation in the mosquito midgut, we did not observe 
flagellum associated terms in the GSEA. The reason for this is that current GO 
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term annotation for Pf has only one gene with the “cilium” GO term for cellular 
component (GO:0005929; PF3D7_1025500), one for “axoneme” (GO:0005930; 
PF3D7_0828700) and none with the biological-process terms “cilium or flagellum-
dependent cell motility” (GO:0001539) or “axoneme assembly” (GO:0035082). 
We supplemented the GO annotation with a list of 28 Pf cilium genes (Methods). 
The newly assembled “cilium” GO term now acquired the highest enrichment 
score in the GSEA (Supplementary Fig S5). This may reflect the formation of the 
flagella of the microgamete but may also (partially) reflect intracellular trafficking 
and or be associated with genome replication as the term has overlap with the 
genes annotated for microtubule processes (Supplementary Table S5 GO terms).
Discussion
Combining proteomic and transcriptomic data from 18 sources, we present an 
integrated consensus score for gametocyte-specific proteins and transcripts. We 
predict 602 gametocyte-enriched proteins of which 186 are currently without 
ascribed function. We illustrate the potential utility of our gametocyte score by 
providing evidence for differential recognition of gametocyte proteins by naturally 
infected gametocyte carriers and the sensitive detection of mRNA of novel 
gametocyte transcripts in field samples.
The gametocyte proteome of P. falciparum (Pf) has been assessed repeatedly. 
Individual lists of gametocyte-specific proteins [13,14,16,17,19,20] have 
unavoidable limitations related to comparator (asexual) parasite stages, sample 
purity, assay sensitivity and arbitrary cut-offs used to define gametocyte-specificity 
and show only partial agreement. To acquire a more robust gametocyte-specificity 
score, we integrated data from these individual studies, along with studies of 
purified asexual parasites and related Plasmodium species. Inclusion of gene 
expression data from multiple species generally increases the likelihood that the 
combined gene expression data reflect underlying biology, as observed in the 
Apicomplexa [40,41]. We applied a Bayesian classifier first applied to ‘omics data by 
Jansen and colleagues [30] and adapted by Van der Lee and colleagues to identify 
genes involved in anti-viral immune responses [31]. This probabilistic approach 
combines the evidence from all studies in an unbiased way, without giving a priori 
preference of one study over another. Instead, the measurements of all studies 
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were weighted inherently during the scoring process by assessing the retrieval of 
a gold standard set of genes. As these gametocyte and asexual gold standard sets 
are of central importance to the study, they have undergone expert curation (see 
Methods and Acknowledgments). The power of this integrative approach lies not 
only in weighting data sets by the retrieval of gold standard genes but also in the 
opportunity to exclude proteins from the gametocyte-specific list by appreciating 
their presence in (other) asexual samples. A further strength of the approach is 
that it allows the ranking of gametocyte proteins that have only been reported in 
a subset of studies. Our integration of data sets reveals that 602 proteins are likely 
to be specific to gametocytes although very few gametocyte-specific proteins 
were detected in every underlying dataset and seven proteins had never before 
been reported as gametocyte-specific. 
A general limitation of all mass spectrometry (MS) studies is their bias toward 
highly abundant proteins. Proteins with low-level expression may be missed in 
a bulk proteome analysis. After integration of the MS studies listed in Table 
1, 1583 Pf proteins were never detected, representing approximately 28% of 
all proteins encoded by Pf. Some of these might be of too low abundance or 
expressed during sporozoite or gamete, ookinete and liver stage, which are 
underrepresented or not included in our data, respectively. New advances in 
MS that include the sensitive detection of peptides from currently understudied 
Plasmodium life stages may shed light on these currently uncharacterized genes. 
In addition, approaches that focus specifically on post translational modifications 
like phosphorylation of proteins as has been done for asexual parasites [42–
45] may add new lines of evidence towards gametocyte-specific functions of 
proteins. Our approach suggests that the currently available MS data is sufficiently 
comprehensive to identify stage-specific proteins when analysed in an integrative 
approach. We examined this directly by incorporating a new Pf gametocyte MS 
study [35] in our scoring. The authors reported 44 new gametocyte-specific 
proteins that were not reported by earlier studies. We compared this data set 
to our integrated data set and found 24 of the 44 had been detected in one or 
more erythrocytic stages or sporozoites [14,18,42,46,47] while 11 others had 
been identified in a (single) gametocyte sample before (Supplementary Fig S6). 
Importantly, the scores and top 100 gametocyte genes remained unaltered by 
integrating this new dataset.
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The ranking of gametocyte-specificity that we provide here can i) aid in 
understanding the biology of this life stage and ii) improve diagnostics related 
to gametocyte exposure and carriage. Regarding gametocyte biology, our high-
ranking gametocyte-specific genes are enriched for mitochondrial, metabolism 
and microtubule processes and DNA replication, supporting the quality of the 
data integration. The enrichment of mitochondrial localization and process 
is consistent with what we know about the enlarged mitochondrion of 
gametocyte stages [48] and increased activity of the citric acid cycle [49]. DNA 
replication terms are highly enriched which is consistent with what happens 
in the subsequent life stage in which the (micro)gamete rapidly duplicates its 
genomic DNA three times. Regarding the use of the gametocyte score to inform 
gametocyte diagnostics, diagnostics can directly detect nucleic acids specific to 
gametocytes [11] or detect antibody responses reflecting past/recent exposure 
as is increasingly used for asexual P. falciparum and P. vivax parasites [50,51]. We 
use our integrated gametocyte list to explore its utility for both approaches. We 
validated 15 transcript targets in four different Pf strains, comparing transcript 
abundance in gametocytes and asexual parasites. All tested targets were enriched 
in gametocytes. Five targets were tested for their sensitivity and can recognize 
100 gametocytes/mL, while the signal is undetectable when fewer than 105-106 
ring-stage parasites/mL are present. In practical terms, these markers may be used 
to reliably detect gametocytes at densities well below the microscopic threshold 
of detection in samples without high-densities of asexual parasites, similar to the 
gametocyte marker that is currently most widely used, the female gametocyte-
specific Pfs25 [38]. 
As an alternative approach to the detection of gametocyte carriage in populations, 
we utilized a gametocyte-enriched protein microarray [36] to determine antibody 
responses to genes that we here describe as highly gametocyte-specific. The 
bacterial expression system used for the array has known limitations with the 
expression of conformational proteins [52] and should thus be considered a ‘rule 
in’ rather than ‘rule out’ approach to immune recognition. Moreover, the array 
was constructed with the aim of detecting surface proteins or exported proteins 
whilst our list does not require these characteristics. Only 30 of our top 100 novel 
gametocyte antigens were thus printed on this array. Antibody responses to five 
gametocyte proteins were significantly more prevalent in gametocyte carriers than 
in carriers of the asexual blood stage only. This is the first evidence that antibody 
responses may be indicative of current gametocyte carriage. Importantly, the 
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dichotomization of gametocyte-exposed and non-exposed individuals was based 
on a single time-point screening for gametocytes by microscopy. Microscopy has a 
low sensitivity for detecting gametocytes that commonly circulate at low densities 
[53] and several of the asexual parasite carriers are likely to have had preceding or 
concurrent low densities of circulating gametocytes. Antibody prevalence in the 
group classified as gametocyte-negative by microscopy may thus be associated 
with concurrent low-density gametoctytemia and/or long-lived antibody responses 
acquired following previous gametocyte exposure. The presently analysed samples 
thus do not allow any conclusions on a possible role of submicroscopic gametocyte 
densities in boosting or maintaining antibody responses to gametocyte antigens. 
Refined studies with longitudinal sampling and gametocyte detection by sensitive 
qRT-PCR methodologies are needed to formally assess antibody kinetics in relation 
to gametocyte exposure and determine whether recent markers of exposure to 
blood stage antigens [50] can be complemented by a set of markers for recent or 
long-term gametocyte exposure. 
We described the assembly of a curated gold standard set of gametocyte and 
asexual proteins and used this new resource to rank the likelihood of all Pf 
proteins and transcripts being specific to the gametocyte stage. Data from 18 
publicly available studies were integrated to resolve partially conflicting evidence. 
The resulting consensus lists can be used for guidance of future investigations as 
we have shown the value of our predictions by in vitro validation.
Materials and Methods
Assembly of a gold standard for gametocyte and asexual proteins to 
weigh whole proteome/transcriptome data sets
To build a gold standard against which the performance of individual data sets 
could be assessed, we identified proteins that are known to be expressed in either 
asexual parasites (mostly blood stage, also including sporozoites and liver stage) 
or gametocytes. This list was initially informed by literature review (Supplementary 
table S1) for expression in the respective stages as detected by immunofluorescence 
assays and/or western blot, supplemented with P. falciparum blood stage or 
transmission blocking vaccine candidates. This initial list was then communicated 
with experts (including the authors DAB, PA, FS, CJJ, SMK, TWAK, MM, CD, RS 
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and TB) and edited. If additional proteins were suggested for inclusion in the list, 
published evidence was requested and examined prior to inclusion of the protein. 
The final asexual gold standard list contains 46 proteins; the final gametocyte list 
contains 41 proteins. These gold standard lists (Supplementary Table 1) represent 
the balance between very strict inclusion criteria and sufficient set size to evaluate 
the quality of all data sets integrated. We tested for the detection of these proteins 
or transcripts in the respective samples, using a Bayesian statistics approach that 
we have successfully applied previously for genes involved in anti-viral immune 
defense [31].
Data selection and integration
Data sets that measured protein and transcript abundance in Pf gametocytes 
were balanced with data from other life stages and supplemented with studies 
of the rodent malaria parasite P. berghei. One MS study on P. vivax was included 
as it is based on of ex vivo blood material as opposed to all other studies that 
used in vitro cultivated parasites. Unique peptide counts were retrieved from 
plasmoDB (version 28) in which sequenced peptides from the published studies 
are always mapped to the most recent genome annotation, or supplementary 
material of the respective studies. Many aspects determine how well a protein 
is represented in proteomics data that are obtained via MS, like its length or 
posttranslational modifications. Remapping original MS data to newly annotated 
genomes improves the quality of the predicted proteins [19]. We were however 
not able to retrieve those data from the studies [13,14,16] and therefore decided 
to take those proteins at face value. Notice that also these early studies contribute 
significantly to our integrated lists.
Expression percentiles were retrieved from plasmoDB (version 28) or calculated 
from raw data in the respective supplementary material. Gametocyte samples 
were summarized if applicable (using the maximum peptide count/expression 
percentile of different stages or male and female gametocytes) as were asexual 
samples, only considering the highest expression in any sample or time point.
For MS and transcriptomics data sets, separate scores for gametocyte-specificity 
of any Pf gene have been calculated. In brief, protein or transcript expression has 
been categorized from absent to high expression levels as given by number of 
unique peptides or expression percentiles, respectively. For each of the respective 
bins, a score was calculated depending on the relative retrieval of gametocyte 
and asexual gold standard genes. The log ratio of these retrieved genes defined 
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the score for all other genes within the same bin. The final gametocyte score 
calculates as the prior probability of a gene being gametocyte-specific that is 
updated using the contributions of the data sets:
where gametocyteGS and asexualGS are the fractions of retrieved gametocyte 
and asexual gold standard genes in sample i, respectively. We used a pseudocount 
of 1 if necessary to prevent division by zero if none of the gold standard genes 
was retrieved in this specific sample and bin. It was assumed that the likelihood of 
a gene to be either gametocyte or asexual specific is equally high, thus the (log-
transformed) prior equals 0 and the final score depends solely on the integrated 
data. In the selection of a set of proteins that we assigned to be gametocyte-
specific we chose a cutoff score of 5.0 (proteomics-derived). The cutoff score 
of 5.0 can be interpreted as: a gene has to be 25 = 32 times more likely to be 
gametocyte-specific than asexual specific. The score of 5.0 was based on the 
behavior of the gold standard genes. Out of the 41 gametocyte gold standard 
genes, 37 have a score higher than 5.0, while none of the asexual gold standard 
genes do.
When applicable, genes from Pb and Pv were treated as their respective Pf 
orthologs as retrieved from plasmoDB [54], to be able to integrate all data sets. 
When no ortholog is known, the respective non-Pf data sets did not contribute 
to the score of this particular gene. Scores using Pf data exclusively were also 
calculated (Supplementary Table S2 includes all scores and rankings with 
expression information from all integrated studies).
Cross-validation of the scoring method
We performed a ten-fold cross-validation to assess the predictive performance of 
the integrated gametocyte-specificity score (i.e. its ability to discriminate known 
gametocyte vs. asexual genes). For that, we subsampled both gold standard gene 
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Cross-validation of the scoring method 
We perf rmed a ten-fold cross-validation to assess the predictive performance of the 
integrated gametocyte-specificity score (i.e. its ability to discriminate known gametocyte vs. 
asexual genes). For that, we subsampled both gold standard gene sets ten times (folds), 
without replacement (i.e. each gene is selected exactly once). Then for each fold we re-
weighed and integrated the data sets based on nine-tenth of gold standard genes, and 
collected the ranks of the one-tenth of genes that were left out in that particular fold. A ROC 
curve was constructed based on those ranks. Using the same strategy, ROC curves for 
individual data sets that comprised both gametocyte and asexual samples were constructed 
for comparison. 
 
Protein microarray to measure humoral immune responses 
A protein microarray that was enriched for gametocyte proteins was produced and probed 
as described earlier for a study aiming to unravel the immune signature of naturally acquired 
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once). Then for each fold we re-weighed and integrated the data sets based on 
nine-tenth of gold standard genes, and collected the ranks of the one-tenth of 
genes that were left out in that particular fold. A ROC curve was constructed 
based on those ranks. Using the same strategy, ROC curves for individual data 
sets that comprised both gametocyte and asexual samples were constructed for 
comparison.
Protein microarray to measure humoral immune responses
A protein microarray that was enriched for gametocyte proteins was produced 
and probed as described earlier for a study aiming to unravel the immune 
signature of naturally acquired transmission-reducing immune responses in 
gametocyte carriers [36]. As a control group, Gambian asexual parasite carriers 
without gametocytes detectable by microscopy were included in the probing. 
For the current study array data from this control group (n=63) and Gambian 
gametocyte carriers were used (n=164) [55–60]. All of these 227 individuals 
were sampled during a period of intense malaria transmission intensity in The 
Gambia and likely had (multiple) previous malaria infections [55,61]. For these 
populations, responses to 30 newly defined highly gametocyte-specific antigens 
(from 24 genes) were compared between gametocyte carriers and non-carriers 
(Mann-Whitney U test). Seropositivity for each of the antigens was determined 
using a mixture model-based cutoff and related to gametocyte carriage using 
Fisher’s exact test, corrected for multiple testing (Benjamini-Hochberg) of a total 
of 70 antigens (including 40 antigens from the gametocyte gold standard).
Transcript abundance in different life stages and strains
The abundance of 15 predicted gametocyte-specific targets was measured in 
asexual parasites and gametocytes of four different Pf strains from in vitro culture. 
The targets were selected from the 100 highest scoring transcripts to account for 
uncertainties about the absolute scoring of transcriptomics data with a protein-
based gold standard. We do not assume a clear hierarchy between these top 
100 scoring transcripts and consider any of these genes highly gametocyte-
specific. The 15 highest-ranking non-gold standard genes were selected based 
on a preliminary analysis of the data, and contain genes that are currently 
not annotated as well as genes with known protein function in gametocytes 
(PUF1 [62] and Ccp4 [63]) . In the final generation of the gametocyte-scores, all 
validation genes were retained in the top 100 scoring genes. The Pf strains used 
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are of West African (NF54, NF166, NF175) and Southeast Asian origin (NF135). 
All strains were cultured and synchronized as described previously [20]. Using 
established standard curves, the same concentrations of parasites were compared 
for Ct values in qRT-PCR (for primers, see Supplementary Table S7). Extracted 
nucleic acids were DNase-treated before reverse transcription when introns were 
absent from the targets. Initial comparison was between mixed asexual blood 
stage parasites (considering the lowest Ct measured in any strain and replicate) 
and stage V gametocyte (highest Ct measured per strain and replicate). Promising 




 were further examined in serial dilutions 
of stage V gametocytes and synchronized asexual material of the strain NF54 (10, 
20, 30, 40 hours post invasion, resembling early rings, late rings, trophozoites 
and schizonts, respectively). All qRT-PCR reactions were analyzed in technical 
triplicates, from biological triplicates (NF54) or duplicates (remaining strains).
RNA samples were used from a clinical malaria trial conducted in Western Kenya 
[39]. Samples from days 3 and 7 after treatment were selected to ensure a range 
of (low-density) gametocyte carriage to test qRT-PCR sensitivity.
Go term enrichment in top 100 proteins or rank-based enrichment
Current GO term annotation for Pf was retrieved from plasmoDB (release 30) 
and analyzed using the topGO R package [64] for the enrichment of terms in 
the 100 highest scoring proteins versus all Pf proteins. Semantic clustering of the 
significant GO terms in Biological Process ontology was done with the Revigo 
webtool for Pf [65]. Second, gene set enrichment analysis (GSEA) based on all Pf 
proteins and their ranks and scores was performed using the software available at 
http://software.broadinstitute.org/gsea/downloads.jsp. Based on the cilium genes 
reported by the Syscilia consortium [66], we assembled a “cilium” GO term of 
mixed ontology (GO:9999999) for Pf with 28 predicted orthologs (Supplementary 
Table S6).
Data availability
All data generated or analyzed during this study are included in the online version 
of this article (and its Supplementary Information files).
- The gold standard lists (Supplementary Table S1)
- Bayesian gametocyte scoring for proteomics and transcriptomics data. Includes 
Pf only-scores and expression values for any gene and individual data set 
(Supplementary Table S2)
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- Potential translationally repressed genes with high transcriptomics score (>7) 
and low proteomics score (<-10, Supplementary Table S3)
- Overview over previously reported gametocyte-specificity per study (Supple-
mentary Table S4)
- Seroprevalence in The Gambia in gametocyte carriers and non-carriers 
(Supplementary Table S5)
- Function predictions for highly gametocyte-specific proteins with lacking 
annotation (Supplementary Table S6)
- Transcript validation in 15 targets, including primer sequences for qRT-PCR 
(Supplementary Table S7)
- GO term analyses with cilium genes (Supplementary Table S8)
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Table 1. Data sets used for integration
Life stages Spz sporozoites, Ri rings, Troph trohozoites, Schiz schizonts, Mer merozoites, Gct 
gametocytes. MS mass spectrometry (highest unique peptide count in any of the samples), T 
transcriptomics (highest percentile in any of the samples).
Data from Miao et al. 2017 was integrated after analyses of high scoring proteins, ranks and 
scores are included in Supplementary Table 2. 
* Asexual microarray data by Llinas and others retrieved from plasmoDB version 28 (Data set 
“Pfal3D7 real-time transcription and decay”), no accompanying publication.
2
Study Reference Species Life Stage Integrated Data
Fl02 Florens et al. 2002 [14] Pf Spz, Troph, Mer, Gct MS asexual/Gct
La02 Lasonder et al. 2002 [13] Pf Troph, Schiz, Gct MS asexual/Gct
Le03 LeRoch et al. 2003 [23] Pf Spz, Ri, Troph, Schiz, Mer, Gct T asexual/Gct
Ha05 Hall et al. 2005 [15] Pb Ri, Troph, Schiz, Gct MS + T asexual/Gct
Kh05 Khan et al. 2005 [16] Pb Mixed blood stage, Gct MS asexual/Gct
Yo05 Young et al. 2005 [24] Pf Gct T Gct
Ll06 Llinas et al. 2006 [25] Pf All blood stages, synchronized T asexual
Ot10 Otto et al. 2010 [26] Pf All blood stages, synchronized T asexual
Bo11 Treeck et al. 2011 [42] Pf Schiz MS asexual
Lo11 Lopez-Barragan et al. [27] Pf Troph, Schiz, Gct T asexual/Gct
Oe12 Oehring et al. 2012 [18] Pf Ri, Troph, Schiz MS asexual
Mo14 Moreno-Perez et al. 2014 [67] Pv Ri, Troph, Schiz MS asexual
Ot14 Otto et al. 2014 [28] Pb Ri, Troph, Schiz, Gct T asexual/Gct
Si14 Silvestrini et al. 2010, Tao et al.  
Pf Troph, Schiz, Gct MS asexual/Gct
 2014 (re-analyzed) [17,19]
Ta14 Tao et al. 2014 [19] Pf Gct MS Gct
Ll15 Llinas et al. 2015* Pf All blood stages, synchronized T asexual
La16 Lasonder et al. 2016 [20] Pf Gct MS + T Gct
Su16 Suarez-Cortes et al. 2016 [21] Pf Gct MS Gct
Mi17 Miao et al. 2017 [35] Pf Gct MS Gct
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Table 2: Properties of putative gametocyte-specific targets. 
Rank in transcriptomics (all data sets) for specificity in gametocytes. Random sample of top 100, 
excluding the gold standard. If primers are not intron-spanning, samples were DNase I treated. Ct 
difference is the difference between the lowest Ct detected in asexual samples and the highest Ct 
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Abstract
Background The transmission of malaria to mosquitoes depends on the 
presence of gametocytes that circulate in the peripheral blood of infected human 
hosts. Sensitive estimates of the densities of female gametocytes (FG) and male 
gametocytes (MG) may allow the prediction of infectivity to mosquitoes and thus 
a molecular estimate of the human infectious reservoir for transmission.
Methods A novel multiplex qRT-PCR assay with intron-spanning primers was 
developed for the parallel quantification of FG and MG. CCp4 (PF3D7_0903800) 
transcripts specific for FG and PfMGET (PF3D7_1469900) transcripts specific 
for MG were quantified in total nucleic acids. The assay was validated on sex-
sorted gametocytes from culture material and on samples from clinical trials with 
gametocytocidal drugs. Synthetic RNA standards were generated for the two 
targets genes and calibrated against known gametocyte quantities. 
Results The limit of detection was determined at 0.1 male and 0.1 female 
gametocyte/µL, which was equal to the limit of quantification (LOQ) for MG, 
while the LOQ for FG was 1 FG/ µL. Results from previously reported clinical 
trials that used separate gametocyte qRT-PCR assays for FG (targeting Pfs25) and 
MG (targeting PfMGET) were reproduced with the multiplex assay. High levels of 
agreement between separate assays and the multiplex approach were observed 
(R2=0.9473, 95% CI 0.9314-0.9632, for FG measured by transcript levels of Pfs25 
in qRT-PCR or CCp4 in multiplex; R2=0.8869, 95% CI 0.8541-0.9197, for MG 
measured by PfMGET in either single or multiplex qRT-PCR).
FG and MG transcripts were detected in pure ring stage parasites at 10,000- and 
100,000-fold reduced frequency for CCp4 and PfMGET, respectively. The CCp4 
and PfMGET transcripts were equally stable under suboptimal storage conditions.
Conclusions Gametocyte densities and their sex ratios can be determined in 
the presented one-step multiplex assay with higher throughput than single assays. 
The interpretation of low gametocyte densities at asexual parasite densities above 
1000 parasites/µL requires caution to avoid false positive gametocyte signals from 
spurious transcript levels in ring stage parasites.
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Background
The significant reduction in malaria mortality and morbidity seen in the last 10 
years is the result of combined efficient control measures such as early diagnosis, 
effective treatment with artemisinin-based combination therapy (ACT), active 
surveillance and vector control. Nevertheless, in 2016, 216 million cases were 
still reported worldwide [1] and major concerns exist about the extent to which 
the emergence and spread of insecticide [2] and artemisinin resistance [3] may 
affect worldwide malaria control and elimination efforts. New strategies may 
be needed to sustain recent gains and accelerate malaria elimination initiatives. 
These new strategies include the development and deployment of transmission-
blocking strategies that aim to reduce malaria incidence by targeting the infection 
reservoir involved in maintaining parasite transmission from humans to Anopheles 
mosquitoes. 
Transmission to mosquitoes is mediated by the presence of gametocytes in 
peripheral blood of a human host. Gametocytes are sexually dimorphic and 
both sexes are required to ensure the development of the parasite inside the 
mosquito. Although the likelihood of mosquito infection is largely dictated by 
gametocyte density [4], the gametocyte sex ratio may also play a significant role 
in ensuring fertilization [5–7]. Since one female gametocyte (FG) produces only 
one gamete, while a male gametocyte (MG) produces eight gametes [8,9], the 
gametocyte sex ratio is usually female-biased in the proportion of 3-5 females:1 
male [10,11] with indications from rodent malarias and natural Plasmodium 
falciparum infections that sex ratios may be adjusted in the presence of other 
parasite clones [6,12], in relation to gametocyte density [7,13] during infections 
and in response to environmental factors, such as anaemia [10]. Recent findings 
further suggest that anti-malarial drugs may have differential effects on MG and 
FG [14,15]. Understanding gametocyte sex ratios is thus of interest to understand 
Plasmodium biology, better predict transmission potential during natural malaria 
infections and estimate the likelihood of onward transmission to mosquitoes after 
treatment with anti-malarial drugs. 
Gametocytes usually circulate in blood at low levels as only 0.2-1% of asexual 
parasites commit to sexual development at every cycle of red blood cell invasion 
[16]. Several studies have observed infected mosquitoes after feeding on blood 
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containing gametocyte densities as low as 0.25-0.3 gametocytes/microliter of 
blood, well below the threshold for detection by routine microscopy [7,17–21]. 
As a consequence of the abundant presence of submicroscopic densities of 
gametocytes in clinical and asymptomatic infections [22–24], they represent a 
silent infectious reservoir in the population. In the last 20 years, sensitive molecular 
techniques based on sexual stage-specific mRNA transcripts have been developed 
to improve the detection and quantification of both gametocyte sexes. Pfs25 
mRNA has been widely used as a mature gametocyte marker [19–21,25] and was 
recently confirmed to be female-specific or at least considerably female-biased 
[26,27]. Based on RNA-seq analysis, PfMGET was recently presented as a novel 
male-specific gametocyte marker [26,28]. The use of intron-spanning primers 
allows for sensitive detection of MG in samples of naturally infected parasite 
carriers [28]. Thus far a combination of separate Pfs25 and PfMGET qRT-PCR 
assays has been used to estimate gametocyte sex ratios in natural and controlled 
infections [7,15,28–30]. However, estimating sex ratios by using two separate 
qRT-PCR assays may affect assay precision and throughput. Here, a novel target 
for FG is proposed, CCp4, that was previously identified as a gametocyte-specific 
transcript [31] and allows for intron-spanning primer design. This manuscript 
describes a one-step multiplex qRT-PCR assay for robust assessments of gametocyte 
sex ratios at densities below the microscopic threshold for gametocyte detection. 
Methods
Selection of male and female marker transcript
The selection of the male marker PfMGET was described previously [28]. The 
female marker CCp4 was identified by integrating transcriptomics data and 
validated as gametocyte-specific [31]. 
Preparation of gametocyte material
Sex-sorted gametocytes were generated as described previously [26,28]. In 
brief, cultures of the PfDynGFP/P47mCherry line [26] were treated with N-acetyl 
glucosamine and stage V gametocytes were FACS sorted for their fluorescence 
signal (MG are sorted as GFP-positive/mCherry-negative, FG as mCherry-positive/
GFP-negative) and afterwards counted with a Bürker-Türk counting chamber. For 
both MG and FG tenfold dilution series were prepared in whole-blood in the 
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range of 106/mL to 101/mL and stored in RNAProtect to serve as standard curves 
for gametocyte quantification.
Preparation of ring stage parasites to assess transcript stage specificity
Asexual parasites of the NF54 strain were synchronized by the selection of late 
trophozoites and schizonts as described [28]. In brief, a 63% Percoll density 
gradient was followed by a 5% sorbitol treatment, killing the remaining schizonts 
after 5 hours and ensuring tight synchronization. NF54 ring stage parasites were 
harvested 10-20 hours after the Percoll treatment and stored in lysis buffer (5.25 
M GuSCN; 50mM Tris-HCl pH6.4; 20mM EDTA; 1.3% Triton X-100) for later 
analysis.
To obtain pure asexual stage reference material without plausible contamination 
by gametocytes, ring stage parasites of the gametocyte-deficient F12 clone were 
used that have a loss-of-function mutation in the gene encoding the gametocyte 
master transcription factor AP2-G [32]. In addition, ring stage parasites were 
generated from the recently described AP2-G knock-down line 3D7/AP2-G-GFP-
DDglmS that does not express AP2-G when grown in the presence of 2.5 mM 
(D)-+-glucosamine (GlcN) (Sigma Aldrich) [33]. Under these conditions both the 
ap2-g-gfp-dd transcript and AP2-G-GFP-DD protein are degraded, resulting in 
no gametocyte production. Parasites were synchronized twice 16 hours apart to 
obtain an eight-hour growth window. 30 ml parasite culture at 3-4% parasitaemia 
and 5% haematocrit was harvested at 8-16 hours post invasion. Parasites were 
released from infected RBCs by saponin lysis and total RNA was directly isolated 
using Ribozol (Amresco) according to the manufacturer’s manual. 
Samples from naturally infected gametocyte carriers
Samples from two previously published clinical trials in light microscopy-positive 
gametocyte carriers from Kenya [28] and Mali [15] were used to directly compare 
gametocyte density estimates using the PfMGET/CCp4 multiplex assay with the 
previous qRT-PCR assays targeting PfMGET (male) and Pfs25 (female) transcripts 
separately. The multiplex assay was performed on Kenyan samples collected prior 
to treatment (day 0; n=31), and after treatment on day 2 (n=16), day 7 (n=46), 
and day 14 with dihydroartemisinin-piperaquine (DP) alone or with primaquine 
(n=28; total n=121). The samples from Mali that were included in the current study 
were collected on day 7 after treatment with either DP (n=15) or DP + methylene 
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blue (15mg/kg given daily for the first three days of treatment; DP+MB, n=19) 
or sulfadoxine-pyrimethamine and amodiaquine (SP-AQ, n=19) or SP-AQ with a 
single dose of primaquine (0.25 mg/kg given together with the first dose of SP-
AQ, SP-AQ+PQ, n=19) [15]. In both studies considerable variation in gametocyte 
densities and sex ratios was previously reported. 
Nucleic acid extraction and target amplification
Total nucleic acids were extracted from 50 µl whole blood in five volumes 
RNAProtect with the MagNAPure LC automated extractor (Roche) using the 
MagNAPure LC Total Nucleic Acid Isolation Kit  High Performance, with the 
exception of F12- and 3D7/AP2-G-GFP-DDglmS-derived material (bulk Ribozol 
(Amresco) extraction according to the manufacturer’s manual). Total nucleic acids 
were eluted in 50 µl of MagNAPure elution buffer, of which 5 µl was used in 
the multiplex assay. For the multiplex assay, we used the Luna® Universal Probe 
One-Step RT-qPCR Kit (NEB). Gene IDs of the male and female markers and 
respective primer and probe sequences can be found in Table 1, for additional 
primer sequences see Additional file 1. Probe and primer concentrations were 
optimized (see Additional file 1) to obtain efficient amplification of both targets. 
The optimal conditions are summarized in Table 2. Negative controls were run to 
ensure there were no unspecific signals detected from no-template controls, or 
from total nucleic acids without reverse transcription (intron-spanning primers do 
not bind to genomic DNA); and melt curves were visually inspected.
Serial dilutions of all ring stage materials were used to detect ring stage 
transcripts (SBP-1) and early gametocyte transcripts (Pfg27, Pfs16, Pfg14-744, 
Pfg14-748) as well as the mature gametocyte transcripts CCp4, PfMGET and 
Pfs25. Total nucleic acids were used for the intron-containing genes SBP-1, Pfg14-
744, Pfg14-748, CCp4 and PfMGET while Pfs16, Pfg27 and Pfs25 required RQ1 
DNase I treatment (Promega). cDNA was prepared with the High Capacity cDNA 
Reverse Transcription Kit (Applied BioSystems) and 2 ul of cDNA was run in the 
GoTaq qPCR Master Mix (Promega). All primers were used at 900 nM, except for 
SBP1, PfMGET and Pfs25 which were run at 225 nM primers.
Synthetic RNA standard curve material
Linear dsDNA templates for the target regions of CCp4 and PfMGET were 
synthesized by BaseClear B.V. the Netherlands (for sequences, see Additional file 
2) and purified by agarose gel electrophoresis. Bulk RNA was transcribed with the 
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MEGAShortscript T7 high yield transcription kit (Invitrogen) at 10-50 nM dsDNA 
input according to the manufacturer’s instructions. Transcription samples were 
DNaseI treated with the TURBO DNA-free kit (Invitrogen) and subsequently purified 
over an RNeasy mini spin column (Qiagen). RNA standards were calibrated against 
sex-sorted gametocyte standards, both standards were prepared using tenfold 
serial dilutions. Copy numbers in initial samples were quantified on a Qubit 2 
(ThermoFisher), absolute RNA amounts were calculated into copy numbers with 
the specific sequence weight.
Gametocyte transcript stability testing
Synchronized mature gametocytes (NF54, 1.8% parasitaemia) were diluted in 
whole EDTA-blood starting at concentrations of 105 gametocytes/mL. These 
samples were either stabilized by adding five volumes of RNAProtect (Qiagen) 
or left unstabilized (no protective buffer added) for further treatments: One to 
three aliquots were kept at room temperature (22-25°C) for 0h, 1h, 2h, 4h, 6h, 
8h or 24h before freezing them at -80°C and subsequent processing. A subset of 
samples (n=3) in RNAProtect (added at 0h) were additionally freeze-thawed five 
times (37°C/-80°C cycling for at least 1h each) before extraction of nucleic acids. 
The stability of the transcripts after extraction was also tested by freeze-thaw 
cycles at which the samples were left at room temperature (22-25°C) or 37°C for 
one hour, interspersed by at least 1h at -20°C.
Statistical analysis
Graphs and statistical analyses were made with GraphPad Prism (version 5.0.3) or 
R statistical software (version 3.4.0). The concordance between separate qRT-PCR 
assays and the multiplex approach was assessed by estimating the slope and 95% 
confidence interval (95% CI) in linear regression. No statistical comparisons were 
made on the CT values of different marker genes since this was beyond the scope 
of the current manuscript and meaningful comparisons would require a larger 
number of replicates. Where transcript abundance differences were estimated, 
this was based on the assumption of doubling of transcript after each cycle (1 Ct 
difference), regardless of reaction efficiencies.
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Results
Male and female gametocyte transcripts are detected in low densities of 
gametocytes 
A multiplex assay was developed to target the female- and male-specific 
gametocyte transcripts CCp4 and PfMGET simultaneously by intron-spanning 
primers. Amplification from genomic DNA was absent when qRT-PCRs were 
performed without reverse transcription. Protocol optimization included limiting 
the primer concentration for the male target, which is explained in detail in 
Additional file 1 and resulted in an assay with two equally efficient amplification 
reactions for both target transcripts. Sorted MG and FG of the NF54-derived 
fluorescent reporter line PfDynGFP/PfP47mCherry [26] were used in dilution 
series to determine the limit of detection (LOD), limit of quantification (LOQ) 
and variation in the multiplex assay. In an octuplicate run of female and male 
standard curve material, the coefficient of within-run variation was assessed 
(Fig. 1A and 1B), which is very low (2-3%) for both target transcripts at high 
gametocyte densities, but increasing to 6% or 29% at densities of 100 sex-sorted 
gametocytes/mL for PfMGET and CCp4, respectively. The LOD is 100 MG or FG/
mL (0.1/µL) with 96.2% or 100% of all experiments at this density (n=26) positive 
for PfMGET or CCp4, respectively. Even at 10 MG/mL (0.01 MG/µL), the male 
signal was detected in the majority of experiments (18 of 26, 69.2%), but with 
an increased variation coefficient (18%). The LOQ was hence equal to the LOD 
LOD and variation (CV as bars) in octuplicate run
A B
Fig 1
Figure 1. Limit of detection and variation of the gametocyte multiplex assay. Individual 
results of 8 technical replicates for female-sorted (A) and male-sorted (B) gametocytes of decreasing 
densities. Seven measurements (dots) obtained by calculating the reference from one randomly 
chosen dilution series. The coefficient of variation (filled bars) was calculated as standard deviation/
mean of the respective calculated densities. Sample positivity in n=26 independent experiments is 
indicated in the white boxes.
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for MG (102 MG/ml or 0.1MG/µL) while for FG the LOD was 10 2 FG/mL (0.1 FG/
µL) and the LOQ was higher (103 FG/mL or 1 FG/µL).
Low densities of male and female gametocyte transcripts are detected in 
high densities of asexual parasites
Whilst previous studies reported negligible Pfs25 and male gametocyte transcripts 
in asexual (ring stage) parasites [25,34,35], low levels of CCp4, Pfs25 and PfMGET 
transcripts were detected in pure asexual parasite material (Fig. 2). About 10,000 
ring stage parasites from the gametocyte-deficient F12 P. falciparum line [32] 
provided a similar quantity of CCp4 transcript as one FG and 100,000 F12 
ring stages carried PfMGET transcript equivalent to one MG. In addition, ring 
stage parasites also contained Pfs25 transcripts. Their concentration was about 
100,000-fold less than FG (Additional file 1, Figure S2 A). Interestingly, compared 
to F12 ring stages the expression of these gametocyte markers in ring stages of 
the 3D7/AP2-G-GFP-DDglmS line [33] was slightly lower when AP2-G was not 
expressed. Under these conditions, the fold-change in transcript between asexual 
rings and FG increased to 50,000-fold for CCp4 and to 200,000-300,000-fold 
for PfMGET (MG over asexual rings). Ring stage material of the F12 line and 
3D7/AP2-G-GFP-DDglmS was then compared with the gametocyte-producing 
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1,000/uL 20/mL 5/mL any any
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100,000/uL 2000/mL 500/mL 2000/mL 500/mL
Numbers in bold are above the detection threshold of the assay
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CCp4 
50,000fold less transcript in AP2G-KO

former estimate 10,000 from F12
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200,000fold less transcript in AP2G-KO

(before 100,000)











Figure 2. Stage-specificity of the multiplex assay. Female-specific (A) and male-specific 
(B) transcripts are detected in high concentrations of ring stage parasites of the F12 line nd 
the 3D7/AP2-G-GFP-DDglmS line. Mean Ct values ± 2SD for varying numbers of independent 
experiments: n=2 and =9 for CCp4 in ring stage parasites and female gametocytes; n=2 and 
n=17 for PfMGET in ring stage parasites and male gametocytes, respectively. NA, not available/not 
measured (samples at these concentrations were not available); ND, not detected. Lines represent 
fitted linear regression curves.
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of sexual differentiation (Pfg27, Pfs16, Pfg14-744 and Pfg14-748). The results 
indicate low-level contamination with early gametocytes in NF54 compared to 
both gametocyte-non producing lines. Consistently, all markers were expressed at 
higher levels in NF54 ring stages compared to F12 and 3D7/AP2-G-GFP-DDglmS 
(Additional file 1, Figure S3).
The measured background expression of PfMGET and CCp4 transcripts in asexual 
ring stages leads to the following precautions, based on a conservative estimate 
of fold change of transcript levels (compared to F12 rings): For the detection of 
MG and FG, the presence of asexual parasites at densities above 1000 parasites/
µL can result in a false-positive signal for FG whilst asexual parasites at densities 
above 10,000 parasites/µL can also result in a false-positive signal for MG (Table 
3).
Both CCp4 and PfMGET were also moderately expressed in the opposite-sex 
gametocyte, detectable at concentrations of 10,000/mL or higher (Fig. 3). The 
opposite sex (MG) accounted for 0.1% (1 in 1000) false positive FG with CCp4 
(Fig. 3A), and about every 100 FG accounted for 1 MG (1% false positives) in 
PfMGET-based detection (Fig. 3B). Pfs25 shows higher background than CCp4 in 
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Aspecific II: Signal in opposite sex gametocytes
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Ct values differ from one experiment to the next, but the trend is still clear.

Error bars: +-2SD from the mean






Figure 3. Sex-specificity of the multiplex assay. Female-specific (A) and male-specific 
(B) transcripts are detected in high concentrations of gametocytes of the opposite sex (empty 
symbols). Mean Ct values ± 2SD for varying numbers of independent experiments: n=3 and 
n=9 for CCp4 in male and female gametocytes; n=4 and n=17 for PfMGET in female and male 
gametocytes, respectively. ND, not detected. Lines represent fitted linear regression curves.
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The male/female gametocyte multiplex assay corroborates earlier density 
estimates in naturally infected individuals
Estimates of MG and FG are highly correlated with the estimates obtained by 
Pfs25 qRT-PCR (FG for Kenya and Mali combined, R2=0.9473, p<0.001) and 
PfMGET qRT-PCR (MG combined, R2=0.8869, p<0.001) (Fig. 4A-4B) using a 
selection of samples from clinical trials in Kenya (n=84 samples )[28] and Mali 
(n=72 samples) [15]. In the Malian study [15], extreme gametocyte sex ratios were 
reported and multiplex qRT-PCR-estimates for sex-specific gametocyte densities 
(Fig. 4A-4B), prevalence (Fig. 4C) and sex ratios (Fig. 4D) were in agreement with 
Figure 4. Performance of the multiplex-assay on clinical trial samples. (A-B) Agreement 
with previously measured gametocyte densities with single assays, using Pfs25 (A) and 
PfMGET (B) transcripts. The linear regression was fitted as follows [95% confidence interval]: 
for FG y=0.9944[0.9497 to 1.040]x+0.0751[-0.0627 to 0.2130] [28], y=1.033[0.977 to 1.092]
x-0.2554[0.4619 to 0.04893] [15] and for MG y=0.8626[0.7744 to 0.9507]x+0.5919[0.2802 
to 0.9037] [28], y=0.9217[0.8633 to 0.9800]x+0.3508[0.1515 to 0.5500] [15]. (C) Gametocyte 
prevalence as determined by single or multiplex qPCR for four treatment arms (Dicko et al. 
2018), 7 days after treatment with either DP, dihydroartemisinin-piperaquine (n=15); DP+MB, 
dihydroartemisinin-piperaquine + methylene blue (n=19); SP-AQ, sulfadoxine-pyrimethamine 
and amodiaquine (n=19) or SP-AQ and a single dose of primaquine (n=19). (D) Sex ratios of 
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the conventional quantification by qRT-PCR targeting Pfs25 for FG [36] or PfMGET 
transcripts for MG [28]. 
A linear regression curve was fitted for single versus multiplex assay density 
estimates. For the MG quantification, there were indications that the slope 
deviated from 1 (95% CI 0.7744-0.9507 for the study in Kenya and 0.8633-
0.9800 for the study in Mali) but resulting estimates in sex ratio were highly 
similar to those obtained after separate qRT-PCR (Fig. 4D).
Male and female targets show similar stability under sub-optimal sample 
storage conditions
Differences in transcript stability upon delays in sample processing or following 
freeze-thaws may affect gametocyte quantification of field samples. To resemble 
freshly taken blood samples with delays in sample processing, whole blood 
samples with NF54 parasites containing a mix of male and female gametocytes 
were stored at room temperature (22-25°C) without an RNA-protecting agent. 
Transcript abundance of CCp4, PfMGET and Pfs25 was determined at baseline 
(0h) and after 1h, 2h, 4h, 6h, 8h or 24h. All targets had stable Ct values after 1 
hour without RNA-protecting agent (n=1). PfMGET and CCp4 showed delayed Ct 
values after 2 hours without protection (n=2, Additional file 1; Figure S4). To study 
the effect of freezing/thawing after storage, blood was stored in RNAprotect and 
subjected to five freeze-thaw cycles at 37°C prior to nucleic acid extraction. A 
minimal transcript loss was observed (0.523 and 0.245 Ct difference to baseline 
for PfMGET and CCp4, respectively, Additional file 1; Supplemental Table 1). 
Extracted total nucleic acids were more stable and showed no loss in signal 
(0.08 and 0.02 Ct reduction) compared to baseline for PfMGET and CCp4, after 
five freeze-thaw cycles at room temperature for the sorted trend line material 
(Additional file 1; Supplemental Table 1).
Synthetic RNA standards can be used to estimate gametocyte densities 
and copy numbers per gametocyte
In vitro-synthesized RNA of the target regions of CCp4 and PfMGET was used 
in serial dilutions alongside sorted gametocyte standards (see Additional file 1, 
Figure S5 A-B). The synthetic RNA standards were used to estimate the copy 
numbers in the gametocyte reference material (see Additional file 1, Figure S5 
C-E). For CCp4, estimated transcript copies were 4 (95% CI 3.2-5.1) mRNA copies 
71multiPlex gametocyte assay 
per female gametocyte and for PfMGET 9.8 (95% CI 8.9-10.2) copies per male 
gametocyte. For comparison, female gametocytes had an average of 231.7 (95% 
CI 199.1-269.8) Pfs25 copies per gametocyte.
Discussion
In the current study, a multiplex assay for the rapid quantification of female and 
male gametocytes is reported. The assay utilizes a new female gametocyte marker 
CCp4 in conjunction with the reported male gametocyte marker PfMGET [28]. 
The use of intron-spanning primers allows simultaneous quantification of male 
and female-specific transcript levels in total nucleic acids without prior DNase I 
treatment. The presented analysis concludes low but non-negligible gametocyte 
transcripts in gametocytes of the opposite sex and gametocyte-free ring-stage 
asexual parasites. The stability of CCp4 and PfMGET transcripts was similar 
under suboptimal storage conditions; gametocytes can be reliably detected and 
quantified at densities 0.1-1 gametocyte/µL. 
CCp4 is a member of the LCCL-domain containing adhesion protein family and 
orthologous to LAP6 in Plasmodium berghei, where this gene is reported to be 
translationally repressed with protein expression occurring at the ookinete stage 
only [37]. Earlier, a DOZI (development of zygote inhibited) knock out indicated 
that LAP6 transcripts (then called PB000955.03.0) are accumulated in an mRNA 
storage complex [38]. In P. falciparum, the CCp4 protein is predominantly expressed 
at the gametocyte stage, with only minor expression in male gametocytes [39] and 
no evidence for translational repression. Gametocyte-specific CCp4 transcripts 
were reported in an integrated analysis of eight Plasmodium transcriptomes [31]. 
The initial validation in qRT-PCR experiments confirmed CCp4 expression to be 
at least 1,000-fold upregulated in gametocytes of different P. falciparum strains 
compared to asexual blood stages. The 1,000-fold higher mRNA levels in FG over 
MG reported here confirm and exceed the previous estimates by RNAseq (38-fold 
higher in females by RPKM values) [26].
Unlike the commonly used female marker Pfs25, CCp4 allows the design of intron-
spanning primers. The current assay utilizes intron-spanning primers of both 
male and female reporter genes with two marker-specific probes. Importantly, 
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the multiplex gametocyte assay can be performed on total nucleic acids without 
DNase I treatment, which may affect gametocyte detection at low densities 
[28,36]. The multiplex male-female assay is thus faster than separate assays. 
Sensitivity for detecting female gametocyte was lower than for the single qRT-PCR 
targeting Pfs25, which is at least in part explained by a lower estimated number 
of CCp4 transcripts per female gametocyte as compared to Pfs25. The LOD for 
female and male gametocytes in the multiplex assay is 0.1/µL, well below the limit 
of microscopic detection and in the same range as other molecular sex-specific 
assays [28,34,35]. More sensitive total gametocyte assays have been reported 
[40] but the current multiplex LOD allows for the detection of infections that are 
likely to be transmissible to mosquitoes. An increasing likelihood of mosquito 
infections is consistently observed at gametocyte densities above 1-5 gametocyte 
per microlitre [7,29,41]. The current assay reliably quantifies gametocytes at these 
densities. The lower sensitivity to detect female gametocytes as compared to 
Pfs25 may be a concern in studies where very low overall gametocyte densities 
are observed [29,30] but the operational attractiveness of a multiplex assay that 
does not require DNase treatment is considerable for many other studies.
Previous work indicated that the stability of transcripts is a relevant concern 
when estimating gametocyte prevalence or density [36,41]. When assessing 
gametocyte sex ratio, transcript stability is a particular concern since differences in 
the stability between target transcripts may affect bias estimates. In a limited set 
of experiments there were no indications for differences in the stability of PfMGET 
and CCp4 transcripts, provided samples are transferred to RNA-protective buffer 
within 1-2 hours of blood collection. Freeze-thaw cycles resulted in limited RNA 
loss once blood samples are in this protective buffer. A similar stability of male 
or female signal is of particular relevance for studies conducted in low resource 
settings where there may be challenges in ensuring optimal storage conditions. 
Repeated or prolonged freeze-thaw cycles may thus affect overall gametocyte 
detection or quantification [41,42] but current results indicate they would not 
disproportionally affect MG or FG quantification and thus sex-ratio estimates.
The presented multiplex assay is a fast route to accurate P. falciparum sex ratio 
determination, saving about 25% of the time – with similar material costs – 
compared to two separate assays of which one requires a DNase treatment step. 
Medium sample through-put in 96-well format is the recommended application, 
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providing accurate gametocyte quantification and sex ratio determination for 
blood and culture samples.
Previous studies concluded no or negligible Pfs25 transcript numbers in asexual 
parasites . In the current set of experiments, we detected gametocyte transcripts 
in different preparations of ring-stage asexual parasite material. Whilst low-level 
contamination of gametocytes in supposedly pure asexual parasites may have 
contributed to the detection of CCp4, Pfs25 and PfMGET transcripts in asexual 
parasite material from the NF54 strain, the detection of these transcripts in the 
gametocyte-deficient F12 line and under knock-down conditions for AP2-G 
in a more recent gametocyte-less line 3D7/AP2-G-GFP-DDglmS [33] provides 
convincing evidence for low-level expression of Pfs25, CCp4 and PfMGET in asexual 
ring stage parasites. The current findings of detectable transcript expression for 
all gametocyte markers in high densities of asexual blood stages despite different 
strategies to avoid gametocyte contamination have implications for past and 
future gametocytaemia estimates. Whilst the difference in transcript abundance 
between gametocytes and asexual parasites is sufficiently pronounced to conclude 
a marginal impact on gametocyte density estimates, gametocyte prevalence 
estimates may be inflated in some populations. Given the high parasitaemia of 
some acute malaria infections (with densities typically above 10,000 parasites/
µL [43] as opposed to asymptomatic infections where densities commonly lie 
below 10 parasites/µL [44]), earlier studies recruiting clinical malaria cases may 
have overestimated gametocyte prevalence by molecular assays. In studies with 
asymptomatic parasite carriers and in low-endemic settings, where lower asexual 
parasite densities dominate, this overestimation will be less pronounced and 
often negligible. A previously reported rapid decline in gametocyte prevalence 
based on Pf25 mRNA detection in the first 3 days following treatment of high-
density asexual infections [45] may thus be (partially) explained by the detection 
of Pfs25 transcripts arising from asexual parasites, whilst the gradual decline 
in gametocyte prevalence following treatment of lower-density asymptomatic 
asexual parasite carriers [15,46] or gametocyte transcript kinetics in the period 
following asexual parasite clearance may better reflect gametocyte clearance and 
gametocyte half-life [47]. With a better appreciation of caveats in gametocyte 
detection, the molecular tools for gametocyte detection are of value for studies 
aiming to quantify the human infectious reservoir for malaria, the kinetics of 
gametocyte production and the impact of interventions on gametocyte carriage. 
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As a consequence of the detection of low level transcripts of gametocyte markers 
in rings, it is advised to report gametocyte prevalence in samples with parasite 
densities >1000 parasites/µl together with a qualifying remark on the reliability 
of gametocyte prevalence and quantification. The presented results suggest that 
gametocyte prevalence determined in samples below assay-specific cut-off values 
indeed can be trusted (Table 3). Stating the limitations of molecularly determined 
gametocyte prevalence for densities, if required, will re-confirm the validity of 
molecular gametocyte detection. 
With a cautious interpretation of low gametocyte density estimates in samples 
with high concurrent asexual parasite densities, molecular gametocyte diagnostics 
such as the multiplex assay presented in this manuscript are valuable tools to 
obtain sensitive and robust estimates of gametocyte prevalence and density. 
With these tools, gametocyte densities and sex ratios can be assessed across 
the gametocyte density range that is likely to contribute to onward transmission 
to mosquitoes [7,19], which in many settings is well below the threshold for 
detection by microscopy. 
Conclusion 
The presented multiplex qPCR assay is a valuable addition to gametocyte 
diagnostic tools. A new female gametocyte marker gene, CCp4 was introduced 
and benchmarked against Pfs25 transcript-based quantification. The use of CCp4 
and PfMGET as targets has the following advantages: throughput is facilitated 
by the use of intron-spanning primers which allow amplification of mRNA only 
without a DNA digestion step, sensitivity is sufficiently high to detect and quantify 
all potentially transmitting gametocyte densities. The target mRNAs result in a 
similar detectability of male and female gametocytes and show similar stability 
under suboptimal storage conditions, allowing robust gametocyte sex-ratio 
estimates in field studies.
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Table 1: Primer and probe sequences for qRT-PCR assays, with references for earlier 
reported methods and primers.
*intron-spanning; MPX=multiplex assay; qRT-PCR=quantitative real time reverse transcription-PCR





















TAGGCGAACATGTGGAAAG        
CACATGAATATGAGAATAAAATTG*




















  Concentration Program 
 Female primers CCp4  900 nM 55°C 15 min RT-step
 Female probe -Texas Red 200 nM 95°C 1 min 
 Male primers PfMGET 225 nM 95°C 10 sec 45 cycles
 Male probe - FAM  200 nM 60°C 1 min 
 Input Total Nucleic Acid 5 µl  
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Table 3: The consequences of low level gametocyte transcripts in asexual parasites and 
gametocytes of the opposite sex for assessing gametocyte prevalence and density.
Numbers in bold are above the limit of detection. Other estimates are presented to illustrate the marginal 
impact of signal derived from asexual parasites on gametocyte quantification. The false positive signal 
strength for female (FG, CCp4) and male target (MG, PfMGET) is based on the comparison of NF54 
(sorted) gametocytes and F12 ring stages.
3
Asexual parasite  False positive signal in Trust prevalence/estimated density
density  gametocyte quantification if density is significantly above
Log10/mL FG MG FG MG
4 10/µL 0.001/µL 0.0001/µL any any
5 100/µL 0.01/µL 0.001/µL any any
6 1,000/µL 0.1/µL 0.01/µL 0.1/µL any
7 10,000/µL 1/µL 0.1/µL 1/µL 0.1/µL
8 100,000/µL 10/µL 1/µL 10/µL 1/µL
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Abstract
A mosquito needs to ingest at least one male and one female gametocyte to 
become infected with malaria. The sex of P. falciparum gametocytes can be 
determined microscopically but recent transcriptomics studies paved the way 
for the development of molecular methods that allow sex-ratio assessments at 
much lower gametocyte densities. These sex-specific gametocyte diagnostics 
were recently used to examine gametocyte dynamics in controlled and natural 
infections as well as the impact of different antimalarial drugs. It is currently 
unclear to what extent sex-specific gametocyte diagnostics obviate the need 
for mosquito feeding assays to formally assess transmission potential. Here, we 
review recent and historic assessments of gametocyte sex ratio in relation to host 
and parasite characteristics, treatment and transmission potential.
85gametocyte sex ratio
Sexual commitment and first appearance of male and 
female P. falciparum gametocytes
The transmission of malaria from human to mosquito depends on the presence of 
gametocytes (see Glossary), sexual stage Plasmodium parasites, in the peripheral 
blood. The development of gametocytes of P. falciparum takes 8 – 12 days, 
and involves transitions from committed rings via early and intermediate stage 
gametocytes that are sequestered in the bone marrow and spleen (stages I - IV) 
[1-3] to mature male and female stage V gametocytes [4]. In other Plasmodium 
species, like P. vivax, P. chabaudi, P. vinckei and P. gallinaceum, gametocytes develop 
much more rapidly, typically within 3 days [5]. In controlled human malaria 
infections (CHMI) less than 10% of all asexual P. falciparum parasites commit to 
form gametocytes [6, 7] and mature gametocytes typically comprise less than 5% 
of the circulating parasite biomass in natural infections [8]. Sexual commitment 
happens before the stage of schizogony [9-12] and all merozoites derived from 
one schizont develop into either microgametocytes (males) or macrogametocytes 
(females) [13, 14]. The lack of sex chromosomes in haploid Plasmodium hampers 
our understanding of the commitment to sexual differentiation and the timing 
of sex determination [15]. Sex determination could occur at the same moment 
when commitment to sexual differentiation is determined [13], or alternatively 
via a two-stage process, where sex determination happens after the decision on 
commitment to sexual differentiation. At the molecular level, the nuclear protein 
P. falciparum gametocyte development 1 (GDV1) triggers the first known part of 
the molecular cascade of commitment and acts as the upstream regulator of the 
DNA-binding protein AP2-G (PF3D7_1222600), by antagonizing heterochromatin 
protein 1 repression of AP2-G transcription [16]. Sufficient activation of AP2-G, 
the master transcriptional regulator of gametocytogenesis, represents the “point 
of no return” in commitment to both male and female gametocytes [11, 17, 18]. 
The molecular basis of sex determination, and its timing during development, is 
currently unknown.
Here, we summarize historic and recent estimates of gametocyte sex ratio in 
natural infections and the limitations of older estimates that relied on microscopy. 
We present the merits and limitations of molecular tools for quantifying 
gametocyte sex-ratio and review evidence for a sex-specific effect of antimalarial 
drugs on circulating gametocytes and the implications for malaria transmission 
potential.
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Figure 1. Intensive microscopy-based quantification of gametocyte sex ratio. Data 
generated by one of the authors (CD) in 1992 – 1993 to illustrate the likely error in gametocyte sex 
ratio estimation when determining sex of only a few gametocytes per sample as routinely done in 
epidemiological studies. Briefly, 100 – 500 gametocytes were sexed per blood smear in 53 samples 
from 43 individuals living in malaria endemic regions in The Gambia and sex-specific counts were 
recorded in groups of 10 gametocytes. Light microscopy images of male and female gametocytes 
stained with Giemsa’s stain are shown in A for illustration. Female gametocytes are blue/violet (as 
opposed to pink males), more crescent-shaped and have more compact nuclei and more centrally 
located pigment. In B, x coordinates represent data from different samples, partially transparent to 
allow visualization of overlapping data points: red crosses (left y axis) correspond to the proportions of 
gametocytes identified as male based on data from groups of 10 gametocytes or the total number of 
gametocytes, respectively; light blue bars represent the difference (right y axis) between the proportion 
of male gametocytes when considering only the first 10 gametocytes observed in each smear versus 
the proportion calculated based on the total number of gametocytes. This difference exemplifies the 
error that might occur in routine measurements, that only quantify limited number of gametocytes. In 
C, the distribution of the proportion of male gametocytes in the different thick smears analyzed, based 
on the total number of gametocytes, is shown. Panel D presents the progressive reduction in error as 
the number of gametocytes counted increases. In this panel, the x axis corresponds to the cumulative 
number of gametocytes sexed, and the y axis, to the difference in the proportion of male gametocytes 
relative to the same proportion when estimated based on all gametocytes observed in the smear. Each 
line represents a different sample, and colors relate to the overall proportion of male gametocytes in 
the smear. The rectangle delimited by the dashed lines encloses error values between -0.1 and 0.1 
when 50 – 100 gametocytes were counted. Only data from thick smears were used in this figure.
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Microscopy is an imperfect tool to quantify gametocyte sex-ratio
In natural infections of P. falciparum, the sex ratio of circulating gametocytes 
is mostly female biased [19]. Only few epidemiological studies have quantified 
female and male gametocytes separately with sex ratios ranging from a mean 
of ~3 to 5 females to 1 male (Table 1) [20-23]. Previously reported sex ratios are 
mainly based on microscopic examination of Giemsa stained thick or thin blood 
smears, relying on subtle morphological differences between mature (stage V) 
macro- and micro-gametocytes [24] (Figure 1). Gametocyte sex determination 
by microscopy is challenging due to the typically low gametocyte densities and 
the difficulty of allocating a sex to the sparsely observed gametocytes [22, 25-
28]. As illustration of their sparseness, in a recent detailed study on gametocyte 
carriage in Burkina Faso, only 20% (95% confidence interval [CI] 14 – 27%) of 
patent asexual parasite carriers had microscopically detected gametocytes and 
only 7% (95% CI 4 – 12%) had more than two gametocytes observed whilst 
enumerating against a conventional number of 500 white blood cells (~0.06 
µL of blood microscopically screened) [29]. The implications of low observed 
gametocyte counts for sex ratio precision are presented in Figure 1, indicating 
that observations based on 500 white blood cells can rarely lead to accurate 
gametocyte sex ratio estimates. Only by observing 50 – 100 gametocytes, can 
a reproducible sex ratio be calculated (Figure 1D) [8, 19] and this is hardly ever 
attainable by routine microscopy. Microscopic investigation of gametocyte sex 
can be improved by concentrating gametocytes with magnetic enrichment 
[30], assuming it enriches male and female gametocytes equally, allowing more 
gametocytes to be examined. The accuracy of differentiating male and female 
gametocytes can be further improved by targeting proteins or transcripts that are 
preferentially expressed in a specific sex using immunofluorescence or probe-based 
hybridization assays, respectively. Assays that target stage-specific expression of 
transcripts such as Pf77 (PF3D7_0621400) and Pfg377 (PF3D7_1250100), both 
enriched in female gametocytes [31, 32] and Pfg27 (PF3D7_1302100, detecting 
both sexes) [33, 34] have been reported previously. Immunofluorescence assays 
based on antibodies that bind proteins specific for early gametocytes such as 
Pfs16 as Pfs16 (PF3D7_0406200) [14, 35], male gametocytes (α-tubulin II, 
PF3D7_0422300) [13, 14, 36] or female gametocytes (Pfg377, PF3D7_1250100) 
[13] have also been used. Insights into sex-differences in the transcriptional and 
proteomic makeup are summarized in Box 1. These immunofluorescent assays 
alleviate common problems that complicate microscopic examination but their 
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reliance on fluorescence microscopy greatly affects their deployment in the 
field. The recent development of molecular assays to quantify male and female 
gametocytes may allow more robust sex ratio determination at low gametocyte 
densities and easier application in field settings. 
New molecular techniques improve sex-ratio quantification 
Gametocyte detection has been improved in the last decade with the introduction 
and wider use of molecular detection tools. Baker et al. reported the first molecular 
assay for an indirect detection of gametocyte sexes based on in situ hybridization 
using a Pf77 RNA probe that targeted female gametocytes [31]. Assays were 
subsequently developed targeting the Pfs25 (PF3D7_1031000) transcript, which 
was considered highly specific for mature gametocytes, using qRT-PCR [37, 38] 
or QT-NASBA [39]. Whilst highly sensitive, with an estimated sensitivity around 
0.1 gametocytes per µL in 50 - 100µL blood samples, this marker (Pfs25) has 
recently been shown to be expressed predominantly by female gametocytes 
[40, 41].. Drew and Reece reported the first molecular approach to gametocyte 
Box 1. The development of male and female gametocytes
Molecular mechanisms underlying the differentiation switch towards becoming male or female 
gametocytes remain largely unknown. Candidate genes that may be associated with sex-
specific differentiation include the AP2-G2 in P. berghei [18], the Puf family of translational 
repressors in P. falciparum [97, 98] and MAPK1 and MAPK2 as potential regulators of female 
and male gametocytogenesis in P. falciparum, respectively [63]. 
Male gametocytes are terminally differentiated forms with one last task ahead; producing motile 
microgametes upon activation. Proteomic and transcriptomic data reflect this, showing 
upregulation of genes involved in nucleic acid metabolism, DNA replication and axoneme 
formation. Female gametocytes, on the other hand, contain many proteins and transcripts 
intended for longer term sustainment of post-fertilization stages including genes involved in 
protein biosynthesis, degradation, transport and metabolic activity. Another important female 
gametocyte-specific mechanism is translational repression where stored transcripts support 
cellular processes immediately after fertilization, when transcription is absent for multiple 
hours [99, 100]. The deletion of genes involved in the maintenance of translationally repressed 
mRNA transcripts such as DOZI [101] and CITH [102] in P. berghei results in full developmental 
arrest during ookinete formation although fertilization is successful. The first indication that 
translational repression is also active in P. falciparum was obtained through deletion of Puf2, 
which resulted in altered expression of genes known to be translationally repressed such as 
Pfs25 and Pfs28 [103, 104]. More recent proteomics and transcriptomics data have uncovered 
a large scale translational repression of hundreds of transcripts in P. falciparum female 
gametocytes [41].
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sex ratio determination [28] in the rodent malaria P. chabaudi using targets that 
were previously described in a proteomics study in P. berghei [42], based on 
the quantification of total gametocytes by common gametocyte gene 1 (CG1 or 
PSOP1: PCHAS_0620900) RNA, and male gametocytes by the male gametocyte-
specific gene 1 (MG1, a putative dynein heavy chain: PCHAS_0417000). Schneider 
and colleagues [40] reported the first qRT-PCR assays that quantify female and 
male gametocytes in P. falciparum through quantification of a combination of 
female- (Pfs25) and male- (Pfs230p) enriched transcripts. The higher limit of 
detection for male (1.8 male gametocytes/µL) compared to female gametocytes 
(0.3 female gametocytes/µL) in this assay, and the typical female-bias in natural 
infections, may affect the sensitivity of sex ratio determination at low gametocyte 
densities. Recently, additional male gametocyte-enriched transcripts (Pf13, 
PF3D7_1311100 and PfMGET, PF3D7_1469900) were identified that improved 
the detection limit of male gametocytes to the level comparable with female 
gametocytes [34, 43]. Details of all currently used transcripts for quantifying male 
and female gametocytes are provided in Box 2. Of note, none of the gametocyte 
markers are exclusively expressed in one sex of gametocytes [34, 43] and low 
levels of ‘gametocyte transcripts’ are also detectable in asexual stage parasites 
[44]. The latter has implications for earlier statements on the high prevalence of 
gametocytes in P. falciparum infected individuals. Whilst it remains plausible that 
(nearly) all infections produce gametocytes [6, 7], the initial wave of high asexual 
parasitaemia that is observed in clinical malaria cases may coincide with false-
positive gametocyte signals. This may result in an over-estimation of gametocyte 
prevalence at the moment of sampling, in particular in clinical malaria cases [19]. 
Sex-ratio plasticity in response to a changing environment
Recently, molecular methods to accurately sex gametocytes have been used 
to assess the first appearance of mature male and female gametocytes after 
experimental infections. Gametocyte appearance is estimated to occur 10 
days post blood stage inoculum [6] or 8.5 – 12 days after the first detection of 
asexual parasites in the peripheral blood[7], supporting previous suggestions of 
gametocyte commitment during the first erythrocytic cycle of asexual parasites 
[45, 46]. During infections, malaria parasites may respond to environmental cues 
to alter their investment into the transmission stages, reviewed in [19]. In addition 
to an overall increased investment in gametocytes [47, 48], malaria parasites may 
adjust their sex ratio to maximize the transmission success when under stress, 
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Box 2. Marker transcripts for molecular detection of male and female gametocytes 
Mature male and female gametocytes can be distinguished on the basis of light morphology 
on giemsa-stained thin smears [24], by electron microscopy [10, 105], by immunofluorescence 
assay based on female- or male-enriched proteins and monoclonal antibodies [14, 35], and by 
sex-enriched transcripts [31, 32]. Sex is not determined chromosomally, since haploid clones 
lines from a single haploid parasite can generate both male and female gametocytes [16, 106]. 
Gametocyte identification is thus solely based on quantification of stage-specific expression of 
transcripts.
Suitable targets for gametocyte diagnostics require high and stable expression of the gene in the 
stage and sex of interest. In the table below, the characteristics of the most important targets 
for gametocyte detection and quantification are summarized. Putative gametocyte sex markers 
rely on abundant transcript expression at the gametocyte stage and not in asexual blood stage, 
with expression at other life stages being irrelevant. Importantly, Pfs25 expression in asexual 
blood stage parasites is not completely absent [43, 44, 107] but approximately100,000-fold 
reduced. This estimate is similar for other reported markers [44] and hence low gametocyte 
transcript numbers may be derived from asexual parasites. Gametocyte prevalence thus needs 
to be interpreted with caution, especially at higher parasite burdens (above 1,000 parasites 
per µL). The high rate of expression of some male markers (Pf13 and Pf230p) [43] in mature 
trophozoites raises questions on the utility of these transcripts as differential sex-specific 
markers. During the dynamics of sequestration in the bone marrow and release into the 
peripheral blood, transcripts derived from these stages may be detected and could affect sex-
specific quantification. 
Differential P. falciparum [41] and P. berghei [108] gene expression studies per sex are resources 
for identification of potential candidates  and may be particularly informative when integrated 
with asexual expression levels [109]. These studies have uncovered an increasing number of 
“sex-specific transcripts” (see table below) that are, however, not sex-specific in the strict sense 
but rather sex-enriched. The commonly used (female) gametocyte marker Pfs25 shows lower 
expression in male gametocytes compared to females, ranging from 35-fold lower as detected 
by RNAseq [41] to 200-fold lower using qRT-PCR [44]. Of note, spurious transcript expression 
in asexual parasites cannot be linked to (functional) protein expression, and so the biological 
relevance of transcripts of “gametocyte genes” in asexual parasites remains unknown. For any 
mRNA target, qRT-PCR specificity can be enhanced if an intron-spanning region is targeted, 
as this ensures amplification of DNA derived from transcripts only rather than genomic DNA, 
and avoids the need for DNase treatment that may decrease sensitivity of the assay through 
RNA damage [110]. The reliability of sex ratio determination can be further enhanced by 
multiplexing targets with the above features in one assay. For example, a multiplexed qRT-
PCR that targets female gametocyte-specific (PF3D7_0630000) and total parasite (18S rRNA) 
transcripts, with no DNase treatment step, was introduced recently [111]. Similarly, a multiplex 
assay for male and female gametocytes with intron-spanning primers for both male (PfMGET) 
and female (CCp4) targets was recently proposed as a more scalable and robust approach to 
molecular gametocyte sex ratio assessments.
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such as that induced by immunity developing as the infection progresses. In an 
early observation of an individual deliberately infected with P. falciparum, the sex 
ratio changed from female biased to equal sexes over thirteen days [49]. 
Data from the avian parasite P. gallinaceum and rodent malaria P. vinckei further 
suggest that the sex ratio in Plasmodium infections varies substantially during 
the course of an infection [50, 51], possibly in response to the host’s immune 
response, anaemia and gametocyte density [50, 52, 53]. A change in concentration 
Box 2 (continued) 
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of erythropoietin, a hormone that controls erythrocyte production, causes an 
increase in the proportion of male gametocytes in P. vinckei and increases overall 
gametocyte density in P. gallinaceum [54] and P. chabaudi [55]. 
Competition between parasites of different genotype can also affect sex ratio. 
Hamilton’s theory of ‘local mate competition’ (LMC) [56] states that female-
biased sex ratios are optimal when genetically-related males compete for mates; 
the optimal sex ratio for malaria parasites depends on rate of self-fertilization 
(inbreeding rate), where sex ratio (here: proportion of male gametocytes) = (1-
f) / 2, and f is Wright’s inbreeding coefficient [57]. Where individuals are infected 
with a single or a low number of distinct parasite genotypes, inbreeding will be 
high and a female-biased sex ratio is predicted. As inbreeding levels fall with 
increased diversity of parasite genotypes within the infection, the optimal sex 
ratio will approach 0.5. In an experimental test of this theory, using the rodent 
malaria P. chabaudi where genetic diversity was adjusted deliberately, sex ratio 
became more male-biased as the number of genotypes present increased [52]. 
The effect of sex ratio on transmission success may depend on total gametocyte 
density [23]. In low-density infections, a larger investment in male gametocytes is 
favorable to increase the chance that all females are fertilized [58, 59]. As male 
gametocytes can produce up to eight microgametes upon activation, female-
biased gametocyte sex ratios contribute to a more balanced number of macro- 
and microgametes in the mosquito midgut [51].At high gametocyte densities, 
a male-biased sex ratio leads to less efficient transmission [60], favoring a less 
male-biased ratio. Recently, molecular gametocyte sex ratio assays supported the 
density-dependency of sex ratio with a higher proportion of male gametocytes 
in low-density infections [23]. The same study also suggested that quantifying 
male and female gametocytes allowed a better prediction of mosquito infection 
rates as compared to previous estimates that quantified female gametocytes only 
[61], and that the number of male gametocytes may become a limiting factor 
in determining transmission success at low densities. These findings require 
replication, but potentially have important implications for gametocyte diagnostics. 
If male gametocytes are indeed a limiting factor for transmission, diagnostics that 
quantify male gametocytes might be better indicators of transmission potential 
than female gametocyte diagnostics that are currently most widely used. 
Differences in the longevity of male and female gametocytes can also contribute 
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to sex ratio differences. Two studies have also hinted towards a shorter circulation 
time of male gametocytes upon clearance of the asexual progenitors [7, 62], 
although a third study observed identical circulation times [62]. An early study on 
induced P. vivax malaria also reported a shorter lifespan of male P. vivax gametocytes 
[49]. The different circulation time estimates may be influenced by differences in 
the ability to detect male and female gametocytes (including a lower sensitivity 
of male markers [6, 34]) but are potentially highly important to understand the 
duration of infectiousness of gametocyte carriers. There is currently no published 
evidence on differences between male and female gametocytes in maturation or 
longevity in vitro. Longitudinal studies are needed to understand the dynamics of 
male and female gametocyte densities during natural infections and their impact 
on transmissibility.
If Plasmodium can indeed alter sex ratio in response to environmental cues, an 
essential outstanding question is what governs sex allocation. Candidate genes 
that may be associated with sex-specific regulation (other than or in addition 
to AP2-G) include MAPK1 (PF3D7_1431500) as potential regulator of female 
gametocytogenesis and MAPK2 (PF3D7_1113900) as possible regulator of male 
gametocytogenesis [63]. Given the 10-12 day maturation time in P. falciparum 
infections and early commitment to the sexual stage (and plausibly gametocyte 
sex), any response to environmental triggers must involve significant “planning 
ahead” and cross-talk between potentially very low numbers of gametocytes or 
precursors. Even if environmental signals are as rapidly translated into elevated 
gametocyte conversion rates as recently shown for P. chabaudi [64], it will only 
have an effect after full maturation. One speculative option that would allow 
P. falciparum to rapidly respond to environmental triggers is the bone marrow 
reservoir for gametocytes. It is conceivable that mature gametocytes may not 
all be immediately released upon completion of maturation but may be in part 
retained for release upon environmental stimuli.
Our understanding of environmental factors that influence gametocyte 
sex-ratio is incomplete. Moreover, some of the ‘known’ stimuli for overall 
investment in gametocyte production appear uncertain when assessed with 
current methodologies [65] and thus require re-examination. Useful markers to 
examine stimuli for gametocyte production and sex allocation include parasite 
AP2-G transcripts [11, 17, 18], the host factor lysophosphatidylcholine [65] and 
molecular markers to distinguish early gametocytes (GEXP5, PF3D7_0936600 [66, 
67]), immature gametocytes (Pfs16, PF14_0748) [35], and mature gametocytes 
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of different sexes (See Table 1.). [68-70] Potential stimuli include anaemia, 
antimalarial treatment, host-immunity and co-infections with other Plasmodium 
parasites or clones [19]. 
Antimalarials influence gametocyte sex ratio 
Malaria parasites may alter their investment in asexual replication and transmission 
in response to drug pressure. Treatment with subcurative doses of antimalarial 
drugs has been shown to increase the rate of gametocytogenesis in the rodent 
malaria P. chabaudi [71] and in laboratory strains of P. falciparum [72]. P. falciparum 
parasites may respond to their proliferation state rather than directly to the 
presence of drugs. Drug pressure may thus lead to an initial increased investment 
in asexual proliferation (aimed towards survival within the infected host) until 
survival is unlikely and a terminal investment in transmission occurs [64, 73]. A 
direct effect of antimalarial drugs on a preferential production of male or female 
gametocytes has not been reported. By comparison, there is increasing evidence 
that antimalarial drugs may influence sex ratio through preferential clearance of 
gametocytes of either sex. In vitro drug tests suggest that male gametocytes are 
more sensitive to a range of antimalarial drugs compared to female gametocytes, 
with impaired male gametocyte fitness (reduction in exflagellation) at drug 
concentrations that do not affect female gametocyte fitness (as measured by 
activation into gametes) [20]. Antifolates, for example, may disproportionally 
affect males by inhibiting the folate-mediated pyrimidine synthesis required 
for DNA replication during exflagellation [20]. Although a sex-specific effect of 
antimalarial drugs has been proposed as explanation for the early sterilizing effect 
of transmission-blocking antimalarials [74], gametocyte sex ratio assessments are 
not commonly incorporated in antimalarial drug efficacy clinical trials. Despite 
initial reports of a reduced duration of male gametocyte carriage [75], and a 
relative decrease in proportion of male gametocytes [76] following artemisinin-
combination treatment (ACT), no obvious pattern on a sex-specific effect of ACT 
emerges when all available data is examined (Figure 2). On the other hand, most 
available (microscopy-based) data suggest that treatment with non-ACTs (such 
as sulphadoxine-pyrimethamine, amodiaquine and chloroquine) results in a male 
biased sex ratio shortly after treatment [77-79] (Figure 2). Whilst a single trial with 
molecular gametocyte sexing tools did not confirm this effect for sulphadoxine-
pyrimethamine plus amodiaquine [62], it is intriguing to consider if this explains 
earlier observations on enhanced infectivity early after treatment with non-ACTs 
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Figure 2. Forest plot on proportion of male gametocytes before and after treatment. 
This plot summarizes available clinical trial data on the effect of antimalarials on gametocyte sex 
ratio. Indicated are the proportion of gametocytes that were male before (open symbols) and after 
treatment (closed symbols, at day 7 post-treatment; if earlier, indicated with asterisks). Study drugs 
are indicated on the y axis and grouped by non-artemisinin-based combination therapies (non-
ACTs), ACTs and drug combinations with a gametocytocidal compound. Blue symbols indicate 
a shift towards males and red indicates a shift towards more females surviving; based on non-
overlapping confidence intervals. In most cases estimates indicate the mean and 95% confidence 
interval; for two studies [34, 62] it is median and interquartile range. AL, Artemether-lumefantrine; 
AQ, Amodiaquine; AS, Artesunate; COT, Cotrimoxazole; CQ, Chloroquine; DP, Dihydroartemisinin-
piperaquine; MQ, Mefloquine; P, Probenecid; PQ, Primaquine; PS, Pyrimethamine–sulfadoxine; SP, 
Sulfalene–pyrimethamine.
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[80]. Recent evidence suggests that adding a single dose of the gametocytocidal 
drug primaquine to ACT is associated with male-biased sex ratios in the first 14 days 
after treatment, followed by a normalization to a female-biased ratio [34, 62] that 
may be a consequence of gametocyte release, ongoing gametocyte production 
or a longer circulation time of female gametocytes. The most pronounced sex-
specific effect may be exerted by the gametocytocidal drug methylene blue that 
appears to preferentially clear male gametocytes [62, 81, 82]. 
One important outstanding question is whether transmission potential is 
predictable after treatment based on gametocyte density and sex-ratio or whether 
mosquito feeding assays remain essential to predict transmission potential 
after treatment [74, 83]. The strong association between gametocyte density 
and mosquito infection rates that is observed before treatment [23, 84] may be 
retained [62, 85] or lost after treatment [84]. If the quantification of gametocyte 
sex-ratio allows mosquito infection rates to be predicted with acceptable precision, 
this may obviate the need for mosquito feeding assays in antimalarial drug trials.
Another scenario is that drugs may sterilize gametocytes, either of both sexes or 
preferentially affecting one sex, without immediately affecting their circulation 
time. Under this scenario mosquito transmission assays will continue to be 
essential to estimate the effects of antimalarial drugs on transmission potential.
Concluding remarks and future perspectives
The transmission of P. falciparum to mosquitoes represents a developmental 
bottleneck in terms of parasite numbers; at the same time it is a very efficient 
process that may even increase in efficiency once transmission intensity declines 
[86]. For successful fertilization in the mosquito midgut, sufficient numbers of 
male and female gametocytes need to be generated during infections. Quantifying 
both male and female gametocytes therefore plausibly allows a better prediction 
of infectivity than the total gametocyte biomass or simple measurement of (the 
more abundant) female gametocytes [23]. Quantifying the densities of male and 
female gametocytes may also assist in the evaluation of the transmission-blocking 
properties of antimalarial drugs but at present cannot replace mosquito feeding 
assays to provide definitive evidence of post-treatment transmission potential 
(see Outstanding Questions). Changes in total parasite density or gametocyte 
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density by antimalarial drugs or other environmental factors may promote 
malaria parasites to adjust their investment in transmission stages; this may be by 
increasing commitment to gametocytes or by increasing the proportion of male 
gametocytes to maximize transmission success [23]. Whilst of clear value in this 
respect, previously published assessments of gametocyte sex ratio are affected 
by the limited sensitivity of microscopy for gametocyte detection and sexing. 
With the recent development of molecular tools to enumerate male and female 
gametocytes, presumed environmental stimuli for sex ratio adjustment should 
be reconsidered. For such studies to provide reliable estimates, it is essential 
to acknowledge the presence of low-levels of male and female gametocyte 
transcripts in both sexes and in asexual parasites, which necessitates a careful 
interpretation of gametocyte prevalence estimates in samples from patients with 
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Table 1. Summary of studies that evaluated sex ratio in natural infections
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1 Inbreeding coefficients calculated directly from oocyst selfing rates from mosquitoes.
2 Inbreeding coefficients calculated from allele frequencies in blood stage infections, but sex ratios not 
determined in these patients. Patients were symptomatic children.
3 Inbreeding coefficients calculated from allele frequencies in blood stage infections, but sex ratios not 
determined in these patients. Patients were symptomatic children and adults.




Controlled human malaria infection (CHMI): Deliberate infection of a healthy non-infected 
human volunteer with malaria under highly standardized conditions. Infection happens 
either by intravenous inoculation of Plasmodium -infected erythrocytes or through the bite of 
sporozoite-infected mosquitoes. Upon reaching blood-stage infection, the volunteer receives 
treatment. In CHMI models aiming to study gametocyte development, treatment aims to 
eliminate asexual parasite replication while allowing gametocytes to develop and mature.  
Gamete: sexually dimorphic parasite forms that develop from gametocytes activating in the 
mosquito gut. Female gametocytes give rise to a single female gamete (macrogamete), male 
gametocytes give rise to up to 8 motile microgametes; each female gamete may be fertilised 
by a male microgamete.
Gametocyte: the sexual stage malaria parasite capable of reproduction in the mosquito. 
Female and male gametocytes circulate in the human peripheral blood, where they may be 
ingested by blood-feeding Anopheles mosquitoes and continue sexual development (see 
Gametes).
Mosquito feeding assay: assay to determine the infectiousness of Plasmodium gametocytes 
to Anopheles mosquitoes. Mosquito feeding assay may refer to assays in which mosquitoes are 
allowed to feed on the patient’s blood (skin feeding or direct membrane feeding assay after 
venous blood was drawn) or on cultured gametocytes (standard membrane feeding assay).
Proportion of male gametocytes: The proportion or percentage of all gametocytes that is 
male (    male gametocytes        )
Proteomics: studies that capture the entirety of proteins of a cell or organism, often at a 
certain life stage. Proteomics is usually based on mass spectrometry. 
Schizogony/erythrocytic schizogony: Creation of on average 16-32 merozoites in an 
infected red blood cell during schizont stage of asexual replication. Schizogony is a rapid 
process in P. falciparum (~48h), and should not be confused with liver-stage (exoerythrocytic) 
schizogony in hepatocytes which takes 6-7 days and produces thousands of merozoites.
Sex determination: used to describe the “decision” to become either a male or female 
gametocyte, plausibly determined at the same time when sexual commitment happens.
Sex ratio: The ratio of male to female gametocytes ( male gametocytes  ). This term is used 
inconsistently in literature, referring to either sex, dependent on context. In the current review, 
we instead use proportion of male gametocytes.
Sexual commitment: The route to the differentiation into a gametocyte, thereby leaving the 
asexual replication cycle. The exact timing of commitment is not entirely understood, but all 
merozoites derived from one committed schizont will develop into gametocytes of one sex.
Transcriptomics: studies that capture the entirety of transcripts of a cell or organism, often at 
a certain life stage. Transcriptomics is usually based on microarrays or RNA sequencing.
Translational repression: A phenomenon where mRNA transcripts are not (yet) translated 
into proteins but accumulated and protected from degradation. Stored transcripts frequently 
support cellular processes immediately after fertilization when translation is needed but 
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Abstract 
Malaria parasite transmission to mosquitoes relies on the uptake of sexual stage 
parasites during a blood meal and subsequent formation of oocysts on the 
mosquito midgut wall. Transmission-blocking vaccines (TBVs) and monoclonal 
antibodies (mAbs) target sexual stage antigens to interrupt human-to-mosquito 
transmission and may form important tools for malaria elimination. Although 
most epitopes of these antigens are considered highly conserved, little is known 
about the impact of natural genetic diversity on the functional activity of 
transmission-blocking antibodies. Here we measured the efficacy of three mAbs 
against leading TBV candidates (Pfs48/45, Pfs25 and Pfs230) in transmission 
assays with parasites from naturally infected donors compared to their efficacy 
against the strain they were raised against (NF54). Transmission-reducing activity 
(TRA) was measured as reduction in mean oocyst intensity. mAb 45.1 (α-Pfs48/45) 
and mAb 4B7 (α-Pfs25) reduced transmission of field parasites from almost all 
donors with IC80 values similar to NF54. Sequencing of oocysts that survived high 
mAb concentrations did not suggest enrichment of escape genotypes. mAb 2A2 
(α-Pfs230) only reduced transmission of parasites from a minority of the donors, 
suggesting that it targets a non-conserved epitope. Using six lab-adapted strains, 
we revealed that mutations in one Pfs230 domain correlate with mAb gamete 
surface binding and functional TRA. Our findings demonstrate that, despite 
the conserved nature of sexual stage antigens, minor sequence variation can 
significantly impact the efficacy of transmission-blocking mAbs. Since mAb 45.1 
shows high potency against genetically diverse strains, our findings support its 
further clinical development and may inform Pfs48/45 vaccine design.
Keywords
Malaria, Plasmodium falciparum, transmission-blocking, monoclonal antibodies, 
genetic diversity
Significance statement 
Current malaria control tools are considered insufficient to eliminate malaria from 
most regions, in part because of the high efficiency of parasite transmission. 
There is a clear need for novel transmission-blocking intervention tools that are 
hypothesized to benefit from the conserved nature of sexual stage antigens. 
Monoclonal antibodies (mAbs) can target sexual stage parasites and prevent 
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infection of mosquitoes. This study is the first to test the efficacy of three 
transmission-blocking mAbs against patient-derived parasites in field settings. We 
show that the potency of one mAb is strongly affected by genetic diversity while 
two other mAbs block transmission of naturally circulating parasites efficiently. 
One of these is a lead transmission-blocking mAb candidate and our data support 





Malaria, caused by the unicellular parasite Plasmodium spp., continues to cause 
high mortality and morbidity worldwide (1). Current tools, while demonstrating 
great impact, are thought to be insufficient to eliminate malaria from all regions. 
One tremendous challenge for malaria control and elimination is the efficient 
spread of malaria to mosquitoes that starts with the uptake of circulating sexual 
stage parasites, gametocytes, by the mosquito vector during a blood meal on an 
infected individual. In the mosquito midgut gametocytes egress from the host 
red blood cells and develop into gametes. Male gametocytes produce up to eight 
motile microgametes upon exflagellation and female gametocytes develop into one 
immotile macrogamete. Zygotes are formed upon fertilization of a macrogamete 
by a microgamete (2, 3). The zygote develops into a motile ookinete that is able 
to traverse the midgut wall to establish an oocyst (4). After differentiation and 
replication inside the oocyst, parasites are released as sporozoites that migrate to 
the salivary glands and render the mosquito infectious. 
Transmission-blocking vaccines (TBVs) aim to induce antibodies that are taken 
up by the mosquito vector together with the infectious blood meal containing 
gametocytes. In the mosquito midgut these antibodies bind to surface antigens 
on sexual stage parasites and thereby interfere with sexual development. Three 
sexual stage antigens are currently under clinical development and are leading TBV 
candidates: Pfs48/45, Pfs230 and Pfs25. Pfs48/45 and Pfs230 are expressed on the 
surface of gametes and antibodies targeting these antigens prevent fertilization 
(5-8). Antibodies against Pfs25 target zygotes and ookinetes, and prevent oocyst 
formation (5, 7, 8). Development of these vaccine candidates has been hampered 
by challenges with recombinant protein expression and replication of pre-clinical 
successes. The first versions of Pfs25-based vaccines have been tested in both 
naïve healthy adults and in malaria-exposed individuals (9-12). Recently, Pfs230-
based vaccines have also entered phase I studies (clinicaltrials.gov: NCT02334462 
and NCT02942277) whilst the first human trials with vaccines targeting Pfs48/45 
are foreseen in the coming years. 
While the development of a highly effective TBV formulation is still challenging, 
a panel of potent monoclonal antibodies (mAbs) targeting these antigens is 
readily available. These have been isolated from immunized rodents and block 
development of cultured parasites in in vitro standard membrane feeding assays 
(SMFA) (13). These mAbs provide insight in protective epitopes and as such may 
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inform vaccine design and development (14). In addition, passive immunization 
with mAbs can form an alternative immunization strategy that conveys predictable 
high-level protection. Fc modifications that extend the serum half-life of IgGs (15) 
make it conceivable that efficacious concentrations of mAbs can be sustained for 
periods that are sufficiently long to support malaria elimination initiatives, contain 
outbreaks or span seasonal peaks of transmission. 
Given the genetic diversity of parasites in endemic settings, cross-strain protection 
is crucial for the efficacy of both active and passive immunization strategies. 
Asexual stage antigens in particular are highly polymorphic and vaccines targeting 
these antigens face challenges to induce cross-strain protection (16). The general 
consensus is that sexual stage antigens are well conserved (SI appendix, Fig. S1); 
natural genetic variation may thus have limited impact on transmission-blocking 
vaccines and antibody efficacy. Nevertheless, genetic variation has been observed, 
especially in Pfs230 (17). Given their increasing prominence in malaria vaccine 
development, it is both timely and important to assess whether active and passive 
immunization strategies are likely to encounter challenges due to genetic diversity. 
Here we compared the efficacy of mAbs targeting Pfs48/45, Pfs230 and Pfs25 in 
membrane feeding assays against cultured parasite strains and parasites derived 
from naturally infected gametocyte carriers in Cameroon and Burkina Faso. 
Results
Three mAbs strongly reduce transmission of reference strain NF54
Transmission-reducing activity (TRA) was determined by SMFA for three mAbs: 
45.1 (α-Pfs48/45) (18), 2A2 (α-Pfs230) (19, 20) and 4B7 (α-Pfs25) (21) that were 
raised against P. falciparum NF54. Cultured NF54 parasites were mixed with serial 
dilutions of mAbs and fed to Anopheles stephensi mosquitoes. Oocysts were 
counted and TRA was calculated as the mean decrease in number of oocysts per 
mosquito (intensity) compared to negative controls from the same experiment. 
In SMFA experiments, reductions in oocyst intensity (rather than prevalence) are 
the most robust and informative read-out (22). All three mAbs showed high TRA 
against the homologous strain NF54 (Fig. 1 A-C). We fitted linear models to the 
TRA data and estimated mAb concentrations needed to achieve 80% reduction in 
mean oocyst intensity (IC80), a consensus minimum level of TRA to warrant further 
pre-clinical development (23). mAbs 45.1 and 2A2 reduced infection intensity 
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in mosquitoes with an IC
80
 of 1.8 µg/mL [95% credible intervals: 1.4, 2.2] and 
1.9 µg/mL [1.2, 3.5] respectively, while mAb 4B7 was approximately 16-fold less 
potent (IC
80
 = 30.7 µg/mL, [20.7, 48.9]). Complete blocking (no oocysts in any 
mosquitoes) was achieved by mAb 45.1 at 15 µg/mL in 9/11 experiments, and by 
mAb 2A2 at >15 µg/mL in 2/3 experiments. In contrast, mAb 4B7 did not achieve 
complete blocking at >94 µg/mL in any of the experiments (n=5).
Two mAbs reduce transmission in field settings 
We then tested the efficacy of monoclonal antibodies in direct membrane feeding 
assay (DMFA) experiments with blood from naturally infected gametocyte carriers 
in Cameroon and Burkina Faso. 
Compared to SMFA, these DMFA experiments more closely resemble natural 
transmission conditions as they cover variation in gametocyte densities, 
genetically diverse strains and potentially multiclonal infections. Gametocyte 
densities were determined for the donors from Burkina Faso and ranged from 
16 to 504 gametocytes/ µL (median:52; SI appendix Table S1). Multiplicity of 
infection was determined by AMA1 sequencing for a subset of donors; 12/13 
donors carried multiple P. falciparum clones (SI appendix Table S1). Naturally 
acquired antibodies were removed by serum replacement and mAbs were added 
in various concentrations before feeding to An. coluzzii mosquitoes. At 94 µg/mL 
mAb 4B7 oocyst intensity was reduced by more than 80% in 35/42 of donors and 
in all (51/51) of donors at 15 µg/mL mAb 45.1. In contrast, at 15 µg/mL mAb 2A2 
80% reduction was only achieved in a minority of the donors (2/9) (Fig. 2). Oocyst 
prevalence (i.e. the proportion of mosquitoes that became infected) was reduced 
by more than 80% after addition of 94 µg/mL mAb 4B7 for 12/39 of donors, 
for all donors (51/51) with 15 µg/mL of mAb 45.1 and for 1/9 of donors with 15 
µg/mL mAb 2A2 (SI appendix, Fig. S2). We observed comparable IC80 values for 
SMFA and DMFA experiments with mAb 4B7 (Fig. 1 A,D) and 45.1 (Fig. 1 B,E), 
demonstrating that these two antibodies reduce transmission of the reference 
strain and field strains equally well. However, for mAb 2A2 there was a clear 
discrepancy between SMFA and DMFA; while mAb 2A2 had an IC
80
 of 1.9 µg/mL 
in SMFA, it showed low TRA at 15 µg/mL in DMFA for most donors with values 
ranging from -207.5% to 100% (median 72%) (Fig. 1F). We therefore suspected 
that many patient-derived blood samples contained parasite strains that were not 
sensitive to mAb 2A2. 
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Figure 1. Comparison of transmission-reducing activity of monoclonal antibodies against 
lab-adapted and field strains. (A-C) Standard membrane feeding assays (SMFA) were perfor-
med with cultured P. falciparum NF54 parasites and An. stephensi mosquitoes. Monoclonal 
antibodies (mAbs) 4B7 (Pfs25, A), 45.1 (Pfs48/45, B) and 2A2 (Pfs230, C) were added at indicated 
concentrations to cultured NF54 parasites. Thin grey lines connect observations from individual 
feeding experiments with multiple mAb concentrations. The green line represents the overall 
fit from linear regression starting at the intercept (0% TRA at 0 µg/ml). Shaded area represents 
95% credible intervals of the fit. mAb concentrations that were not tested in direct membrane 
feeding assays are omitted from the overall fit (B, open circles). (D-F) Direct membrane feeding 
assays (DMFA) were carried out in Burkina Faso (red) and Cameroon (cyan). Thin grey lines connect 
observations from individual patients. mAbs 4B7 (Pfs25, D), 45.1 (Pfs48/45, E) and 2A2 (Pfs230, 
F) were added at indicated concentrations to venous blood samples. For mAb 2A2 (Pfs230), 
DMFA was only carried out in Burkina Faso, with two concentrations per donor. The cyan and 
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Genetic variation affects transmission blocking efficacy of Pfs230 mAb 2A2
To further investigate the impact of genetic variation on the efficacy of mAb 2A2, 
SMFA experiments with several lab-adapted parasite strains were performed. 
SMFAs with six P. falciparum strains demonstrated variation in antibody efficacy 
of mAb 2A2 (Fig. 3A) in line with the observed variation in the DMFA (Fig. 1F). 
The tested parasite strains can be broadly divided in sensitive, partially sensitive 
and non-sensitive to mAb 2A2. Transmission of the reference strain NF54 was 
effectively blocked, while for NF135 and NF183 substantially higher concentrations 
were needed to achieve >80% TRA (Fig. 3A). Strains NF175, NF176 and NF149 
were not sensitive to mAb 2A2, even at the highest antibody concentrations 
tested. 
red line represent the overall fit from linear regression starting at the intercept (0% TRA at 0 µg/
ml). Shaded area represents 95% credible intervals of the fit. The mAb concentration is shown 
on the x-axis (square root-transformed). The ratio of oocyst intensity in control conditions over 
antibody test conditions is shown on the left y-axis and corresponding transmission-reducing 
activity (TRA) on the right y-axis. An oocyst ratio of 5 equals 80% TRA, which is indicated by a 
dashed horizontal line. Calculated IC
80
 values are shown in graphs, with 95% credible intervals 
shown between brackets.
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Figure 2. Stratified transmission-reducing activity of three different monoclonal anti-
bodies in direct membrane feeding assays on naturally infected gametocyte carriers. The 
concentration of (A) monoclonal antibody (mAb) 4B7 (Pfs25), (B) mAb 45.1 (Pfs48/45), (C) mAb 
2A2 (Pfs230) in the feeder is indicated below bars. Transmission-reducing activity (TRA) was 
quantified as the reduction in mean oocyst intensity between antibody control and mAb condition 
for each donor. Complete transmission-reducing (>99 % TRA) is depicted in dark green and 
strong reduction (80-99 % TRA) in bright green. All donors with >1 oocyst/mosquito in antibody 
control condition (i.e. successful feeds) were included. mAbs 4B7 and 45.1 were tested at two 
sites (Burkina Faso and Cameroon) and mAb 2A2 was only tested in Burkina Faso. DMFA: Direct 
Membrane Feeding Assays.
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Binding experiments in which female gametes were incubated with mAb 2A2 
demonstrated a similar heterogeneity in antibody binding to parasite strains 
(Fig. 3B and SI appendix, Fig. S3). Strong reactivity of the monoclonal antibody 
with native protein on the gamete surface of NF54 parasites was observed, even 
at a low concentration of 0.2 µg/mL (SI appendix, Fig. S3). Reactivity with the 
Figure 3. Transmission-reducing activity of monoclonal antibody 2A2 (Pfs230) is strain 
dependent. (A) Transmission-reducing activity (TRA) of monoclonal antibody (mAb) 2A2 
in standard membrane feeding assays with six lab-adapted parasite strains from different 
geographical regions that were fed to An. stephensi mosquitoes. Lines represent the fitted linear 
models and shaded areas the 95% credible intervals. IC
80 
values are shown with 95% credible 
intervals between brackets. For strains NF175 and NF176 no meaningful IC
80 
values of mAb 2A2 
could be obtained due to very low efficacy.
 
(B) Female gamete surface immunofluorescent assay 
using lab-adapted parasite strains incubated with 25 µg/mL of mAb 2A2 or serum from mice that 
were immunized with a fragment of Pfs230 (Pro+I, amino acids 443-736). Note that NF176 was 
incubated with 125 µg/mL mAb 2A2 (indicated with red asterisk). White arrows in bright field 
images indicate activated female gametes. Scale bars represent 10µm. (C) Amino acid sequence 
alignment of Pfs230 domain IV (amino acids 1134-1268) of lab-adapted parasite strains. Non-
synonymous single nucleotide polymorphisms (SNPs) encoded amino acids are specified and 
invariant amino acids are shown as dots. (D) Surface model of Pfs230 domain IV, based on the 
crystal structure of Pf41 (Pf3D7_0404900; PDB id: 4YS4), highlighting amino acids that vary 
among tested strains. Histidine 1159 (H1159) is mutated to aspartate in all strains that are not 
sensitive to mAb 2A2, and is highlighted in red. Other amino acid variants are shown in blue. 
Histidine 1180 (H1180) is located in a non-structured loop which is presented as a dashed line.
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surface of NF135 and NF183 gametes was observed at 25 µg/mL (Fig. 3B), but 
not at concentrations below 1 µg/mL (SI appendix, Fig. S3). Strikingly, no antibody 
reactivity was observed with strains NF175, NF176 and NF149 (Fig. 3B). Binding 
of mAb 2A2 is thus in line with its TRA in SMFA. The observed differences in 
antibody binding were not the result of variation in Pfs230 antigen abundance 
as demonstrated by binding experiments with polyclonal anti-Pfs230 mice serum 
(Fig. 3B), suggesting that polymorphisms affect binding and thereby cause differ-
ences in functional activity. 
The Pfs230 domain that is targeted by mAb 2A2 is currently not known. In 
western blots, mAb 2A2 did not recognize recombinantly expressed fusion of 
Pro-domain and Domain I, whilst it did recognize Pfs230 in gametocyte extract 
(SI appendix, Fig. S4). We explored Pfs230 sequence data to identify the antibody 
binding site. We had full genome sequences available for three of the strains and 
full length Pfs230 gene sequences revealed five domains that contain unique 
non-synonymous single nucleotide polymorphisms (SNPs) for NF175 that are not 
present in NF54 and NF135 (SI appendix, Fig. S5). Sequencing of these five domains 
in the other three strains indicated that domain IV contains the presumed binding 
site of mAb 2A2, since this is the only domain that contains non-synonymous 
SNPs in all three non-sensitive strains (NF149, NF175 and NF176) that are absent 
in the sensitive strains (Fig. 3C and SI appendix, Fig. S6). One non-synonymous 
SNP, resulting in an H1159D mutation, is unique to non-sensitive strains, 
suggesting that this residue could be critical for antibody binding. However, other 
identified non-synonymous SNPs may further affect binding, explaining the lower 
reactivity against NF135 and NF183 compared to NF54. A 3D model of domain 
IV revealed that most of these non-synonymous SNP-encoded amino acids are in 
close proximity to each other and it is therefore plausible that several are located 
in the mAb 2A2 binding site (Fig 3D). 
The identified SNPs in domain IV are found in parasite strains from all 
geographical regions (24) indicating no geographical fixation (SI appendix, Fig. S7). 
Analysis of all known non-synonymous SNPs in Pfs230 as reported by PlasmoDB 
v46 demonstrates that domain IV is the most polymorphic region of the protein 
(SI appendix, Fig. S8). Altogether, our data strongly suggest that domain IV is 
the binding domain of mAb 2A2 and that amino acid mutations affect antibody 
binding and thereby efficacy. 
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Frequency of non-synonymous SNPs is not associated with antibody 
pressure
Based on variation in activity of mAb 2A2 in SMFA and DMFA, we hypothesized 
that oocysts that formed despite high concentrations of mAb were more likely to 
contain non-sensitive gene variants. 
We therefore extracted DNA from single oocysts that formed in mosquitoes that 
fed on gametocytes in the presence of high mAb concentrations and sequenced 
the targeted domains. Oocyst DNA was also sequenced from control samples 
without test antibodies. We did not find non-synonymous SNPs in Pfs25 in oocysts 
from both the antibody and control condition (Fig. 4A and SI appendix Table S2). 
Five non-synonymous SNPs have previously been reported in the 6C domain of 
Pfs48/45, which is targeted by mAb 45.1 (PlasmoDB.org v46 (25)). We detected 
three of these among the sequenced oocysts (Fig. 4B and SI appendix Table S3). The 
most frequent amino acid change (L314I), with a reported minor allele frequency 
Figure 4. Genotypes of single oocysts that formed in the presence of high concentrations 
of monoclonal antibodies. Oocyst genotypes from direct membrane feeding experiments 
with high concentrations of mAb 4B7 (Pfs25), mAb 45.1 (Pfs48/45) and mAb 2A2 (Pfs230) and 
from an antibody control condition were determined. The sequences were compared to the NF54 
reference strain to identify non-synonymous single nucleotide polymorphisms (SNPs). Regions 
that were analyzed were full length Pfs25, 6C-domain of Pfs48/45 and Domain IV of Pfs230. 
Only oocysts from Burkina Faso were available and included in this analysis. Single oocysts were 
not available for all donors or conditions, the ‘n’ represents the number of oocysts analysed per 
condition with in brackets the number of donors. The raw data of this figure can be found in the 
supplementary material (SI appendix, Table S2, 3 & 4). 
*: SNPs L314I and V304D; **: SNPs L314I, V304D and S322N.
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of 40%, was present in 13/14 oocysts isolated from mosquitoes that received 
a blood meal with high mAb 45.1 concentrations and in 9/13 antibody control 
oocysts. All three non-synonymous SNPs are distal to the previously characterized 
binding site of mAb 45.1 and thus unlikely to affect binding (SI appendix, Fig. S9). 
A minority of oocysts contained the NF54 sequence (1/14 high mAb oocysts and 
3/13 antibody control oocysts) (Fig. 4B). For some donors we sequenced multiple 
oocysts and obtained more than one unique sequence, as could be expected from 
multiclonal infections. 
For Pfs230, we examined the sequence of domain IV which we identified as the 
likely target of mAb 2A2. No exact NF54 reference sequence was observed. Two 
to eight non-synonymous SNPs were detected in every oocyst examined (n=15 for 
15 µg/mL mAb 2A2 and n=16 for control) (Fig. 4C, SI appendix Table S4). At three 
positions (amino acid mutations H1180Y, Y1194S and Q1250K), NF54 carries the 
minor allele while most oocysts and all five analyzed lab-adapted strains carry the 
major allele (Fig. 2C). The eight non-synonymous SNPs observed in the oocysts 
were reported before and exact combinations of these SNPs for each oocyst are 
diverse (SI appendix, Table S6). Five oocysts were identical to the NF135 genotype, 
but none of the other 31 oocysts matched with any of our lab strains. No clear 
difference was observed in number or combination of non-synonymous SNPs 
in oocysts that appeared at high mAb 2A2 concentration compared to control 
condition.
Discussion
One of the major hurdles in malaria vaccine and antibody development is genetic 
variation across Plasmodium strains. Since monoclonal antibodies target single 
epitopes, they are particularly vulnerable to polymorphisms. Although sexual 
stage antigens are more conserved than asexual stage antigens, it is unknown 
whether transmission-blocking antibodies indeed provide cross-strain protection. 
In in vitro experiments with P. falciparum strains and ex vivo assessments of mAb 
potency against naturally acquired gametocytes, we demonstrate considerable 
variation in functional activity between three potent transmission-blocking mAbs 
that target antigens that are currently considered for vaccine development. 
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mAbs are now increasingly considered as interventions for malaria (26, 27). 
mAbs that block transmission to mosquitoes may be considered in areas aiming 
for the elimination of (drug-resistant) malaria and areas characterized by short 
seasonal malaria transmission. We evaluated the potency of three established 
transmission-blocking mAbs against naturally acquired P. falciparum strains in 
Cameroon and Burkina Faso and compared to the potency against the strain 
they were raised against (NF54). mAb 45.1 showed similar potency in field-based 
DMFA compared to SMFA with NF54, demonstrating that it efficiently blocks 
genetically diverse parasite strains and multiclonal infections. While the overall 
potency of mAb 45.1 was similar, we did observe more oocysts at high mAb 
concentrations in DMFA than in SMFA (Fig. 1B and E). Since many of our donors 
carried multiclonal P. falciparum infections, introduction of the mAb could result in 
reduced transmission but not full blocking activity if at least one of the circulating 
clones is resistant. We therefore sequenced the Pfs48/45-6C locus of single 
oocysts that appeared at high concentrations of mAb 45.1 to determine whether 
these are enriched for certain parasite genotypes as compared to control feeds. 
Although the number of oocysts that were available was too low for statistical 
comparison we observed no clear enrichment of ‘escape’ variants (Fig. 4B). In 
total we identified three previously described SNPs (28), all of which are outside 
the mAb 45.1 binding site and thus unlikely to abrogate binding (SI appendix, 
Fig. S9). Moreover, at high mAb 45.1 concentration we identified one oocyst that 
had an identical sequence of the 6C domain as NF54. Taken together, it seems 
unlikely that parasites escape antibody pressure due to polymorphisms in the 6C 
domain. Possible explanations for the appearance of oocysts at high mAb 45.1 
concentrations could be increased fitness of naturally circulating gametocytes 
compared to in vitro cultured gametocytes or difference in mosquito species used 
in DMFA and SMFA (29). mAb 4B7, although with considerably lower potency, 
also blocked transmission of genetically diverse parasite strains in DMFA, as was 
previously suggested for another Pfs25-targeting mAb (30). 
In contrast, the Pfs230 targeting mAb 2A2 efficiently blocked transmission of 
the strain it was raised against but failed to block transmission of gametocytes 
from most gametocyte donors tested. This contrasts with findings with polyclonal 
antibodies (30, 31) and strongly suggests that genetic variation in the Pfs230 
locus of circulating gametocytes affects the efficacy of this mAb. Using six lab-
adapted strains from geographically distinct locations we demonstrated that mAb 
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2A2 did not bind to the gamete surface of certain strains and that binding was in 
line with functional TRA. The target epitope of mAb 2A2 is currently unknown. 
mAb 2A2 did not recognize a properly folded recombinant protein that covers 
domain I and the Pro-domain (SI appendix, Fig. S4); sequence data from our six 
lab-adapted strains highlighted domain IV of Pfs230, the domain with the highest 
SNP density of all Pfs230 domains (SI appendix, Fig. S8), as plausible target. 
Importantly, many immunogenicity studies with recombinant Pfs230 fragments 
have demonstrated that only antibodies induced against the Pro-domain and 
Domain I of Pfs230, which together encompass the leading vaccine construct 
D1M (32), block transmission. Our data strongly suggest that another domain 
of Pfs230 can also be the target of potent transmission-blocking antibodies. 
Recombinant fragments covering domains outside the Pro-domain and domain 
I may have failed to induce efficacious antibodies in previous studies due to 
improper folding of recombinant immunogens. Our data support renewed efforts 
to produce properly folded Pfs230 fragments which could lead to the discovery of 
potent novel Pfs230-based vaccine candidates. 
In conclusion, we demonstrate that evaluating potency of transmission-blocking 
mAbs against field strains is important in the (pre-)clinical development process 
and for identification of potent and conserved epitopes to inform vaccine design 
and development. We tested three different monoclonal antibodies against 
three leading TB vaccine candidates. One of these, mAb 45.1, is the most potent 
transmission-blocking mAb described to date and shows potent cross-strain 
protection in our DMFA experiments. A humanized version of mAb 45.1, TB31F, is 
currently being tested in a phase I experimental medicine study (clinicaltrials.gov: 
NCT04238689). Based on our equivalent SMFA and DMFA data for mAb 45.1, it 
can be assumed that SMFA data obtained from this clinical trial will be predictive 
for field settings. Importantly, our data show that mAb 45.1 targets a conserved 
protective epitope, which may be used in the design of Pfs48/45-based vaccines 
to specifically induce antibodies against this epitope. Potent human mAbs may 
be obtained from scheduled phase I vaccination trials with Pfs48/45. Here we 
provide a framework for testing these novel mAbs against genetically diverse 
parasites to further inform design of this leading transmission-blocking vaccine 
candidate.
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Material and methods
Monoclonal antibody production
The generation of the monoclonal antibodies against Pfs48/45 (18), Pfs230 
(19, 20) and Pfs25 (21) have been described previously. Briefly, Pfs230 mAb 
2A2.2a has been derived from mice immunized with Plasmodium falciparum 
NF54 gametocyte extracts and underwent isotype switch to IgG2a as described 
previously (19, 20). The Pfs48/45 targeting mAb 85RF45.1 (IgG1) has been 
derived from rats immunized with NF54 gametocyte extracts (18). Pfs25 mAb 
4B7 (IgG1) has been derived from mice immunized with recombinant vaccinia 
virus expressing Pfs25 (21). mAb 45.1 and 2A2 antibodies were affinity purified 
from clarified hybridoma supernatant using MabSelect Xtra™ and HiTrap Protein 
G columns (GE Healthcare Life Sciences), respectively. Elution fractions containing 
the IgGs were dialyzed against PBS, concentrated and freeze-dried for storage. 
They were dissolved in distilled water before use. mAb 4B7 was a kind gift from 
PATH Malaria Vaccine Initiative. 
Lab-adapted parasite strains and culture
Plasmodium falciparum strains were isolated from malaria patients and were 
adapted to culture as described previously (33). Briefly, parasites were cultured 
in RPMI1640 medium supplemented with 10% human serum at 5% hematocrit 
in a semiautomated suspension culture system and cloned by limited dilution. 
The West-African NF54 (34), Cambodian NF135.C10 (35) and Nigerian NF175.
D5 (36) parasite strains have been described previously. Furthermore, NF149.
A3 (Southern-Asia), NF176.B8 (East-Africa) and NF183.F7 (West-Africa) were 
used in this study. The clonality and identity of parasite strains was confirmed 
using polymerase chain reaction (PCR) on glutamate-rich protein (GLURP) and 
merozoite surface proteins 1 and 2 (MSP1 and MSP2) as described previously 
(37).
Standard membrane feeding assay (SMFA)
SMFAs were performed as described previously (38). In brief, Anopheles stephensi 
mosquitoes were fed with P. falciparum mature gametocyte cultures (day 15-17) 
mixed with human serum and active human complement. Monoclonal antibodies 
were added to the gametocytes to achieve the indicated final concentrations in 
the offered blood meals. Mosquito midguts from a minimum of 20 mosquitoes 
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per condition were dissected, stained with mercurochrome and checked for the 
presence of oocysts 6-8 days after the blood meal.
Naturally infected gametocyte donors
Asymptomatic gametocyte carriers, aged 5-15 years, were enrolled in Mfoe 
district (Cameroon) and Bobo -Dioulasso (Burkina Faso). Venous blood samples 
were collected after written informed consent was obtained from participants or 
their guardian(s). Ethical approval was provided by the National Ethics Committee 
of Cameroon; Ethical Review Committee of the Ministry of Health, Burkina Faso; 
Institutional ethics review committee for health science research Bobo-Dioulasso; 
University of California, San Francisco, and London School of Hygiene and 
Tropical Medicine. Participant characteristics of these cohorts have been described 
previously (39). 
Direct membrane feeding assay (DMFA)
Patient blood containing gametocytes was collected in heparin tubes. Per tested 
condition, 500 µL of heparinized blood was centrifuged (5 minutes at 2,000 g) 
and plasma was removed, then replaced by 250 µL naïve serum or by naïve serum 
pre-mixed with monoclonal antibody, achieving the final concentrations of mAb 
in the total 500 µL volume. DMFA experiments that included testing of mAb 2A2 
were done with naïve serum containing active complement. Minifeeders were 
then filled with the mixture. Anopheles coluzzii mosquitoes were allowed to feed 
for 30 minutes and up to 50 fully fed mosquitoes were kept until dissection 
6-8 days post feeding. During dissection, infected midguts were collected and 
stored in absolute ethanol at -80°C. Subsequently, a selection of midguts were 
gradually rehydrated in distilled water and single oocysts were isolated according 
to the method described by Annan et al. (40). The single oocysts were stored in 
RNAprotect (Qiagen®, Hilden, Germany) at -80°C. 
Surface immuno-fluorescent assay (SIFA)
Cultured gametocytes (day 15-17) were activated by incubation in foetal calf 
serum (FCS) for one hour at room temperature. Cells which include gametes 
were washed with phosphate buffered saline (PBS) and incubated with mAb 
2A2 dilutions in SIFA-buffer (PBS/0.5% FCS/0.05% sodium azide). The presence 
of Pfs230 on gamete surfaces was confirmed by incubation with 1:20 dilution 
of serum from mice immunized with Pfs230 fragment Pro+I (amino acids 443-
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736) (41). Gamete preparations were washed three times with SIFA-buffer and 
incubated with 1:200 Alexa Fluor® 488 Goat Anti-Mouse IgG (H+L) (Invitrogen, 
Lot. 1907294) at a 1:200 dilution in SIFA-buffer. All incubation steps were 
performed on ice for one hour. For each antibody concentration, three individual 
gametes were imaged and representative pictures are shown. 
Pfs230 domain IV model
The sequence of domain IV (amino acids E1134 - D1268) was used to generate a 
3D model using the Fold & Function Assignment Server (FFAS) of the Godzik lab 
(42). The best hit in the PDB database (PDB1018) was Pf41 (Pf3D7_0404900; PDB 
id: 4YS4). Based on the alignment of the two sequences and the structure of Pf41, 
a model was generated using default settings (SCWRL modelling method and 
All-atom model type). Figures were generated with PyMOL (Molecular Graphics 
System Version 2.3 Schrödinger, LLC).
Target antigen sequencing 
DNA from single oocysts was isolated using phenolchloroform (PC) extraction, 
following a slightly modified protocol published by Ranford-Cartwright et al. (43). 
In brief, the oocyst and surrounding mosquito midgut material were digested 
overnight at 56°C in oocyst lysis buffer containing proteinase K. PC extraction 
was followed by isopropanol precipitation and the obtained pellet was washed 
with 70% ethanol, dried and dissolved in 20 µL H
2
O. The target sequences were 
amplified from the obtained genomic DNA by nested or semi-nested PCRs. 
In some cases, mixed signals were obtained. These were either caused by the 
presence of multiple oocysts or single oocysts that were a product of a male and 
female gamete with different genotypes. These mixed oocysts were counted as 
non-synonymous SNPs. 
For sequence analysis of Pfs230 from cultured parasite strains, genomic DNA 
was isolated from mixed parasite cultures using the QIAamp® DNA Blood Mini Kit 
(Qiagen®, Hilden, Germany). The Pfs230 gene (Domain I to VIIII) was amplified by 
PCR using PrimeSTAR GXL DNA Polymerase (TaKaRa Bio, Shiga, Japan) according 
to manufacturer’s instructions. Domains that were sequenced were selected 
based on the observed phenotypes of NF54, NF135 and NF175 in the SMFA 
and the previously available sequence data of these strains (SI appendix, Fig. 
S2). Mutations were confirmed in duplicate PCR reactions and two independent 
sequencing reads per PCR reaction. 
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Sanger sequencing was performed at BaseClear (Leiden, the Netherlands) and 
data was analyzed using Chromas Lite (Version 2.1.1, Technelysium Pty., Australia). 
Primers for amplification and sequencing are listed in the supplementary material 
(SI appendix, Table S5).
In silico sequence variation analysis
The available Pfs230 (PF3D7_0209000) protein sequences were downloaded 
from PlasmoDB (25). The domain composition as defined in Gerloff et al. (44) was 
used to calculate the density of polymorphisms per region. For the distribution 
of the polymorphisms in domain IV over various regions we used version 6 of 
the MalariaGEN Plasmodium falciparum Community Project that contains VCF 
files of 7113 sequenced strains (24). Per strain we included the most frequently 
detected variant. Nucleotide changes were translated into proteins and the 
sequence variation per region was visualized using the sequence logo generator 
WebLogo after performing a multiple sequence alignment using Clustal Omega 
(45). [WebLogo version 2.8.2 Crooks GE, Hon G, Chandonia JM, Brenner SE 
WebLogo: A sequence logo generator, Genome Research, 14:1188-1190, (2004)] 
Multiplicity of infection
Parasite material (total nucleic acids isolated from whole blood) from study 
participants was analyzed by amplicon deep sequencing of apical membrane 
antigen 1 (AMA-1). Hemi-nested PCR was used to amplify a 236 base-pair 
segment of AMA-1 using a published protocol (46). Samples were amplified 
in duplicate, indexed, pooled, and purified by bead cleaning. Sequencing was 
performed on an Illumina MiSeq platform (150bp paired-end). Data extraction, 
processing, and haplotype clustering were performed using SeekDeep (47). 
Multiplicity of infection (MOI) was calculated as the number of haplotypes present 
in both replicates of a given sample. 
Statistical analysis of the membrane feeding assay data
Transmission reducing activity was quantified as the relative reduction in oocyst 
intensity (mean oocyst count per positive mosquito) when using mAbs compared 
to the serum replacement (no antibody control) condition. We quantified 
transmission reduction as suggested by Miura et al. (48). We fitted linear models 
to the TRA data, by modelling the relationship between the (log transformed) 
ratio of the oocyst counts observed in the control and test arms and the (square 
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root transformed) mAb concentration. When oocysts with added mAb are 
completely absent or at least 200-fold lower than in the control, we assumed a 
1:200 ratio (99.5% TRA). As we assumed zero TRA (i.e. an oocyst ratio of one) 
in the absence of antibodies, we did not allow the intercept of the regression 
models to vary when fitting the models. For each antibody, we began with the 
simplest model possible, using the same slope for the DMFA and SMFA data. No 
model was fit for the DMFA data of 2A2, because of the heterogeneity of the 
results. We then developed more complicated models and examined whether 
the model fit improved. We allowed the slopes to vary for the assay used and, 
for the DMFA data, the country from which parasites were collected. We also 
included a random effect in the slope for either the donor (DMFA data) or the 
experiment (SMFA data). The regression modelling was carried out using RStan 
(49, 50), and the goodness of fit assessed via the widely applicable information 
criterion (WAIC) (51). For mAb 45.1, allowing the slopes to vary by assay and 
country slightly improved the goodness of fit. For mAb 4B7, the more complicated 
models did not out-perform the simpler model (the same average slope for all the 
data). For the results shown in Figure 1, we present model predictions from an 
ensemble of models, generated using the Akaike weight associated with each 
model (51). In the case of mAb 4B7, for example, the models for the DMFA data 
from Burkina Faso and Cameroon are nearly identical, as not much weight was 
attributed to models that contained the country-specific term. For mAb 45.1, the 
country-specific differences are more apparent but still quite small. All models 
and respective goodness of fit are summarized in the supplementary material (SI 
appendix, Table S6). The slopes of the regression models fitted to the SMFA data 
of mAb 2A2 against the lab-adapted strains are provided in the supplementary 
material (SI appendix, Table S7). SMFA and DMFA feeds were excluded from 
analysis for transmission reducing activity if control mosquitoes had on average 
less than one oocyst/mosquito or less than 30% of mosquitoes became infected, 
with the exception of SMFA data for NF149 since transmission of this line is in 
general less efficient. The raw data for DMFA and SMFA experiments can be 
found in the supplementary material (SI appendix, Table S1 and 8).
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Supplementary Files Chapter 5
Supplementary Table 1. Non-synonymous SNPs in Pfs25 in sequenced oocysts 
We detected two non-synonymous SNPs that were not reported before in any database. We 
therefore repeated the amplification and sequencing of these oocysts but retrieved NF54 reference 
sequences. These oocysts were therefore excluded from this analysis. ND: Not determined; MOI: 
Multiplicity of infection. 
 Sample ID SNPs Donor ID  mAb 4B7 MOI
    condition 
 48 None BF17.004 Control ND
 7 None BF17.006 Control ND
 13 None BF17.010 Control 10
 56 None BF17.013 Control 7
 47 None BF17.013 Control 7
 54 None BF17.014 Control ND
 52 None BF17.015 Control ND
 L07 None BF17.020 Control ND
 L14 None BF17.002 94 µg/mL 7
 L13 None BF17.002 94 µg/mL 7
 2 None BF17.002 94 µg/mL 7
 3 None BF17.002 94 µg/mL 7
 L12 None BF17.003 94 µg/mL 15
 L10 None BF17.003 94 µg/mL 15
 L16 None BF17.003 94 µg/mL 15
 5 None BF17.003 94 µg/mL 15
 6 None BF17.003 94 µg/mL 15
 8 None BF17.006 94 µg/mL ND
 9 None BF17.006 94 µg/mL ND
 L15 None BF17.007 94 µg/mL ND
 11 None BF17.007 94 µg/mL ND
 14 None BF17.010 94 µg/mL 10
 15 None BF17.010 94 µg/mL 10
 17 None BF17.015 94 µg/mL ND
 18 None BF17.016 94 µg/mL ND
 20 None BF17.016 94 µg/mL ND
 L04 None BF17.016 94 µg/mL ND
 L05 None BF17.016 94 µg/mL ND
 22 None BF17.018 94 µg/mL 12
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Supplementary Table 2. Non-synonymous SNPs in Pfs48/45-6C in sequenced oocysts
Occasionally, two different nucleotides are mentioned. These are either due to the presence of 
multiple oocysts or, single ‘mixed’ oocysts, derived from the gametes of two distinct clones present 
in the respective donor (MOI>1). These mixed signal oocysts were counted as non-synonymous 
SNPs. 
*  Sample contained two oocysts
** Sample contained three oocysts
#  Oocysts from mAb 4B7 experiment sequenced for Pfs48/45
Ref  Reference allele (3D7 and NF54)
Alt Alternative allele
MOI Multiplicity of infection
ND Not determined
  V304D L314I S322N
 Sample ID ref T, alt A ref T, alt A ref G, alt A Patient ID mAb 45.1 condition MOI
 23 T A G BF17.001 Control 3
 1 T T G BF17.001 Control 3
 3** A/T A/T A/G BF17.002 Control 7
 6** T A/T G BF17.003 Control 15
 48* T A G BF17.004 Control ND
 8 T A G BF17.004 Control # ND
 11 A/T A A/G BF17.006 Control ND
 13# T A G BF17.006 Control ND
 50 T A G BF17.006 Control ND
 49 A/T T G BF17.008 Control ND
 44 T A/T G BF17.009 Control ND
 43 T A G BF17.009 Control ND
 9 A/T A A/G BF17.004 15 µg/mL ND
 25 T A G BF17.004 15 µg/mL ND
 29 T A G BF17.011 15 µg/mL ND
 30 T A G BF17.012 15 µg/mL 3
 32 T A G BF17.015 15 µg/mL ND
 34 T A G BF17.015 15 µg/mL ND
 14 T T G BF17.016 15 µg/mL ND
 17* A/T A/T G BF17.017 15 µg/mL ND
 16* T A G BF17.017 15 µg/mL ND
 18 T A G BF17.019 15 µg/mL ND
 19 T A G BF17.019 15 µg/mL ND
 20 T A G BF17.019 15 µg/mL ND
 21* T A/T G BF17.021 15 µg/mL ND
 B07 T A/T G BF18.002 15 µg/mL 5
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Supplementary Table 4. Oligos used for amplification and sequencing of antigen loci. 
Note that for sequencing of single Pfs230 domains, the gene (domain I-XIII) was PCR amplified 
and subsequently single domains were sequenced with indicated primers.
 
 
5’-3’ sequence PCR Domain Used for  Domain
   amplified sequencing sequenced
 TTATTCTTTTAAAAATGAATAAACTTTAC Nested 1 forward Full length  
Pfs25 ATTTACATTATAAAAAAGCATACTGA Nested 1 reverse Full length  
Oocysts ATGAATAAACTTTACAGTTTGTTTCT Nested 2 forward Full length Yes Full length
 TGAAAATAGTATAAACATAATGCTTAG Nested 2 reverse Full length  
Pfs48/45
 ATGTACGTGTATTAAAATATCC Nested 1 forward 6C  
Oocysts
 GATCTTTTTACATATTTGCCG Nested 2 forward 6C Yes 6C
 TATAATAATATTGCTACAATTAGG Nested 1&2 reverse 6C  
 CATTTCAGGTTCCACCATATATAG Nested 1 forward IV  
Pfs230 GATCTTTGGCTGGACAAAATATTTG Nested 1 reverse IV  
Oocysts ACCTTTTTATTTTATGTTTGGTTG Nested 2 forward IV Yes IV
 ATCAAATGTTTTATTTACTCTTGG Nested 2 reverse IV  
 GGAGATACTGCTGTATCCGAAG Forward I – XIV Yes II 
 GATGGCTCTTGATTGAGGTTCTGG Reverse I – XIV  Yes XIII
 GATTGTAGAAGTGTATGTAGAACC   Yes II (forward)
 GAATACCACCTATATCTCCGCTA   Yes II (reverse)
Pfs230 CATTTCAGGTTCCACCATATATAG   Yes IV (forward)
Parasite GATCTTTGGCTGGACAAAATATTTG   Yes IV (reverse)
strains AGCTCCAAAATTAATGATGTCTGC   Yes VII (forward)
 CATTATCACATATGATACCAAATACT   Yes VII (reverse)
 CACTACACTACCAACTGATGGTG   Yes XII (forward)
 GGCTCCTGGTAAGATATGTTCTA   Yes XII (reverse)
 GTTGCTACTTGTGAAATTATTGATAC   Yes XIII (forward)
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Supplementary Table 5. Regression models fitted to membrane feeding data.  For each 
antigen, our starting point was a simple model, using the same mean value of the slope for all the 
data (parameter a). This parameter contains a random effect for the experiment (SMFA data) or 
the donor (DMFA). We then fitted more complicated models, allowing the slope to vary depending 
on the assay used and, in the case of the DMFA data, the country in which the experiment was 
carried out. We then assessed the goodness of fit using the widely applicable information criterion 
(WAIC), showing the disparity (∆WAIC) in the fit between each model and the best-performing 
model. The corresponding Akaike weights, indicating the weight that each model is attributed 
in the ensemble of models used to generate Figure 1. We here summarise the slopes obtained 
from the model ensemble. For mAb 4B7, the slope for the SMFA model was 0.126, and for the 
DMFA model 0.124 (both countries). For mAb 45.1, the slope for the SMFA model was 0.521, for 
the DMFA models it was 0.476 (BF) and 0.538 (CAM). For mAb 2A2, the slope is as stated in the 
table (0.510), as we did not include the DMFA data in the regression modelling carried out here, 
because only two datapoints per donor were available. SMFA: Standard Membrane Feeding assay; 
DMFA: Direct Membrane Feeding Assay; BF: Burkina Faso; CAM: Cameroon. 
Model [parameters]
One slope for all data [a]
Slope correction for the assay ([b]: 
SMFA=0, DMFA=1)
Slope correction for the country for the 
DMFA data ([d]: BF=0, CAM=1)
Slope correction for the assay ([b]: 
SMFA=0, DMFA=1), and the country for 
the DMFA data ([d]: BF=0, CAM=1)
Slope correction for the assay ([b]: 
SMFA=0, DMFA=1), and the country for 
the DMFA data ([d]: BF=0, CAM=1)
Slope correction for the country of origin 
for the DMFA data ([d]: BF=0, CAM=1)
One slope for all data [a]
Slope correction for the assay ([b]: 
SMFA=0, DMFA=1)
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Supplementary Table 6. Slopes of the regression models fitted to the standard membrane 
feeding data of monoclonal antibody 2A2 with lab-adapted parasite strains.  For NF175 
and NF176, the 95% credible intervals (CI) of the slope include zero, because of this the 80% 
inhibitory concentration presented in Figure 3 is an estimate and no credible intervals are given.
Strain Slope (95% CI)
NF54 0.51 (0.38, 0.64)
NF135 0.31 (0.22, 0.40)
NF183 0.35 (0.26, 0.45)
NF175 0.01 (0, 0.02)
NF176 0.03 (0, 0.05)
NF149 0.05 (0.02, 0.09)
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Supplementary Figure 1. Genetic variation of Plasmodium falciparum vaccine candidates 
and targets. Pre-erythrocytic stage (CSP), asexual blood stage and sexual stage targets are 
depicted. Non-synonymous, synonymous Single Nucleotide Polymorphisms (SNPs) and pre-mature 
stops (nonsense-mutations) as reported on PlasmoDB (v.46) are indicated in dark grey, light grey 
and red, respectively. All SNP counts were normalized to the length of the coding sequence.
5
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Supplementary Figure 2. Transmission-blocking activity of three different monoclonal 
antibodies in direct membrane feeding assay on naturally infected gametocyte carriers. 
The concentration of (A) monoclonal antibody (mAb) 4B7 (Pfs25), (B) mAb 45.1 (Pfs48/45), (C) 
mAb 2A2 (Pfs230) in the feeder is indicated. Transmission-blocking activity was quantified as a 
reduction in the percentage of mosquitoes with oocysts present between antibody control and 
mAb condition for each donor. Complete transmission-blocking (>99 % TBA) is depicted in dark 
petrol and moderate reduction (80-99% TBA) in cyan. All donors with >1 oocyst/mosquito and 
>30% mosquito prevalence in antibody control condition were included from two sites (Burkina 
Faso and Cameroon), except for mAb 2A2 (C) which was only tested in Burkina Faso. The 
number of distinct donor samples (n) tested for each antibody is given above bars.  DMFA: Direct 
Membrane Feeding Assay. 
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Supplementary Figure 3. Antibody binding of monoclonal antibody (mAb) 2A2 to 
the female gamete surface.  Six lab-adapted parasite strains were incubated with different 
concentrations of Pfs230 mAb 2A2 and imaged using fluorescent microscopy. White arrows in 
bright-field images indicate activated female gametes. Scale bar represent 20µm.
5
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Supplementary Figure 4. Dot blot of mAb 2A2 with recombinant Pfs230 Pro+I and 
gametocyte extract.  Serial dilutions of recombinant protein 230CMB (Pro+I, aa444-730) (1) 
and gametocyte extract were spotted on nitrocellulose membranes. After drying, the membranes 
were blocked for one hour with 5% milk in PBS. Subsequently, incubated for one hour with 5 
µg/mL mAb 2A2 or mAb 15C5 in 1% milk in PBS with 0.1% Tween20. The blots were washed 
three times with PBS with 0.1% Tween20 and incubated for one hour with 1:10,000 Goat Anti-
Mouse IRDye680RD (for mAb 2A2) (LI-COR, Cat. No. 926-68070) or Goat Anti-Human IRDye680 
(for mAb 15C5) (LI-COR, Cat. No. 926-68078). The membranes were washed 3 times with PBS 
with 0.1% Tween20 and ones with PBS before imaging on the Odyssey CLx (Li-COR). mAb 15C5 
is a conformational humanized sister mAb of the published mAb 15A4 and was a kind gift of 
MVI-Path (2). 
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Supplementary Figure 5. Schematic representation of Pfs230. Domains are indicated 
with roman numbers.  Number of non-synonymous Single Nucleotide Polymorphisms (SNPs), 
compared to the reference strains NF54, in each domain are shown for NF135 and NF175. SNPs 
that are shared by both strains are shown in the bottom row. Based on this analysis, domains 
highlighted with a red box were selected for sanger sequencing of other lab-adapted parasite 
strains (NF149, NF183 and NF176). Amino acid numbers for these domains were retrieved from 
Gerloff et al. (3). 
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Supplementary Figure 6. Amino acid sequence alignments of six lab-cultured parasite 
strains for Pfs230 domains.  Amino acid residues that differ from NF54 are specified. Domain 
boundaries were retrieved from Gerloff et al. (3). Identical amino acids are indicated by dots.
 XII 
Domain II (amino acids 731 – 886) 
NF54       GNKINGCAFLDEDEEEEKYGNQIEEDEHNEKIKMKTFFTQNIYKKNNIYPCYMKLYSGDI 60 
NF135      ............................................................ 60 
NF183      ............................................................ 60 
NF175      .................I.......................................... 60 
NF176      ............................................................ 60 
NF149      ............................................................ 60 
 
NF54       GGILFPKNIKSTTCFEEMIPYNKEIKWNKENKSLGNLVNNSVVYNKEMNAKYFNVQYVHI 120 
NF135      ............................................................ 120 
NF183      ............................................................ 120 
NF175      ............................................................ 120 
NF176      ............................................................ 120 
NF149      ................K........................................... 120      
 
NF54       PTSYKDTLNLFCSIILKEEESNLISTSYLVYVSINE 156 
NF135      .................................... 156 
NF183      .................................... 156 
NF175      .................................... 156 
NF176      .................................... 156 
NF149      .................................... 156 
 
Domain VII (amino acids 1694-1907) 
NF54       NRHVCDFSKNNLIVPESLKKKEELGGNPVNIHCYALLKPLDTLYVKCPTSKDNYEAAKVN   60 
NF135      ............................................................ 60 
NF183      ............................................................ 60 
NF175      ............................................................ 60 
NF176      ............................................................ 60 
NF149      ............................................................ 60          
 
NF54       ISENDNEYELQVISLIEKRFHNFETLESKKPGNGDVVVHNGVVDTGPVLDNSTFEKYFKN 120 
NF135      ............................................................ 120 
NF183      ..........................................L................. 120 
NF175      ............................................................ 120 
NF176      ............................................................ 120 
NF149      ............................................................ 120 
            
NF54       IKIKPDKFFEKVINEYDDTEEEKDLESILPGAIVSPMKVLKKKDPFTSYAAFVVPPIVPK 180 
NF135      ...............N............................................ 180 
NF183      ...............N........................................V... 180 
NF175      ...............N........................................V... 180 
NF176      ...............N............................................ 180 
NF149      ...............N............................................ 180 
            
NF54       DLHFKVECNNTEYKDENQYISGYNGIIHIDISNS 214 
NF135      .................................. 214 
NF183      .................................. 214 
NF175      .................................. 214 
NF176      .................................. 214 
NF149      .................................. 214 
 
Domain XII (amino acids 2664-2818) 
NF54       RNIIHGCDFLYLENQTNDAISNNNNNSYSIFTHNKNTENNLICDISLIPKTVIGIKCPNK 60 
NF135      ............................................................ 60 
NF183      ............................................................ 60 
NF175      ............................................................ 60 
NF176      ............................................................ 60 
NF149      ............................................................ 60 
         
NF54       KLNPQTCFDEVYYVKQEDVPSKTITADKYNTFSKDKIGNILKNAISINNPDEKDNTYTYL 120 
NF135      ............................................................ 120 
NF183      ............................................................ 120 
NF175      ...................................................D........ 120 
NF176      ............................................................ 120 
NF149      ............................................................ 120        
 
NF54       ILPEKFEEELIDTKKVLACTCDNKYIIHMKIEKST 155 
NF135      ................................... 155 
NF183      ................................... 155 
NF175      ................................... 155 
NF176      ................................... 155 




Domain II (amino acids 731 – 886) 
NF54       GNKINGCAFLDEDEEEEKYGNQIEEDEHNEKIKMKTFFTQNIYKKNNIYPCYMKLYSGDI 60 
NF135      ............................................................ 60 
NF183      ............................................................ 60 
NF175      .................I.......................................... 60 
NF176      ............................................................ 60 
NF149      ............................................................ 60 
 
NF54       GGILFPKNIKSTTCFEEMIPYNKEIKWNKENKSLGNLVNNSVVYNKEMNAKYFNVQYVHI 120 
NF135      ............................................................ 120 
NF183      ............................................................ 120 
NF175      ............................................................ 120 
NF176      ............................................................ 120 
NF149      ................K........................................... 120      
 
NF54       PTSYKDTLNLFCSIILKEEESNLISTSYLVYVSINE 156 
NF135      .................................... 156 
NF183      .................................... 156 
NF175      .................................... 156 
NF176      .................................... 156 
NF149      .................................... 156 
 
Domain VII (amino acids 1694-1907) 
NF54       NRHVCDFSKNNLIVPESLKKKEELGGNPVNIHCYALLKPLDTLYVKCPTSKDNYEAAKVN   60 
NF135      ............................................................ 60 
NF183      ............................................................ 60 
NF175      ............................................................ 60 
NF176      ............................................................ 60 
NF149      ............................................................ 60          
 
NF54       ISENDNEYELQVISLIEKRFHNFETLESKKPGNGDVVVHNGVVDTGPVLDNSTFEKYFKN 120 
NF135      ............................................................ 120 
NF183      ..........................................L................. 120 
NF175      ............................................................ 120 
NF176      ............................................................ 120 
NF149      ............................................................ 120 
            
NF54       IKIKPDKFFEKVINEYDDTEEEKDLESILPGAIVSPMKVLKKKDPFTSYAAFVVPPIVPK 180 
NF135      ...............N............................................ 180 
NF183      ...............N........................................V... 180 
NF175      ...............N........................................V... 180 
NF176      ...............N............................................ 180 
NF149      ...............N............................................ 180 
            
NF54       DLHFKVECNNTEYKDENQYISGYNGIIHIDISNS 214 
NF135      .................................. 214 
NF183      .................................. 214 
NF175      .................................. 214 
NF176      .................................. 214 
NF149      .................................. 214 
 
Domain XII (amino acids 2664-2818) 
NF54       RNIIHGCDFLYLENQTNDAISNNNNNSYSIFTHNKNTENNLICDISLIPKTVIGIKCPNK 60 
NF135      ............................................................ 60 
NF183      ............................................................ 60 
NF175      ............................................................ 60 
NF176      ............................................................ 60 
NF149      ............................................................ 60 
         
NF54       KLNPQTCFDEVYYVKQEDVPSKTITADKYNTFSKDKIGNILKNAISINNPDEKDNTYTYL 120 
NF135      ............................................................ 120 
NF183      ............................................................ 120 
NF175      ...................................................D........ 120 
NF176      ............................................................ 120 
NF149      ............................................................ 120        
 
NF54       ILPEKFEEELIDTKKVLACTCDNKYIIHMKIEKST 155 
NF135      ................................... 155 
NF183      ................................... 155 
NF175      ................................... 155 
NF176      ................................... 155 




Domain XIII (amino acids 2831-2979) 
NF54       GKDICKYDVTTKVATCEIIDTIDSSVLKEHHTVHYSITLSRWDKLIIKYPTNEKTHFENF 60 
NF135      .......................................L.................... 60 
NF183      .......................................L.................... 60 
NF175      ............................................................ 60 
NF176      ............................................................ 60 
NF149      .......................................L.................... 60      
 
NF54       FVNPFNLKDKVLYNYNKPINIEHILPGAITTDIYDTRTKIKQYILRIPPYVHKDIHFSLE 120 
NF135      ............................................................ 120 
NF183      ............................................................ 120 
NF175      ............................................................ 120 
NF176      ............................................................ 120 
NF149      ............................................................ 120           
 
NF54       FNNSLSLTKQNQNIIYGNVAKIFIHINQG 149 
NF135      ............................. 149 
NF183      ............................. 149 
NF175      .............N............... 149 
NF176      ............................. 149 
NF149      ............................. 149 
 
Supplementary Figure 6. Amino acid sequence alignments of six lab-cultured parasite strains for 
Pfs230 domains. Amino acid residues that differ from NF54 are specified. Domain boundaries were 
retrieved from Gerloff et al. (3). Identical amino acids are indicated by dots. 
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Supplementary Figure 7. Sequence variation Pfs230 domain IV per geographical region. 
Variation in amino acid sequence of domain IV of Pfs230 in the regions covered by the malariagen 
Pf3k project (https://www.malariagen.net/apps/pf3k/release_3/index.html). WAF: West Africa, 
EAF: East Africa, CAF: Central Africa, WSEA: Western South East Asia, ESEA: Eastern South East 
Asia, SAS: South Asia, OCE: Oceania, SAM: South America. All but eight residues (indicated by 
arrows and coloured amino acid code) are highly conserved. 
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Supplementary Figure 8. Genetic variation in the protein domains of Pfs230. Domain 
boundaries were retrieved from Gerloff et al. (3). Non-synonymous Single Nucleotide 
Polymorphisms (SNPs) as reported by PlasmoDB v46 were counted and normalized for the length 
of the respective coding sequence.
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Supplementary Figure 9. Crystal structure surface presentations of the 6C domain of 
Pfs48/45 (PDB id: 6E62). Amino acid mutations that were identified by oocyst sequencing are 
highlighted in blue. The antibody binding sites are shown in green and are based on the crystal 
structure of a Pfs48/45-6C complex with Fab 45.1 (4).
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Abstract
Plasmodium species, the causative agent of malaria, have a complex life cycle 
involving two hosts. The sporozoite life stage is characterized by an extended 
phase in the mosquito salivary glands followed by free movement and rapid 
invasion of hepatocytes in the human host. This transmission stage has been 
the subject of many transcriptomics and proteomics studies and is also targeted 
by the most advanced malaria vaccine. We applied Bayesian data integration 
to determine which proteins are not only present in sporozoites but are also 
specific to that stage. Transcriptomic and proteomic Plasmodium data sets 
from 26 studies were weighted for how representative they are for sporozoites, 
based on a carefully assembled gold standard for Plasmodium falciparum (Pf) 
proteins known to be present or absent during the sporozoite life stage. Of 5418 
Pf genes for which expression data were available at the RNA level or at the 
protein level, 1105 were identified as enriched in sporozoites and 90 specific to 
them. We show that Pf sporozoites are enriched for proteins involved in type II 
fatty acid synthesis in the apicoplast and GPI anchor synthesis, but otherwise 
appear metabolically relatively inactive, in the salivary glands of mosquitos. Newly 
annotated hypothetical sporozoite-specific and sporozoite-enriched proteins 
highlight sporozoite-specific functions. They include PF3D7_0104100 that we 
identified to be homologous to the prominin family, which in human has been 
related to a quiescent state of cancer cells. We document high levels of genetic 
variability for sporozoite proteins, specifically for sporozoite-specific proteins that 
elicit antibodies in the human host. Nevertheless, we can identify nine relatively 
well-conserved sporozoite proteins that elicit antibodies and that together can 
serve as markers for previous exposure.
Our understanding of sporozoite biology benefits from identifying key pathways 
that are enriched during this life stage. This work can guide studies of molecular 
mechanisms underlying sporozoite biology and potential well-conserved targets 
for marker and drug development. 
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Author Summary
When a person is bitten by an infectious malaria mosquito, sporozoites are 
injected into the skin with mosquito saliva. These sporozoites then travel to the 
liver, invade hepatocytes and multiply before the onset of the symptom-causing 
blood stage of malaria. By integrating published data, we contrast sporozoite 
protein expression with other life stages to filter out the unique features of 
sporozoites that help us understand this stage. We used a “guideline” that we 
derived from the literature on individual proteins so that we knew which proteins 
should be present or absent at the sporozoite stage, allowing us to weigh 26 data 
sets for their relevance to sporozoites. Among the newly discovered sporozoite-
specific genes are candidates for fatty acid synthesis while others might play a 
role keeping the sporozoites in an inactive state in the mosquito salivary glands. 
Furthermore, we show that most sporozoite-specific proteins are genetically more 
variable than non-sporozoite proteins. We identify a set of conserved sporozoite 
proteins against which antibodies can serve as markers of recent exposure to 
sporozoites or that can serve as vaccine candidates. Our predictions of sporozoite-
specific proteins and the assignment of previously unknown functions give new 
insights into the biology of this life stage. 
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Introduction
Malaria is a mosquito transmittable disease resulting in over 220 million clinical 
cases and half a million deaths annually. Most deaths are caused by Plasmodium 
falciparum (Pf), one of the five species of Plasmodium that can infect humans. 
The infection begins with the deposition of liver-infective sporozoite forms in the 
skin by blood-feeding mosquitoes. These sporozoites travel to the liver where 
they invade, differentiate and multiply asymptomatically inside hepatocytes for 
approximately a week before releasing red blood cell (RBC)-infective merozoites 
into the circulation. The subsequent asexual multiplication, rupture and re-
invasion of the parasites into circulating RBCs cause the symptoms associated 
with malaria.
Identifying specific sporozoite proteins will aid in the understanding the 
biology of this highly motile stage in which the parasite is directly exposed to the 
body’s immune system, similar to blood stage-infective merozoites. Sporozoites 
deposited in the skin can take up to 90 minutes to reach the liver [1], a much 
longer potential exposure to immune system than the 90 seconds of merozoites. 
Mosquito midgut-derived and circulating sporozoites are less infectious for 
hepatocytes than those that have resided in the salivary gland [2, 3]. The ability to 
improve and remain infectivity in the salivary gland of mosquitoes for an extended 
period of time (approximately 1 week) is an intriguing phenomenon that is poorly 
understood [4]. It is suggestive of a molecular landscape where the parasite is 
kept in low activity but can quickly activated to evade immune systems, invade 
and develop in hepatocytes. Understanding the specific molecular make-up of 
sporozoites will shed light on this aspect of its biology and may reveal new targets 
for interventions.
A number of studies have identified genes that are expressed in sporozoites 
during both their development in mosquito midgut (oocyst) and in the salivary 
gland. They have identified expression at the RNA level[5] and at the protein 
level[6] with a specific emphasis on surface proteins[7]. The studies varied in 
their focus and resolution, with RNA level studies facing the challenge of their 
relevance for protein expression[8] while proteomics studies face challenges in 
detecting low abundance proteins. More importantly, while such studies address 
the question what is present in the sporozoite, they do not address what is specific 
to it. Therefore, to prioritize sporozoite specific proteins, we implemented a naïve 
Bayesian data integration in which both transcriptomics and proteomic data 
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were included. For informed data integration, gold-standard lists representing 
proteins that are either sporozoite specific or non-sporozoite specific were 
manually assembled from the existing literature on individual proteins. Using this 
gold standard, published Plasmodium datasets were weighted by the presence of 
sporozoite specific proteins and the absence of proteins known to be absent from 
sporozoites, allowing us to obtain an extended list of predicted sporozoite specific 
proteins. We classified 90 proteins as sporozoite-specific, of which 67 were not 
part of the gold standard. “Conserved, hypothetical proteins with unknown 
functions” were examined using sensitive homology and orthology detection 
tools [9, 10] to predict their function and shed light on the biology of sporozoites. 
From the proteins that in the assembled proteomics data were identified to 
be present in sporozoites, we examined whether we can identify a limited set 
of proteins for which human antibodies are generated[11] and that can serve as 
or markers of exposure to sporozoites. As attractive targets would be conserved 
between different P. falciparum strains, we sequenced three P. falciparum strains, 
NF54, NF135 and NF166, and required selected proteins to have limited genetic 
diversity between those strains as well as in sequenced genomes in PlasmoDB[12].
Methods
Sporozoite protein and transcriptomic data sets
The data integration was performed using transcriptomic and proteomic data sets 
from 22 studies describing all life cycle stages of P. falciparum (S1 Table). Data 
sets were obtained from PlasmoDB version 43 [12], and literature (S1 Table). In 
addition to that, transcriptomics data on the liver and blood stage of Plasmodium 
cynomolgi and the sporozoites of Plasmodium vivax were included, as well as 
proteomics studies covering the sporozoite stage of P. vivax and the liver stage of P. 
yoelii, respectively, resulting in a total of 48 data samples from 26 different studies 
(S1 Table). Data from non-falciparum studies were converted into P. falciparum 
IDs using the orthologs lists available on PlasmoDB, favouring orthologs that are 
syntenic in the case of multiple options.
Gold standards
Bayesian data integration requires gold standards, in this case of proteins known 
to be highly enriched in sporozoites or depleted from them. We required positive 
6
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gold standard proteins to be present dominantly in sporozoites based on western 
blot or immunofluorescent assay data, resulting in a selection of 31 sporozoite-
specific proteins (S2 Table).
The negative gold standard was curated by searching literature for non-
sporozoite proteins. We selected 19 proteins based on their literary evidence of 
absence from sporozoites. Additionally, 20 gametocyte specific proteins [13] were 
added to the negative gold standard, increasing the total number to 39 negative 
gold standard proteins (S3 Table). These proteins spanned the remaining P. 
falciparum life cycle stages in the human host, with the majority being found in 
(a)sexual blood stages.
Bayesian data integration
The used data sets were examined for their correlations with each other (S1 
Figure). By and large most data sets show little correlation. We did leave the few 
correlated data sets in to keep the data integration transparent and maximize the 
amount of included information. Oocyst-derived and salivary gland sporozoites 
showed high correlations with each other, which led us to combining all respective 
studies into the “sporozoite” data input and not make a distinction between 
those stages.
Proteomic data were converted into unique peptide counts for each protein 
identified and transcriptomic data were converted into expression percentiles for 
a total of 5668 P. falciparum gene IDs. Proteomic and transcriptomic data was 
binned consistently for all data sets, with 0, 1, or >1 identified unique peptides, or 
into four bins, containing transcripts that are in the >80 percentile, >60 percentile, 
>40 percentile and <40 percentile, respectively. The data sets were then weighted 
according to their ability to retrieve the gold standard proteins. Each bin in each 
data set was given a log2 score according to equation (1), where B = present in 
bin, S = sporozoite specific and nonS = not sporozoite specific.
 
The Bayesian score for an individual protein is then the sum of the scores for 
the bins in which it occurs (one bin per data set). As the expected number of 
sporozoite-specific proteins was unknown, no prior was included, rather we used 
cutoffs based on the position of known sporozoite specific proteins to define 
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number to 39 negative gold standard proteins (S3 Table). These proteins spanned the remaining P. 
falciparum life cycle stages in the human host, with the majority being found in (a)sexual blood 
stages. 
 
Bayesian data integration 
The used data sets were examined for their correlations with each other (S1 Figure). By and large 
most data sets show little correlation. We did leave the few correlated data sets in to keep the data 
integration transparent and maximize the amount of included information. Oocyst-derived and 
salivary gland sporozoites showed high correlations with each other, which led us to combining all 
respective studies into the “sporozoite” data input and not make a distinction between those stages. 
Proteomic data were converted into unique peptide counts for each protein identified and 
transcriptomic data were converted into expression percentiles for a total of 5668 P. falciparum gene 
IDs. Pr teomic nd transcriptomic data was bi ned consistently for all data sets, with 0, 1, or >1 
identified unique peptides, or into four bins, containing transcripts that are in the >80 percentile, >60 
percentile, >40 percentile and <40 percentile, respectively. The data sets were then weighted 
according to th ir ability to retri ve the gold standard proteins. Each bin in each data set was given a 
log2 score according to equation (1), where B = present in bin, S = sporozoite specific and nonS = not 
sporozoite specific. 
!"#$(&('	|*)) = !"#$( &(*	|')&-*./"/'0)   (1) 
The Bayesian score for an individual protein is then the sum of the scores for the bins in which it 
occurs (one bin per data set).  As the expected number of sporozoite-specific proteins was unknown, 
no prior was included, rather we used cutoffs based on the position of known sporozoite specific 
proteins to define sporozoite specific proteins and sporozoite enriched proteins. 
Overrepresentation of function categories in sporozoite proteins 
GO terms were acquired from PlasmoDB and formatted into a .gmt file according to the format 
specified by the GSEA server at the Broad Institute[14]. GSEAPreranked on the ranked list of 
sporozoite-specific proteins was used with the conservative “preranked” option in the “classic mode”, 
i.e. using Kolmogorov Smirnoff statistics to determine enriched GO terms. The large variable protein 
families RIFIN, STEVOR and PfEMP1 (var genes) were left out of the analysis. A new GO term for gliding 
motility in Plasmodium was assembled by searching literature for proteins associated with gliding 
motility in sporozoites, ookinetes and merozoites. For this we extended the list of glideosome 
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Overrepresentation of function categories in sporozoite proteins
GO terms were acquired from PlasmoDB and formatted into a .gmt file 
according to the format specified by the GSEA server at the Broad Institute[14]. 
GSEAPreranked on the ranked list of sporozoite-specific proteins was used with 
the conservative “preranked” option in the “classic mode”, i.e. using Kolmogorov 
Smirnoff statistics to determine enriched GO terms. The large variable protein 
families RIFIN, STEVOR and PfEMP1 (var genes) were left out of the analysis. A 
new GO term for gliding motility in Plasmodium was assembled by searching 
literature for proteins associated with gliding motility in sporozoites, ookinetes 
and merozoites. For this we extended the list of glideosome associated proteins 
assembled by Lindner et al.[15] with 10 new proteins possibly associated with 
the glideosome. These proteins were either annotated with the motility GO 
term GO:0071976 (SSP3, CelTOS, LIMP protein, plasmepsin VII and glideosome-
associated connector), or otherwise known to be involved in gliding motility 
(CTRP[16], SIAP1[17], GAPDH[18], GAP40[19], IMC1l[20]). Similarly we added 
a list of GPI-anchored proteins to the set of processes for which we examined 
enrichment using the list of Gilson et al.[21], based on the hypothesis that the 
type II fatty acid synthesis was required for the creation of GPI anchors [22]. To 
investigate Pfam domain enrichment in sporozoite proteins, Pfam annotations for 
all proteins were downloaded from PlasmoDB and were used as gene sets in the 
GSEA. To prevent the GSEA analysis results for enriched pathways to be affected 
by the large numbers of hypothetical proteins in P. falciparum, those were filtered 
out before the analysis. Furthermore, proteins that were part of the gold standard 
were left out of the analysis to prevent circular arguments. Proteins for which no 
transcriptomic and proteomic data were available were left out as well. Manual 
examination of the Gene Set Enrichment Analysis results showed that some gene 
sets were significantly enriched in sporozoites only because they were depleted 
from the low scoring proteins. Therefore, we required for the significantly 
enriched processes in sporozoites that they actually contained proteins in the set 
of “sporozoite enriched proteins.”
Sequencing of P. falciparum strains
NF54 originates from West Africa, and is isolated from a woman infected in 
the Netherlands nearby an airfield[23]. The NF135 clone is a clinical isolate that 
originates from Cambodia[24]. The NF166 clone is a clinical isolate from a child 
that visited Guinea[25]. Whole genome sequencing of the three strains was 
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performed with Illumina NextSeq 500, resulting in raw paired-end fastq reads of 
151 base pairs (bp). 
Quality control and trimming
To examine the quality of the raw fastq reads, FastQC (version 0.11.5) was 
used[26]. The Nextera Transposase sequence contamination at the 3’ ends of the 
reads were trimmed off with a stringency of 12 bp, using Trim Galore (version 
0.4.3)[27]. CleanNextSeq_paired was used to remove excess of G’s from 3’ ends 
of the reads after 100 bp[28]. Only reads with a minimal length of 35 base pairs 
were retained.
Alignment and variant calling
The P. falciparum 3D7 reference genome (v3.0, PlasmoDB, plasmodb.org, 14 
chromosomes, mitochondrial genome and apicoplast genome) was indexed and 
the trimmed fastq reads were aligned to the reference genome using Bowtie2 
(version 2.2.8) with the local alignment setting[29]. The SAM files obtained were 
converted to BAM files and subsequently sorted and indexed with SAMtools 
(version 1.4.1)[30]. SNPs and indels were called using SAMtools and BCFtools 
(version 1.4.1). Alignments were visually inspected with the Integrative Genomics 
Viewer (IGV, version 2.3.98)[30]. Coverage was calculated with BEDtools (version 
2.26.0)[31]. 
Filtering of SNPs and indels
Filtering of SNPs and indels was performed with BCFtools (version 1.4.1)[30]. SNPs 
with a base Phred quality (Q) > 30 were used for further analysis. Furthermore, 
we required that the proportion of high quality bases (the DP4 scores in the VCF 
files) supporting the indel or the SNP in >= 75% of the called bases to include 
them for further analysis.
Effect of SNPs and indels on protein sequences
The effect of the mutations on the predicted protein sequences was determined 
using the Genomic Ranges package in R [32]. Amino acid sequences of all proteins 
were compared to amino acid sequences of the reference genome and with each 
other. Any variation at the amino acid level between reference and the examined 
strain and among the examined strains was denoted. 
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Homology detection
Homology detection of P. falciparum proteins with unknown function was 
done using HHPred[9] with default settings (HHblits, 3 iterations). For orthology 
detection we used best bidirectional best hits at the level of sequence profiles[10].
Detecting a set of proteins that elicit antibodies in all CPS volunteers
We used a greedy “set cover” algorithm that in each step selects, from a list 
of evolutionary conserved sporozoite proteins (less than eight nonsynonymous 
SNPs per kb in PlasmoDB), the one that is immunogenic (elicits antibodies) in the 
highest numbers of volunteers for which no immunogenic protein was already 
in the set. In the analysis from Obiero et al. [11], some long proteins were split 
into separate peptides. Those were analyzed separately by the algorithm: i.e. as 
if they were separate proteins. When multiple proteins were immunogenic in 
the same number of volunteers for which no immunogenic protein had been 
selected yet, we chose from those the one that had the highest immunogenicity 
in all the volunteers. We furthermore required genes to have maximally two non-
synonymous SNPs in the combined NF135 and NF166 strains.
Results
Data integration 
At least 26 studies, containing 48 data sets have been published of P. falciparum, 
P. cynomolgi, P. vivax and P. yoelii transcripts and proteins at various developmental 
stages, including 11 that were specific to the sporozoite stage (S1 Table). In 
order to optimally exploit those data to obtain sporozoite-enriched proteins we 
integrated them in a Bayesian manner (Methods). Integrating the data sets using 
the sets of 31 positive and 39 negative gold standard proteins (S2 Table, S3 Table) 
produced a list of all proteins in P. falciparum ranked according to their likelihood 
of being sporozoite-specific (S4 Table). The score distribution of the negative and 
positive gold standard proteins varied depending on using all available data sets, 
or proteomic or transcriptomic data separately (Figure 1A and S2 Figure). The 
Bayesian integration using only transcriptomic data sets resulted in a ranked list 
where 14 negative gold standard genes scored higher than the lowest scoring 
positive gold standard gene (S2 Figure). This overlap was lower when using only 
proteomic data sets (S2 Figure), but still contained 8 proteins. The least overlap 
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between positive and negative gold standard members was observed when 
combining transcriptomic and proteomic data (Figure 1A). This also produced an 
outlier, STARP. Although this protein was identified as being a sporozoite protein 
[33], in our combined data sets it scored 42 times lower than the second to last 
scoring positive gold standard protein. It therewith does not appear specific to 
sporozoites in the available data. STARP was excluded from the score distribution 
of gold standard proteins that was used to define the sporozoite specific proteins 
(see below), but gold standard list and integration where not changed post hoc. 
Based on the observed overlaps, we decided to continue our research using the 
ranked list based on the combined proteomic and transcriptomic data sets.
Sporozoite specific proteins and sporozoite enriched proteins
Proteins were considered sporozoite-specific when ranking in the first quartile of 
the gold standard protein list i.e. scoring above 12.27, which represents a factor 
of being at least 212.37 to 2~ 5200 more likely to be specific to sporozoites than to 
any of the other stages. Do note that hereby we ignore the prior probability of 
a protein being sporozoite specific at all. Although such a prior is standard in 
Bayesian data integration, in this case a prior, e.g. of 1/5, is given the high cut-off 
for sporozoite specific proteins that we used, not very relevant. As we did not 
Figure 1. Bayesian data integration identifies sporozoite-specific genes in P. falciparum. 
A) Bayesian score distributions of the proteins from the negative gold standard, the positive gold 
standard and the remaining proteins, B) cross validation of our predictions (5-fold cross validation) 
with all data sets (Black solid line) and predictions with individual data sets (dashed coloured lines).
163data integration for sPorozoites 
consider STARP to be sporozoite specific (see above), we considered proteins that 
scored higher than the second to lowest positive gold standard protein (LIMP 
protein, score = -1.31), to be enriched in sporozoites. Finally, the abundance of 
unique peptides by mass-spectrometry was assessed for each protein. Proteins 
were deemed present in sporozoites when identified in two independent studies 
or with more than 1 unique peptide in at least one study. Our analysis thus 
identified 90 sporozoite-specific proteins, 1105 sporozoite-enriched proteins 
and 2736 that were present in sporozoites (S4 Table). Out of the 90 sporozoite-
specific proteins, 67 were not part of the positive gold standard list. We validated 
our predictions by 5-fold cross validation (5-fold CV) by randomly skipping 1/5th of 
the gold standard proteins from the data integration and assessing their predicted 
sporozoite specificity based on the remaining data (Fig 1B). The high sensitivity 
and specificity indicated that novel sporozoite-specific proteins would also score 
higher than non-sporozoite specific proteins. We also compared the ranking of 
the gold standard proteins based on the integrated data with a ranking based 
on individual data sets of sporozoite RNAs and proteins. The cross validation 
separated the gold standard proteins better than individual data sets, supporting 
the integration of multiple data sets (Fig 1B).
Function prediction of non-annotated proteins
Many of the genes in the P. falciparum genome encode hypothetical proteins with 
unknown molecular function [34]. The fraction of unknowns that is specific for 
sporozoites (32 out of 90, 36%) is at least as high as in the rest of the genome 
(32%). To improve understanding of their potential functions, we examined the 
proteins for domains with known functions from any species using sensitive 
homology detection with HHpred[9], combined with manual examination 
of conserved residues. We compared sporozoite specific proteins with PFAM 
domains, the human proteome, and the proteome of Toxoplasma gondii, an 
apicomplexan related to P. falciparum that is present in the HHpred database. 
The sporozoite specific protein with the highest score that was not part of the 
gold standard, PF3D7_0104100, showed (barely) significant sequence similarity 
with the prominin family (E=10E-4) and low levels of sequence identity with e.g. 
human prominin-2 (12%). To cross-check the homology of PF3D7_0104100 with 
prominin we examined homology with T. gondii proteins. The sequence similarity 
between the P. falciparum protein and T. gondii TGME49_218910 (E=3.4e-44) 
and between the T.gondii protein and the human prominin-2 were highly 
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significant (E=2.3e-21), indicating that PF3D7_0104100 is indeed member of the 
prominin family. PF3D7_0104100 has like the prominin family five (predicted) 
transmembrane regions with most of the protein localized outside the cell (Figure 
2). Analysis of a sequence alignment with orthologs in other Plasmodium species 
reveals the conservation of ten cysteine residues that are all predicted to be 
extracellular (Figure 2). Such extracellular cysteines can form disulphide bonds 
as has been observed for other extracellular Plasmodium protein domains [35] 
and has been suggested for human prominin[36]. Two pairs of the extracellular 
cysteines were conserved between the human prominin and PF3D7_0104100 
(Figure 2, S3 Figure). We were able to predict molecular functions of three other 
sporozoite specific proteins and 27 sporozoite enriched proteins using HHpred 
and best bidirectional hits with human proteins at the level of sequence profiles 
(S6 Table)[10]. 
Over-represented domains and pathways 
We examined whether specific protein domains and pathways were over- or under-
represented in the sporozoite proteins using Gene Set Enrichment Analysis[14]. 
For this we augmented the list of proteins involved in specific processes from 
PlasmoDB with the glideosome and glycosylphosphatidylinositol (GPI) anchor 
proteins that we considered specifically relevant to sporozoites (Methods)[14]. 
At the domain levels there was an over-representation of three protein domains: 
PF09175 (also named Plasmod_dom_1, unknown function), PF08373 (the RAP 
domain, putatively RNA binding) and PF12879 (the C-terminal domain of the 
SICA proteins that are associated with parasitic virulence). Two of these three 
domains are either unique to Plasmodium species (PF12879) or to P. falciparum 
(PF09715). At the level of pathways, we observe significant enrichment of the 
Type-II fatty acid synthesis (FAS-II) and the GPI anchor biosynthesis pathways. The 
enzymes present in the FAS-II pathway are located in the apicoplast – a reduced 
plastid-like organelle that shares similarity with chloroplasts of algae and plants 
[37]. This over-representation is consistent with its essentiality for sporozoite 
development [38]. Interestingly, P. falciparum has fourteen Acyl CoA synthetases 
[39], of which the distribution over the various fatty acid metabolizing processes 
is largely unresolved. There is one Acyl CoA synthetase, ACS2, that is specific 
to sporozoites and that would be an interesting candidate to convert the fatty 
acids produced in the apicoplast to acyl-CoA. Curiously, there was no enrichment 
in sporozoites of members of the acyl-ACP thioesterase family (PF3D7_1135400 
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and PF3D7_0217900). Acyl-ACP thioesterases play an important step in the 
pathway by hydrolyzing the acyl moiety from the ACP before it can be converted 
to acyl-CoA. 
The second enriched pathway is GPI-anchor biosynthesis, with three proteins 
(GPI mannosyltransferases 1, 2 and 3: PF3D7_1210900, PF1247300 and 
PF3D7_1341600) enriched in sporozoites. GPI represents a class of glycolipids 
found as either free lipids or attached to proteins [40, 41]. Surface parasite 
proteins (such as the merozoite surface proteins 1, 2 and 4) anchor to the parasite 
cell-membrane via GPI moieties [42]. Sporozoites shed surface proteins (such as 
circumsporozoite protein and thrombospondin related anonymous protein) when 
moving [43]. With GPI being used to anchor proteins to the parasite surface, it 
would have to be synthesized constantly to replace the surface proteins shed during 
motility. There was no enrichment of the glideosome or of GPI anchor proteins 
among proteins specific to the sporozoite. However, 39 of the 52 glideosome 
associated proteins are “present” in the sporozoite stage (75%), representing a 
slight overrepresentation when compared to the 2,736 of 5,447 proteins (50,2%) 
detected in sporozoites (Fisher’s exact, P=0.0018). Similarly, there are 19 out of 
28 GPI-anchor proteins identified in Gilson et al.[21] among the proteins present 
Figure 2. Predicted membrane topology of Pf3D7_0104100, a sporozoite-specific protein 
that is homologous to the prominin/CD133 protein family. The level of polymorphisms 
among P. falciparum strains is indicated for the separate regions as the average number of 
polymorphisms per nucleotide in the strains in PlasmoDB. PF3D7_0104100 has a high density 
of polymorphisms within P. falciparum strains that are concentrated in the second extracellular 
loop. Cysteines that are conserved among the homologs in Plasmodium species are indicated. 
The cysteines that are conserved also in human homologs are in bold. Note that the conserved 
cysteines occur in close proximity to each other, suggesting the formation of disulphide bonds.
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at the sporozoite stage, but they are not specifically enriched in sporozoites and 
hence are also expressed in other developmental stages. The fact that proteins 
involved in movement (such as glideosome and GPI) are enriched but not specific 
to sporozoites indicated that sporozoite share a common movement machinery 
with other the life-cycle stages.
Protein functions of sporozoite-specific proteins in the context of 
sporozoite biology
Apart from examining over represented pathways we also examined the individual 
sporozoite specific proteins with regard to their potential function in sporozoite 
biology. One of the interesting features of sporozoites is their inactivity in the 
sporozoite glands, which is among others maintained by translational repression 
with the Puf2 protein [44]. In view of the observation that the translational 
repression occurs in two waves [44], it is interesting that the sporozoite specific 
protein PF3D7_0411400 contains a Dead box helicase like its paralog of DOZI 
that is involved in translational repression in gametocytes of Plasmodium berghei 
[45]. From a gene expression regulatory perspective are furthermore interesting: 
three Zinc finger proteins (PF3D7_0615600, PF3D7_0521300, PF3D7_1008600), 
and the transcription factor AP2-04 that has mainly been implicated in ookinetes 
[46]. With respect to the epigenetic regulation, the histone deacetylase sir2b 
(PF3D7_1451400) that is involved in epigenetic silencing of var gene expression[47] 
is sporozoite specific, in contrast to its paralog sir2a that is not enriched in 
sporozoites.  Examining the sporozoite specific signaling proteins with respect 
to their potential function in maintaining the temporal inactivity of the parasite 
we noted the RAC-beta serine/threonine protein kinase PfAKT (PF3D7_1246900) 
and  two 14-3-3 domain proteins (PF3D7_1422900 and PF3D7_1362100). The 
PfAKT that is involved in Artemisinine resistance [48]  is specifically interesting 
in view of the role of its metazoan orthologs, AKT1/2/3, in regulating cellular 
metabolism to support cell survival [49]. In human it phosphorylates a large 
number of targets, a number of which are after phosphorylation bound by 14-3-3 
proteins. Two 14-3-3 proteins are sporozoite specific: Pf14-3-3I (PF3D7_1422900) 
and PF3D7_1362100. Pf14-3-3I has been shown to bind phosphorylated Histone 
H3 [50]. The Raf kinase inhibitor RKIP (PF3D7_1219700), which may be a 
substrate of the calcium -dependent protein kinase 1 [51], may also be involved 
in keeping sporozoites in an inactive state as its human ortholog in inhibits the 
MAPK pathway [52]. Furthermore, with respect to inactivity of sporozoites it is 
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interesting to mention that Prominin-1/CD133, one of the two human orthologs 
of the Prominin gene (PF3D7_0104100), is known as a marker for dormant stem 
cells, e.g. in melanoma [53] or in Neural cells [54], and has been shown to activate 
the PI3K/AKT pathway[55]. Together, these data suggest that these proteins may 
also modulate sporozoite survival via a mammalian Akt-like pathway as previously 
shown in asexual blood stages. 
Finally, the presence of the tubulin polymerization promoting protein p25 
alpha (PF3D7_1236600) as well as thioredoxin-like protein (PF3D7_0919300) 
and thioredoxin-like associated protein 1 (PF3D7_1230100) whose orthologs 
are associated with tubulin in T. gondii [56] are worth noting in view of 
the essential role of the microtubules in the sporozoite stage [57]. In contrast 
to these proteins, the α‐tubulin, the two α‐tubulins and the other thioredoxin-
like associated proteins associated with tubulin [56] are not enriched in 
sporozoites. Given the presence of α‐ and α‐tubulins in all stages of the life-cycle, 
PF3D7_1236600, PF3D7_0919300 and PF3D7_1230100 may be crucial players 
involved in providing sporozoites with their characteristic, thin cylindrical shape. 
Figure 3. Apicoplast fatty acid synthesis proteins are enriched among sporozoites. The 
width of the arrows is determined by the Bayesian score reflecting the level of over representation 
of that enzyme in sporozoites, e.g. 16 for ACS2 and 8 for FabB/F (S4 Table). For PDH that 
consists of three proteins, the width of the arrow was determined by the average of those three. 
Most of FASII proteins are enriched in sporozoites, except PKII, FABZ and LipA. The scheme is a 
simplification of the pathway as depicted by Shears et al.[22], to which ACS2 was added as it is 
highly enriched in sporozoites and relevant for fatty acid synthesis.
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Under-represented pathways
In contrast to the paucity of upregulated processes, there is significant under 
representation (FDR =< 0.001) of processes linked to splicing, translation, 
translation elongation, folding of proteins as well as proteolysis (S5 Table). These 
processes are primarily modulated by a number of sporozoite specific proteins 
involved in transcriptional silencing e.g. PF3D7_0411400 that contains a Dead 
box helicase domain[45] and PF3D7_1451400, a histone deacetylase involved 
in the epigenetic silencing of virulence (var) gene expression [47]. Furthermore, 
there is significant depletion of proteins involved in carbon metabolism: glycolysis 
and citric acid cycle (S5 Table).
Selecting sporozoite proteins as targets or markers of past infection
Antibodies that bind sporozoite proteins have been induced in 38 volunteers after 
chloroquine chemoprophylaxis with P. falciparum sporozoites (CPS)[11], Table 
S7. Induced antibody profiles represent a blue print of immunogenic proteins 
in sporozoites, liver stages and early blood stages. Here we focus on the set of 
sporozoite target proteins that may be used as markers of previous sporozoite 
exposure or may act as potential targets for vaccines. Minimal sequence variation 
between Pf strains would thereby strengthen the candidature of the proteins 
for epidemiological or clinical applications, however antibody eliciting proteins 
including CSP, show relatively high levels of polymorphisms among sequenced 
malaria strains (S4 Figure), and also sporozoite specific proteins show high 
levels of polymorphisms (S5 Figure). The selection of proteins that could serve 
as markers of exposure or vaccine candidates is a compromise between on the 
one hand protein sequence conservation and on the other hand the frequency 
of volunteers with antibodies to that protein. As the maximum level of sequence 
variation between candidate marker proteins we used 8 non-synonymous SNPs 
per kilobase, which is lower than the variation in for instance Pfs48/45, a highly 
conserved gametocyte protein with 8.9 nonsynomymous SNP per kilobase. As the 
minimum number of people in which a protein should elicit antibodies we chose 
six (out of the 38). Using a “greedy search algorithm” (methods) we selected a set 
of nine proteins of which at least one elicited antibodies per volunteer (Table 1). 
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Variation in sporozoite proteins among selected Pf strains NF135 and 
NF166
Aside from the criteria that the proteins selected as markers for sporozoite 
exposure are conserved in sequenced P. falciparum strains in PlasmoDB, we also 
required them to be conserved in two strains that have been used in research into 
heterologous protection after CPS: NF135 and NF166. We therefore sequenced 
these strains, as well as NF54 (Methods). The mean coverage of mapped reads 
in the coding regions ranged from 28 for NF54 to 44 for NF166 (S8 Table). A 
Phred quality score cut-off of 30 was applied similar to other studies involving 
Plasmodium vivax and P. falciparum sequencing and variant calling, [58-61]. 
Manual examination of SNPs still uncovered SNPs with a high Phred score (> 
100) that were polymorphic within a single, in principle haploid genome, possibly 
reflecting mapping issues in duplicated regions. Next to a Phred score of 30, we 
also introduced a required the presence of a variant nucleotide in at least 75% 
of the high quality bases. Both criteria were also applied to the indels. Numbers 
of called SNPs and indels were roughly similar for NF135 and NF166, reflecting 
their independent geographic origins. As expected, NF54 showed much lower 
numbers of called SNPs and indels than the other strains, as it is the parental line 



















































Table 1. Putative markers of exposure to sporozoites. Genes selected by the greedy method 
to cover all volunteers with their gene ID, function and number of volunteers with antibodies after 
CPS immunization as reported by Obiero et al. [11]. The non-synonymous SNPs are given as a 
proxy for genetic variability, with PlasmoDB and two sequenced laboratory strains as reference.
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and NF135 showed high levels of polymorphisms for antibody-binding proteins 
enriched in sporozoites (Figure S6). Nevertheless, most of them had few or no 
variations in the set of proteins that we selected as markers for previous exposure 
(Table 1). Lowering the maximum allowed variation in these two strains further, 
e.g. to zero polymorphisms for all proteins, did not allow us to select a set of 
proteins that together elicited antibodies in all 38 volunteers. 
 
Discussion
The sporozoites stage of the Plasmodium life cycle represents the parasite’s 
first interaction with the human immune system and can be used to effectively 
vaccinate against infection [11]. The set of genes and proteins expressed at this 
stage has been determined in at least 11 studies on Plasmodium spp, of which 
nine on P. falciparum, creating a conundrum of which dataset to use when 
studying sporozoite biology, and when deciding to use multiple datasets, how 
to integrate the datasets. The individual sporozoite studies did not focus on 
determining which expression patterns are specific to the sporozoite stage, rather 
they examined the presence of transcripts or proteins. Such data of course can 
be integrated by combining them in a relatively straightforward manner as has 
e.g. been done for sporozoite RNA expression[62], but that does not address 
how specific the expression of a gene is to sporozoites. By combining RNA and 
protein expression data measured across life stages with sets of proteins known 
to be present or absent from sporozoites in a Bayesian manner we have created 
a single list of proteins ranked by their overrepresentation in sporozoites relative 
to other stages. Despite translational repression, which is expected to reduce the 
correlation between mRNA and protein levels, including the mRNA levels led to a 
better performance at the protein level that only including proteomics data. Cross 
validation shows furthermore that the integrated list is better at separating the 
gold standard positive and negative data sets from each other than the individual 
data sets. 
In this study, we did not separate datasets derived from oocyst sporozoites (the 
earliest form of this stage) and salivary gland sporozoites (the mature form). There 
may have been subtle difference in protein expression between sporozoites in 
the two differing host environments (midgut versus salivary gland) that were not 
detected. However, oocyst-sporozoite data represent a minority of the combined 
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data set (2/26) and are highly correlated with salivary gland-derived sporozoite 
data (S1 Figure). A list of proteins with its own sporozoite specificity score will 
be a valuable resource for studying sporozoite biology and understanding novel 
protein function. Genetic manipulations of malaria parasites can only occur during 
blood stage development, which makes studying proteins that are essential for 
both blood and sporozoite stages difficult. Using our list in combination with 
the recently published piggyBac whole genome mutagenesis study [63], will 
allow researchers to determine the approach required for generating a knockout 
parasite i.e. whether an inducible (for essential blood stage and low sporozoite 
specificity score) or straight knockout (for a high sporozoite specificity score) 
system should be considered. 
In our analysis, we found an enrichment in the proteins involved in type II fatty 
acid synthesis which consistent with literature [38]. An increased output of lipids 
from this pathway may feed into the production of GPI anchors that are made up 
of different sugar and lipid components. We did observe a slight enrichment in 
proteins involved in creating GPI anchors, i.e. the three GPI mannosyltransferases. 
Although there is currently no established relationship between type II fatty acid 
pathway and synthesis of GPI anchors[22], it may be interesting to pursue it for 
this stage of the life-cycle given the importance of CSP – the most abundant 
protein on sporozoites, that is anchored to the surface via a GPI anchor.
Processes involved in the production, folding and catabolism proteins were under-
represented in the sporozoite specific and enriched list. Similarly, genes involved 
in metabolism such as those part of glycolysis and citric acid cycle were also 
under-represented, suggestive of sporozoites existing in a low metabolic state. 
Sporozoites are released in the mosquito’s circulation as early as day 12 post 
blood meal [3] and make their way to the salivary gland. Nevertheless they are 
generally less infectious for liver cells until after a period of maturation within the 
salivary gland[64]. Although the exact nature of this maturation is not known, 
there is evidence that these parasites remain in a latent state until ejected into the 
human host[4, 65]. To understand how sporozoites exist in this state of inactivity, 
we have identified several interesting targets such as an ortholog of AKT1/2/3, 
two 14-3-3 proteins, an ortholog of the raf kinase inhibitor and an ortholog of 
the quiescent stem cell marker prominin/CD133. 
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Sequence variation among Plasmodium strains is pervasive [66], and is possibly 
responsible for the limited heterologous protection after CPS vaccination with 
NF54 and challenge with NF135 and NF166 [67]. Indeed, as we have shown here, 
both sporozoite specific proteins and proteins that elicit antibodies are highly 
polymorphic, and only a fraction of those are conserved between NF54, NF135 
and NF166 (Fig S6, S7). The correlation between immunogenicity and level of 
sequence conservation suggest that antigenic drift plays a role in the sequence 
variation. It is not clear whether antigenic drift would also be responsible for high 
variation among sporozoite specific proteins, as we did not observe a correlation 
between the Bayesian score of sporozoite specificity and the immunogenicity. 
Nevertheless, among the large number of sporozoite proteins that elicit antibodies 
there are still proteins that show limited sequence variation and allow selecting of 
a small set of proteins that are well conserved and against which antibodies could 
serve as potential vaccine targets or markers of previous exposure to sporozoites. 
In summary, we show a set of previously unidentified sporozoite-specific proteins 
and assign functions potentially related to the enduring state of inactivity of 
the salivary gland sporozoite. We further identify sporozoite-directed humoral 
immune responses and their potential as functional or diagnostic responses that 
can be elucidated in future studies.
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Abstract 
Background A highly efficacious vaccine is needed for malaria control and 
eradication. Immunization with Plasmodium falciparum NF54 parasites under 
chemoprophylaxis (CPS-immunization) induces the most efficient long-lasting 
protection against a homologous parasite. However, parasite genetic diversity is a 
major hurdle for protection against heterologous strains. 
Methods We conducted a double-blind, randomized controlled trial in 39 
healthy participants, of NF54-CPS-immunization by bites of 45 NF54-infected 
(n=24 volunteers) or uninfected mosquitoes (placebo; n=15 volunteers) against a 
Controlled Human Malaria Infection (CHMI) with the genetically distinct NF135.
C10 and NF166.C8 clones. Cellular and humoral immune assays were performed 
as well as genetic characterization of the parasite clones.
Results NF54 CPS-immunization induced complete protection in 5/5 volunteers 
against NF54 challenge infection at 14 weeks post-immunization, but sterilely 
protected only 2/10 and 1/9 volunteers against NF135.C10 and NF166.C8 
challenge infection, respectively. Post-immunization plasma showed a significantly 
lower capacity to block heterologous parasite development in primary human 
hepatocytes compared to NF54. Whole genome sequencing showed that NF135.
C10 and NF166.C8 have amino acid changes in multiple antigens targeted by 
CPS-induced antibodies. Volunteers protected against heterologous challenges 
were among the stronger immune responders to in vitro parasite stimulation.
Conclusions Although highly protective against homologous parasites, NF54 
CPS-induced immunity is less effective against heterologous parasite clones 
both in vivo and in vitro. Our data indicate that whole sporozoite-based vaccine 
approaches require more potent immune responses for heterologous protection.
Trial registration
This trial is registered in clinicaltrials.gov, under identifier NCT02098590.
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Background
Malaria has a significant impact on human health and economic welfare worldwide, 
causing over 200 million cases of disease and nearly half a million deaths in 2015 
[1]. Though a significant decrease in malaria deaths has been observed in the 
last 15 years [1], the emergence of insecticide-resistant mosquitoes [2] and drug-
resistant parasites [3] are threatening malaria control efforts and underscore the 
need for a highly effective vaccine. 
While naturally acquired immunity likely never results in sterile protection 
against the parasite [4], generation of long-lasting and sterilizing immunity against 
malaria is the goal of pre-erythrocytic vaccine approaches. So far, only one sub-
unit vaccine, RTS,S (Mosquirix, Glaxo Smith Kline), has been recommended for 
defined clinical application [5]. This vaccine is based on a major sporozoite surface 
protein, the circumsporozoite protein (CSP), and has shown to induce a short-
term 30-50% efficacy in reducing the incidence of clinical malaria in endemic 
areas, as well as in the Controlled Human Malaria Infection (CHMI) model [6, 7]. 
Sterilizing immunity can be induced by attenuated whole sporozoite approaches. 
Immunization with radiation-attenuated sporozoites requires bites of at least 
1000 infected mosquitoes to induce sterile protection in 50% of volunteers [8], or 
a total dose of 675k cryopreserved sporozoites for full homologous protection [9]. 
In contrast, bites by only 30-45 malaria infected mosquitoes or 150k cryopreserved 
sporozoites in the ChemoProphylaxis and Sporozoite (CPS) regimen induces 
complete sterile protection against the homologous parasite [10, 11]. CPS-induced 
protection can last for at least 2.5 years, showing unprecedented efficiency and 
sustainability of the protective immune response [12]. Specifically, strong effector 
memory T cell responses are induced [10, 11], as well as memory B-cell and 
antibody responses targeting pre-erythrocytic stage antigens with functional 
activity against homologous sporozoites, inhibiting parasite development in liver 
cells in vitro and in vivo in human liver-chimeric mice [13-15]. 
Despite these advances, a major hurdle for the induction of protection 
against heterologous strains is the well-known genetic diversity of Plasmodium 
falciparum, allowing parasite evasion and reducing protective efficacy. More 
recently, immunization with radiation attenuated sporozoites provided 53% 
protection against a heterologous challenge [16]. There is also incidental evidence 
for CPS-induced heterologous protection in the CHMI model [17], but this has not 
been systematically addressed.
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Here we describe the first double-blind, placebo-controlled CHMI trial of NF54-
CPS-immunization by a total of 45 P. falciparum NF54-infected mosquitoes 
followed by a challenge infection with either P. falciparum NF135.C10 clone 
from Cambodia or NF166.C8 clone from Guinea. Parasites were characterized 
by whole genome sequencing and CPS-induced cellular and humoral responses 
were analyzed. 
Methods
Study design and participants
This single center, double-blind, randomized, placebo-controlled trial was 
conducted at the Radboud university medical center (Nijmegen, The Netherlands) 
between February and November 2015. Study participants were healthy 
male and female volunteers (18-35 years old) with no history of malaria and 
screened for eligibility including a complete medical and family history, physical 
examination, blood hematological and biochemical parameters, and serology for 
human immunodeficiency virus (HIV), hepatitis B and C and the asexual stages 
of P. falciparum as previously described [18]. All candidate participants provided 
written informed consent at the screening visit. 
Study approval
The study was approved by the Central Committee for Research Involving Human 
Subjects of The Netherlands (CCMO NL48732.091.14) and conducted according 
to the principles outlined in the Declaration of Helsinki and Good Clinical Practice 
standards. This trial is registered at ClinicalTrials.gov, identifier NCT02098590. 
Procedures
All included study subjects (n=41, Figure 1) received chloroquine in a prophylactic 
dose (i.e. a loading dose of 300mg of chloroquine on each of the first two days, 
followed by 300mg once a week), for a total duration of 13 weeks. While under 
chloroquine prophylaxis, study groups 1, 2 and 3 received three immunizations 
with bites of 15 P. falciparum NF54-infected Anopheles stephensi mosquitoes. 
Groups 4, 5 and 6 received three mock-immunizations with bites of 15 uninfected 
mosquitoes. 
Volunteers were followed on an outpatient basis from days 6 to 10 after each 
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immunization. Blood was examined daily, including hemocytometry, white-blood 
cell counts, lactic acid dehydrogenase (LDH) and highly sensitive troponin-T. From 
day 7 to 9, blood was also checked for malaria parasites by thick blood smear 
microscopy and quantitative real-time PCR (qPCR) was performed retrospectively 
(after study de-blinding) as described previously [19, 20]. 
Fourteen weeks after discontinuation of chloroquine prophylaxis, all participants 
were exposed to bites of five P. falciparum infected Anopheles stephensi mosquitoes 
(Table 1). Subjects of groups 1 and 4 were challenged with the heterologous 
NF135.C10 clone; groups 2 and 5 with the heterologous NF166.C8 clone; groups 
3 and 6 with the homologous NF54 strain. Mosquitoes were examined to verify 
that a blood meal was taken and the presence of sporozoites in mosquito salivary 
glands was confirmed by dissection. If insufficient infected mosquitoes had taken 
a blood meal, subjects were exposed to additional mosquitoes. 
After challenge infection, subjects visited the clinical trial site twice daily from 
day 6 to day 15 and once daily from day 16 until day 21. Blood was drawn 
for parasitological assessments at every visit and safety laboratory measurements 
were performed once daily as described above. The following symptoms were 
solicited: fever, headache, malaise, fatigue, myalgia, arthralgia, nausea, vomiting, 
chills, diarrhea and abdominal pain. All signs and symptoms (solicited and 
unsolicited) were recorded and graded by the attending physician as follows: mild 
(easily tolerated), moderate (interferes with normal activity), or severe (prevents 
normal activity), or in case of fever grade 1 (>37·5°C – 38·0°C), grade 2 (38·1°C 
– 39·0°C) or grade 3 (>39·0°C).
Subjects were treated with a curative regimen of 1000mg atovaquone 
and 400mg proguanil once daily for three days, when parasitemia above the 
treatment threshold (100 parasites per milliliter of blood) was detected by qPCR 
[20]. Subjects that remained qPCR negative were presumptively treated with the 
same regimen 28 days after challenge infection. Complete cure was confirmed by 
two consecutive negative qPCR measurements after treatment.
Randomization and masking
All study subjects, in two time-separated cohorts, were randomly allocated to 
one of the six study groups using a computer-generated list of random numbers 
(Microsoft Excel 2007, Redmond, WA, USA), with study groups stratified equally 
over each cohort. Randomization was prepared by two independent investigators 
and was stored securely, in sealed opaque envelops with restricted access. 
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Subjects, investigators and primary outcome assessors were masked to group 
assignment.
During the study, the homologous (NF54) challenge strain infection of the second 
cohort was delayed as there was no sufficiently infected batch of mosquitoes 
available (>40% infected; according to our standard operating procedures). 
Challenge strain blinding had to be lifted for this group (6 subjects), allowing 
them to be challenged two weeks later. The investigators remained blinded to 
immunization allocation of all participants and to the challenge strain allocation 
of the NF135.C10 and NF166.C8 groups until the end of study. All study subjects 
and immunology assessors remained blinded during the entire study. The partial 
de-blinding procedure was documented and reported to the Central Committee 
for Research Involving Human Subjects of The Netherlands (CCMO).
Primary study outcome
The primary outcome was pre-patent period: time to parasitemia (a single qPCR 
measurement with a parasite density greater than 100 parasites per milliliter of 
blood) in subjects after challenge infection. 
Parasites 
NF54 is a longstanding and well-characterized strain isolated several decades 
ago from a person with airport malaria near Schiphol Airport (Amsterdam, The 
Netherlands) and likely originating from West Africa [21]. The NF135.C10 clone 
originated from a clinical isolate in Cambodia [22]. The NF166.C8 clone originated 
from a patient after a recent visit to Guinea (West Africa) (McCall and Wammes 
et al, in press). 
Parasite culture and generation of infected mosquitoes
Plasmodium falciparum NF54, NF135.C10 and NF166.C8 asexual and sexual blood 
stages were cultured in a semi-automated culture system [23-26]. Anopheles 
stephensi mosquitoes for immunizations and challenge infections were reared 
in the Radboud university medical center insectary (Nijmegen, The Netherlands) 
according to standard operating procedures. Infected mosquitoes were obtained 
by standard membrane feeding on gametocyte cultures of the different strains as 
described previously [26]. 
For in vitro sporozoite infectivity assays, salivary glands from infected Anopheles 
stephensi mosquitoes were hand dissected and collected in complete William’s B 
185modest heterologous Protection
culture medium without serum. Salivary glands were homogenized in a homemade 
glass grinder and the number of P. falciparum sporozoites was counted in a 
Bürker-Türk counting chamber using phase contrast microscopy [13].
Plasma samples
Citrated plasma samples were collected from 24 CPS-immunized volunteers 
at different time points using citrated vacutainer cell preparation tubes (CPT 
vacutainers; Becton Dickinson). Samples collected 11-14 days before the first 
CPS-immunization (pre-immunization) and one day before challenge infection 
(18 weeks after the last immunization; post-immunization) were used for analysis 
of malaria-antigen specific antibody levels and assessment of functional activity 
in vitro. Plasma samples were stored in aliquots at -20 °C and re-thawed no more 
than three times.
Prior to use for in vitro sporozoite infectivity assays in primary human hepatocytes, 
citrated plasma aliquots were heat-inactivated for 30 minutes at 56 °C and spun 
down at 13,000 rpm for 5 minutes at room temperature. 
PBMC isolations and cryopreservation 
Venous whole blood was collected in CPT vacutainers at different time points. 
Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood 
samples, cryopreserved and stored as described previously [10]. Briefly, PBMCs were 
isolated by centrifugation, washed in ice-cold phosphate buffered saline (PBS), and 
counted in 0·1% Trypan blue with 5% Zap-o-Globin II Lytic Reagent (Beckman 
Coulter) to assess cell viability. Cells were cryopreserved at a concentration 
of 107 PBMCs/ml in ice-cold fetal bovine serum (FBS, Gibco) containing 10% 
dimethylsulfoxide (DMSO, Merck, Germany) using Mr. Frosty freezing containers 
(Nalgene). Subsequently, PBMC samples were stored in vapor-phase nitrogen. 
PBMC samples collected 11-14 days before the first CPS-immunization (pre-
immunization) and one day before challenge infection (18 weeks after the last 
immunization; post-immunization) were used for flow cytometric analysis.
Humoral immunological assays 
Malaria antigen-specific antibody levels
Specific antibodies to P. falciparum circumsporozoite protein (CSP) in citrated anti-
coagulated plasma samples were determined by a standardized enzyme-linked 
7
186 Bottlenecks of malaria transmission
immunosorbent assay (ELISA) at indicated time points as previously described. 
Antibody levels were expressed as arbitrary units (AU) in relation to a pool of 100 
sera from adults living in an area in Tanzania where malaria is highly endemic 
(HIT), with this positive control set at 100 AU [11] see also Supplementary 
information S1 for detailed information [15]. ELISA data analysis was performed 
with Auditable Data Analysis and Management System for ELISA (ADAMSEL, 
version 1.1) as previously described [15]. Post-immunization plasma samples were 
corrected for baseline responses for CSP.
In vitro sporozoite infectivity assay of primary human hepatocytes
To test CPS-induced functional antibody activity against sporozoite development, 
fresh primary human hepatocytes were isolated and cultured from patients 
undergoing partial hepatectomy as described in Supplementary information 
S2. Briefly, viable hepatocytes (5*104 hepatocytes/well) in complete William’s B 
medium were seeded into 96-well flat-bottom plates (Falcon, 353219) coated 
with 0·056 mg/ml rat tail collagen I per well (Roche Applied Science, 11179179-
001), and cultured at 37 °C in an atmosphere of 5% CO
2
. 
Two to three days after seeding of hepatocytes, batches of fresh P. falciparum 
NF54, NF135.C10 or NF166.C8 sporozoites in Williams B medium with 10% 
heat-inactivated naive human control serum were pre-incubated with 10% 
heat-inactivated pre- or post- CPS-immunization plasma for 30 minutes on ice. 
Sporozoites pre-incubated with an anti-CSP monoclonal antibody (mAb 2A10, 
10 µg/ml final concentration, MR4; MRA-183A) served as a positive control. 
Sporozoites in the presence of 20% heat-inactivated naive human control serum 
served as standard control. 5*104 of pre-incubated sporozoites were added to 96-
well plates containing monolayers of primary human hepatocytes in triplicates. 
Five to six days post-infection, the number of P. falciparum infected hepatocytes 
was assessed by staining for P. falciparum Hsp-70 and indirect immuno-
fluorescence analysis using a Leica DMI6000B inverted microscope as described 
in Supplementary information S3 and S4. 
Cellular immunological assays
For the assessment of P. falciparum-specific cellular immune responses, pre- and 
post-immunization PBMCs from CPS-immunized volunteers whom received 
NF135.C10 and NF166.C8-challenge infection, were re-stimulated in vitro with 
cryopreserved P. falciparum NF54-infected erythrocytes (PfRBCs) as described 
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previously [10, 12] and described in detail in Supplementary information S5. 
Briefly, after thawing, PBMCs in complete culture medium (final concentration of 
10*106cells/ml) were stimulated in vitro in duplicate with either 106 cryopreserved 
NF54 PfRBCs or 106 uninfected erythrocytes (uRBC; negative control) for 24h at 
37 °C with 5% CO
2
. Fluorochrome-labeled monoclonal antibody to CD107a was 
added for the duration of the stimulation. During the last four hours, 10 µg/ml 
Brefeldin A and 2 µM monensin were added, and 10 ng/ml PMA (Sigma-Aldrich) 
and 1 µg/ml ionomycin were added to positive control wells.
After 24 hours of stimulation in total, cells were stained with a Live/Dead fixable 
dead cell stain dye and fluorochrome-labeled antibodies against the surface 
markers CD3, CD4, CD8, gamma delta T cell receptor and CD56, and against 
the intracellular cytotoxic marker granzyme B and the cytokine IFN-ƴ. Samples 
were kept cold and dark in 1% paraformaldehyde (PFA) in PBS until measured 
by flow cytometry on the same day. Both time points for each volunteer were 
thawed, stimulated and stained within the same experimental round. Samples 
were acquired using a 10-colour Gallios flow cytometer (Beckman Coulter), and 
single stained cells were run every round for compensation. Data analysis was 
performed using FlowJo software (Version 10·0·8, Tree Star). uRBC responses 
were subtracted from PfRBC-specific responses for every volunteer for each time 
point, and post-immunization responses were corrected for pre-immunization 
responses.
Statistical analysis
Statistical analysis was performed using GraphPad Prism software (version 5, 
GraphPad Software Inc., California, USA). Differences in prepatent period by 
qPCR between groups were determined by Log-Rank test. Differences in antibody 
levels across the immunization groups were analyzed with One-way ANOVA with 
Bonferroni’s multiple comparison post-hoc correction. For analysis of in vitro 
sporozoite infectivity data, differences were tested using the paired Student’s 
t-test, except when comparing between immunization groups, when a one-way 
ANOVA with Bonferroni’s multiple comparison post-hoc correction was used. A 
p-value of <0·05 was considered significant. 
Genetic analysis of parasites
Genomic DNA was obtained from the three study strains and 2.3 µg each were 
submitted for Illumina sequencing. The resulting fastq reads (150 bp) were 
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aligned to the P. falciparum 3D7 reference genome (v.3, plasmoDB) using bowtie2 
software (bowtie-bio.sourceforge.net). Single nucleotide polymorphisms (SNPs) 
were called with samtools and bcf/vcftools software (samtools.sourceforge.net). 
An alignment of all SNPs (with bcftools quality score > 100) was used to compare 
the study strains to others from Ghana, Guinea, Kenya, Cambodia, Thailand and 
Vietnam in a combined analysis of genetic variation, as described by Campino el 
al. [27]. Furthermore, we examined genes that were identified to elicit a humoral 
immune response in CPS-immunization [14]. This panel of 11 pre-erythrocytic 
genes including CSP and LSA-1, complemented by MAEBL, was checked for 
amino acid changes in the translated protein.
Results
Protective efficacy of CPS-immunization against heterologous challenge 
Forty-one volunteers were included into the study and twenty-four immunization 
and fifteen placebo-control volunteers completed the clinical trial, and were 
included in the per protocol analysis. One volunteer withdrew after being unable 
to attend the study visits and one volunteer was excluded due to a concomitant 
condition (Figure 1). Baseline characteristics of the study population are shown 
in table 1. 
As previously observed, NF54 CPS-immunization induced sterile protection 
against a homologous NF54 challenge in five out of five volunteers (Figure 2A) 
[10, 11, 28]. In contrast, two out of ten volunteers were sterilely protected after 
challenge with NF135.C10, with six out of ten volunteers showing a prolonged 
pre-patent period compared to mock-immunized controls (Figure 2B). After 
NF166.C8 challenge, one out of nine NF54-immunized volunteers was fully 
protected, while eight out of nine volunteers showed no delay to patency (Figure 
2C). Overall, NF54-CPS immunization induces only modest protection against 
heterologous clones. 
As marker for the induction of immune responses, antibody levels to the major 
sporozoite vaccine-target antigen CSP [6, 7] were measured. All volunteers 
showed a post-immunization CSP antibody titer as determined by ELISAs and 
corrected for baseline (median 3·7 AU); IQR 2·9-4·5), which did not significantly 
differ between groups (Group 1: 24·7 (10·4-45·2); Group 2: 24·7 (17·0-37·1) and 
Group 3: 74·1 (20·9-187·0)).
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Figure 1. Clinical trial profile. 
CVD = cardiovascular disease; BMI = body mass index; ECG = electrocardiogram
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In vitro inhibition of intra-hepatic sporozoite development by CPS-
induced antibodies
Next, functional antibody activity to inhibit sporozoite development in primary 
human hepatocytes in vitro was tested. Post-immunization plasma from all 24 
NF54 CPS-immunized volunteers significantly reduced homologous intra-hepatic 
sporozoite development (p<0.0001; Figure 3A). However, inhibition of intra-
hepatic NF135.C10 and NF166.C8 development was significantly lower (p<0·01), 
with median percentages inhibition of 40·7% (IQR 29·6-59·1), 26·9% (IQR 15·6-
35·0) and 31·0% (IQR 22·6-43·2) for NF54, NF135.C10, NF166.C8 sporozoites, 
respectively (Figure 3B). Intra-hepatic development of both heterologous clones 
was equally inhibited by NF54 CPS-immunization induced antibodies (Figure 
3B). While these in vitro data reflect the clinical outcome in vivo at group level, 
individual inhibition in vitro did not correlate with in vivo pre-patent periods and/
or parasitemia (data not shown). 
Genetic diversity of NF54, NF135.C10 and N166.C8 challenge strains
The genetic diversity among P. falciparum mutants has been shown to be a strong 
factor in parasite evasion of protective immune responses. Whole genomes of the 
parasite clones used in this study were sequenced. High quality Single Nucleotide 
Polymorphisms (SNPs) were called with about equal numbers for NF135.C10 
and NF166.C8 (Supplementary Table 1). All polymorphisms were used to infer 
 
Number of  
participants (n=39)
Sex 
    Male




    Immunization
    Challenge
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
10 9 5 5 5 5
     
3 (30%) 2 (22%) 2 (40%) 3 (60%) 2 (40%) 5 (100%)
7 (70%) 7 (78%) 3 (60%) 2 (40%) 3 (60%) 0 (0%)
21.5 (1.8) 21.1 (2.6) 22.4 (1.6) 20.1 (1.3) 20.4 (2.5) 22.6 (3.1)
21.8 (2.3) 21.4 (1.7) 22.0 (3.1) 20.6 (2.0) 24.8 (3.3) 23.2 (1.7)
     
NF54 NF54 NF54 uninfected uninfected uninfected
NF135.C10 NF166.C8 NF54 NF135.C10 NF166.C8 NF54
Table 1.  Baseline characteristics of subjects included in the analysis.
Data are n (%), mean (SD). BMI=body-mass index
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a phylogeny including isolates from Southeast Asia and East and West Africa 
[27]. As expected, NF54 and NF166.C8 were very similar to West African isolates, 
while NF135.C10 showed more resemblance to other Southeast Asian strains. 
We next compared amino acid changes of twelve genes encoding target antigens 
for CPS-induced antibodies as previously described [14]. With the exception of 
EIF3A, all examined proteins showed amino acid changes in either NF135.C10 or 
NF166.C8 with respect to NF54 (Table 2). Remarkably, in contrast to their relative 
geographical distances, eleven out of twelve proteins in NF166.C8 and eight out 
of twelve in NF135.C10 were different compared to NF54.
Figure 2. Parasitemia following homologous and heterologous challenge infection.   The 
percentage of volunteers remaining qPCR negative (Kaplan-Meier survival proportions) after 
challenge infection with a homologous NF54 (n=5 immunized; n=5 controls) (A) or heterologous 
NF135.C10 (n=10 immunization; n=5 controls) (B) or NF166.C8 (n=9 immunized; n=5 controls) 
(C) strain is shown. Solid lines represent CPS-immunized volunteers and dotted lines represent 
placebo-control immunized volunteers. ** p<0.01 as determined by Log-rank (Mantel Cox) Test.
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Humoral and cellular markers of protection 
Next, we tested a number of previously established markers that associate with 
exposure and homologous protection after CPS-immunization [10, 29]. Figure 5 
shows the distribution of antibody-mediated inhibition of intra-hepatic sporozoite 
development as well as the cellular markers interferon (IFN)-γ and granzyme B 
in CD4+ and CD8+ cells in all immunized volunteers undergoing heterologous 
challenge. Remarkably, CD107a expression in particularly CD4+ T cells was not 
increased as previously found (data not shown) [10]. Two out of three heterologous 
protected volunteers were among the highest antibody-mediated inhibitors of in 
vitro heterologous intra-hepatic development (Figure 5, orange square: NF135.
C10-challenged; green triangle: NF166.C8-challenged), with the highest numbers 
of IFN-y-producing CD8+ T cells against PfRBC. The third protected volunteer 
showed only average neutralizing antibody responses and IFN-y-producing CD4+ 
and CD8+ T cells, but had the highest numbers of granzyme B+ CD8+ T cells 
(orange upside down triangle: NF135.C10-challenged). 
Figure 3. Neutralizing effect of CPS-induced antibodies on in vitro sporozoite functiona-
lity of homologous and heterologous P. falciparum strains. A. The number of primary 
human hepatocytes infected by homologous NF54 sporozoites in the presence of Pre- or Post-
immunization plasma in all n=24 CPS-immunized volunteers was determined by microscopy. 
B. P. falciparum NF54, NF135.C10 or NF166.C8 sporozoites were pre-incubated with Pre- or 
Post-immunization plasma from CPS-immunized volunteers and the percent inhibition of intra-
hepatic development of NF54, NF135.C10 or NF166.C8 was calculated for Post- compared to 
Pre-immunization plasma for each individual volunteer and presented as squares (NF135.C10), 
triangles (NF166.C8) or circles (NF54). Data are shown as the mean of triplicate measurements for 
each individual volunteer (Figure 3A) or the median of all data points with an interquartile range 
(Figure 3B). Differences in the percent inhibition of intra-hepatic development between parasite 
strains were tested using One-way ANOVA with Bonferroni’s multiple comparison correction
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Table 2. Amino acid changes in proteins targeted by the humoral immune response 
after CPS immunization. Alterations in gene and protein sequences, based on whole genome 
sequencing, for 12 genes from NF135.C10 and NF166.C8 compared to NF54. Single nucleotide 
polymorphisms and small insertions/deletions are shown together as sequence changes with 
expected changes in the in silico translated protein sequence (counting altered amino acids).
  NF135.C10   NF166.C8 
Gene Sequence changes Protein changes Sequence changes Protein changes
PF3D7_1036400
LSA-1 6 4 14 9
PF3D7_0108300 
Conserved unknown 21 12 15 8
PF3D7_1033100
AdoMetDC/ODC 10 9 9 8
PF3D7_0108300
MSP2 13 7 8 7
PF3D7_0304600
CSP 6 6 7 7
PF3D7_0509400
RNApol 6 4 9 6
PF3D7_0630600
Conserved unknown 7 2 8 3
PF3D7_0502400
MSP8 2 1 4 3
PF3D7_1147800
MAEBL 2 0 3 1
PF3D7_0703700
Conserved unknown 0 0 1 1
PF3D7_0829000
Conserved unknown 0 0 1 1
PF3D7_1212700
EIF3A 1 0 1 0
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Discussion
This randomized, controlled clinical trial shows that CPS-immunization with P. 
falciparum NF54 sporozoites induces modest sterile protection against challenge 
infection with genetically distinct P. falciparum parasites. In line with these clinical 
observations, antibodies induced by NF54 CPS-immunization inhibit intra-hepatic 
development of both homologous and heterologous sporozoites in vitro, but less 
efficiently inhibit heterologous clones. P. falciparum specific IFN-y and granzyme 
B T cell responses are also induced, corroborating previous studies [10, 11]. 
Volunteers protected against heterologous challenge show relatively high cellular 
and/or antibody responses. However, none of these individual markers predicts 
protection. 
Plasmodium falciparum parasite strain diversity is a major impediment to the 
development of effective, sterilizing immunity [30]. Indeed, previous studies with 
single-protein vaccines show that antigenpolymorphisms decrease vaccine efficacy 
[31-33]. However, genetic diversity may be less challenging for whole sporozoite 
vaccines representing a broader antigen repertoire that could increase the chances 
for generating functional, cross-strain immunity. In fact, immunization with 
radiation-attenuated sporozoites has been shown to induce protection against 
challenge with the heterologous strain 7G8 (IMTM-22 isolate from Brazil) [34, 
35], most recently showing 53% efficacy in an open-label re-challenge 33 weeks 
after immunization [16]. These studies with irradiated sporozoites show that even 
heterologous protection can be achieved but at a cost of relatively large numbers 
of sporozoites which is unfavorable from a manufacturer and cost perspective. In 
contrast, the CPS regimen shows a 10-20 fold higher efficiency for homologous 
protection likely because volunteers are exposed to the full pre-erythrocytic cycle 
and the initial phase of blood stage [36]. Previously, two out of thirteen NF54 CPS-
immunized volunteers receiving a sub-optimal immunization dose, were protected 
against a re-challenge infection with NF135.C10 at fourteen months after the last 
immunization [17]. Both studies with radiation-attenuated and CPS immunization 
showed higher homologous than heterologous protective efficacy. However, none 
of these studies used an immunization regimen sufficient for >90% homologous 
protective efficacy. The current study is the first randomized, controlled trial with 
a whole sporozoite immunization regimen sufficient for complete homologous 
protection, testing primary heterologous challenge infections eighteen weeks 
after the last immunization [10]. 
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Despite 100% protection against homologous challenge, we obtain only a 
modest 10-20% protection against heterologous strains. The observed difference 
in protection against homologous and heterologous infections may be explained 
by i) unequal distribution of induced immune responses between study groups; 
however, anti-CSP antibody titers show a clear consistency and similarity between 
study groups; ii) differences in numbers of inoculation sporozoites or stringency 
of the challenge infection. The former is unlikely as mosquito salivary gland 
infections were similar between the generated strain batches (Supplementary 
Table 2).
As NF135.C10 and NF166.C8 show higher sporozoite infectivity compared to 
Figure 4. Whole-genome sequencing shows genetic variations between study strains. 
Phylogenetic positions of the three P. falciparum strains (NF54, NF135.C10 and NF166.C8) used 
in the study relative to other known P. falciparum strains. Whole-genome sequencing was used 
to infer relatedness to P. falciparum strains from different areas [27] . Asian strains, THA, Thailand 
(dark red). VIE, Vietnam (light red). CAM, Cambodia (orange). East Africa represented by KEN, 
Kenya. West African strains, GUI, Guinea (light green) and GHA, Ghana (dark green). NF strains 
(blue).
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NF54, (McCall and Wammes et al, in press), it may be more difficult to protect 
against the NF135.C10 and NF166.C8 clones. However, intra-hepatic sporozoite 
development of NF135.C10 and NF166.C8 is equipotently inhibited by a functional 
anti-CSP mAb, 2A10 (Supplement figure 1; IC50 concentrations of 2·5 ug/mL 
(95% CI 0·58-11 ug/mL), 3·5ug/mL (95% CI 1·1-11ug/mL) and 0·88ug/mL (95% 
CI 0·26-2·9ug/mL)), which makes this explanation less likely; iii) genetic  variation 
between the challenge parasites, shown to be considerable with amino acid 
changes in either NF135.C10 or NF166.C8 in eleven out of twelve target proteins 
for CPS-induced antibodies [14]. We consider decreased immune efficacy against 
genetically diverse parasite strains as the most likely explanation for the modest 
protection against heterologous parasites. 
As the three out of nineteen volunteers with sterile protection against 
heterologous challenge tend to show more potent responses to previously 
identified immune markers [10, 13, 29], decreased efficacy against heterologous 
parasites may be overcome by stronger immune responses.
Improvement of the strength of cellular and antibody responses may be 
achieved by altering immunization regimens. For instance, this may be achieved 
Figure 5. Analysis of in vitro intra-hepatic sporozoite development inhibition by CPS-
induced antibodies, cellular responses and protection status in vivo. CPS-induced 
antibody-mediated inhibition of in vitro challenge strain intra-hepatic development and cytotoxic 
and cytokine-producing T cell responses to NF54 infected RBCs are shown. The 10th and 90th 
percentile of each response in all (n=19) CPS-immunized volunteers that received a heterologous 
challenge infection are shown as grey box-and-whisker plots. The green triangle represents one 
out of nine CPS-immunized volunteers sterilely protected against NF166.C8 challenge infection, 
while the orange square and upside-down triangle represent the two out of ten CPS-immunized 
volunteers with sterile protection against NF135.C10 challenge infection.
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by increasing the immunization liver-stage antigen load, by raising the NF54 
sporozoite immunization dose, as has been done with radiation attenuated 
sporozoites [16, 37]. Alternatively, within the more efficient CPS immunization 
model, we propose making use of the increased liver-stage infectivity of a parasite 
such as NF135.C10, to increase the antigen load without the need for increasing 
the number of sporozoites administered. Taken together, our findings highlight 
the need to further explore the immunological basis of cross-strain protection in P. 
falciparum, to improve existing whole-sporozoite immunization strategies. 
7
198 Bottlenecks of malaria transmission
Declarations
Ethics approval and consent to participate
The study was approved by the Central Committee for Research Involving Human 
Subjects of The Netherlands (CCMO NL48732.091.14) and conducted according 
to the principles outlined in the Declaration of Helsinki and Good Clinical Practice 





Availability of data and material
The datasets used and/or analysed during the current study are available from the 
corresponding author on reasonable request. 
Conflict of interest
The authors declare that they have no competing interests.
Funding
This study was funded by the Bill and Melinda Gates Foundation, grant ID number 
OPP1080385. The funder agreed with the study design as proposed by the 
authors and had no role in the collection, analysis or interpretation of the data, the 
preparation of the report or decision to publish. MCB is supported by a Nijmegen 
Institute for Infection, Inflammation and Immunity (N4i) PhD scholarship. JW, IJR, 
MCB and RWS had full access to all study data with final responsibility to submit 
the report for publication.
Author’s contributions
EMB and RWS conceived and designed the clinical trial, which was performed by 
JW, IJR, QdM, AJvdV and RWS. MvdVB, WG, RS, and GJvG generated parasites 
and infected mosquitoes for the clinical trial, and provided sporozoites and blood 
stage parasites for the immunological assays. JW, MCB, WG, RS and AS were 
involved in plasma sample collection, PBMC isolations and cryopreservation. 
MCB conducted humoral immunological experiments; JW and MCB conducted 
cellular immunological experiments. MCB, CCH and TJ were involved in primary 
199modest heterologous Protection
human hepatocyte isolations and hepatocyte cultures. CCH and KT performed 
qPCR analysis. JHWdW coordinated obtaining fresh liver segments from patients 
undergoing elective (partial) hepatectomy. JW, IJR, MCB, LMK and AS analyzed 
and interpreted the clinical and immunological data. LMK, EDB, SC, TGC, MAH 
performed the genetic characterization of the parasite strains. JW, IJR and MCB 
wrote the manuscript, which was critically reviewed and approved by all authors.
Acknowledgements
We would like to thank all the volunteers who participated in this trial and 
thank Jolanda Klaassen, Laura Pelser-Posthumus, Jacqueline Kuhnen, Astrid 
Pouwelsen for technical assistance with generation of infected mosquitoes and 
with performing the malaria challenge infections. We also thank Annet Bens 
and Michelle Brouwer for technical assistance with isolation, culture of primary 
human hepatocytes.
List of used abbreviations
95% CI: 95% confidence interval; CHMI: controlled human malaria infection; 
CSP: circumsporozoite protein; CPS: ChemoProphylaxis and Sporozoites 
immunization; ELISA: Enzyme-Linked ImmunoSorbent Assay; FBS: fetal bovine 
serum; IFN-ƴ: interferon gamma; IQR: interquartile range; mAb: monoclonal 
antibody; peripheral blood mononuclear cells: PBMCs; PBS: phosphate buffered 
saline; PFA: paraformaldehyde; P. falciparum: Plasmodium falciparum; PfRBCs: 
P. falciparum-infected erythrocytes; qPCR: quantitative real-time PCR; RAS: 
radiation-attenuated sporozoites; SD: standard deviation; SNPs: Single nucleotide 
polymorphisms; uRBCs: uninfected erythrocytes.
7
200 Bottlenecks of malaria transmission
References
1. WHO: World Malaria Report 2015. In.; 2015.
2. Hemingway J, Ranson H: Insecticide resistance in insect vectors of human disease. 
Annual review of entomology 2000, 45:371-391.
3. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, 
Anderson JM, Mao S, Sam B et al: Spread of artemisinin resistance in Plasmodium 
falciparum malaria. The New England journal of medicine 2014, 371(5):411-423.
4. Tran TM, Li S, Doumbo S, Doumtabe D, Huang CY, Dia S, Bathily A, Sangala J, 
Kone Y, Traore A et al: An intensive longitudinal cohort study of Malian children 
and adults reveals no evidence of acquired immunity to Plasmodium falciparum 
infection. Clinical infectious diseases : an official publication of the Infectious 
Diseases Society of America 2013, 57(1):40-47.
5. Agency EM: First malaria vaccine receives positive scientific opinion from EMA: 
Mosquirix to be used for vaccination of young children, together with established 
antimalarial interventions. 2015:3.
6. Moorthy VS, Okwo-Bele JM: Final results from a pivotal phase 3 malaria vaccine 
trial. Lancet 2015, 386(9988):5-7.
7. Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, Lievens M, 
Leboulleux D, Njuguna P, Peshu N et al: Four-year efficacy of RTS,S/AS01E and its 
interaction with malaria exposure. The New England journal of medicine 2013, 
368(12):1111-1120.
8. Hickey BW, Lumsden JM, Reyes S, Sedegah M, Hollingdale MR, Freilich DA, Luke 
TC, Charoenvit Y, Goh LM, Berzins MP et al: Mosquito bite immunization with 
radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, 
protective efficacy and humoral immunogenicity. Malaria journal 2016, 15(1):377.
9. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman 
LA, James ER, Billingsley PF, Gunasekera A et al: Protection against malaria by 
intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 
341(6152):1359-1365.
10. Bijker EM, Teirlinck AC, Schats R, van Gemert GJ, van de Vegte-Bolmer M, van 
Lieshout L, IntHout J, Hermsen CC, Scholzen A, Visser LG et al: Cytotoxic markers 
associate with protection against malaria in human volunteers immunized with 
Plasmodium falciparum sporozoites. The Journal of infectious diseases 2014, 
210(10):1605-1615.
11. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de 
Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T et al: Protection against a malaria 
challenge by sporozoite inoculation. The New England journal of medicine 2009, 
361(5):468-477.
201modest heterologous Protection
12. Teirlinck AC, McCall MB, Roestenberg M, Scholzen A, Woestenenk R, de Mast Q, 
van der Ven AJ, Hermsen CC, Luty AJ, Sauerwein RW: Longevity and composition 
of cellular immune responses following experimental Plasmodium falciparum 
malaria infection in humans. PLoS pathogens 2011, 7(12):e1002389.
13. Behet MC, Foquet L, van Gemert GJ, Bijker EM, Meuleman P, Leroux-Roels G, 
Hermsen CC, Scholzen A, Sauerwein RW: Sporozoite immunization of human 
volunteers under chemoprophylaxis induces functional antibodies against pre-
erythrocytic stages of Plasmodium falciparum. Malaria journal 2014, 13:136.
14. Felgner PL, Roestenberg M, Liang L, Hung C, Jain A, Pablo J, Nakajima-Sasaki R, 
Molina D, Teelen K, Hermsen CC et al: Pre-erythrocytic antibody profiles induced 
by controlled human malaria infections in healthy volunteers under chloroquine 
prophylaxis. Scientific reports 2013, 3:3549.
15. Nahrendorf W, Scholzen A, Bijker EM, Teirlinck AC, Bastiaens GJ, Schats R, Hermsen 
CC, Visser LG, Langhorne J, Sauerwein RW: Memory B-cell and antibody responses 
induced by Plasmodium falciparum sporozoite immunization. The Journal of 
infectious diseases 2014, 210(12):1981-1990.
16. Lyke KE, Ishizuka AS, Berry AA, Chakravarty S, DeZure A, Enama ME, James ER, 
Billingsley PF, Gunasekera A, Manoj A et al: Attenuated PfSPZ Vaccine induces 
strain-transcending T cells and durable protection against heterologous controlled 
human malaria infection. Proceedings of the National Academy of Sciences of the 
United States of America 2017, 114(10):2711-2716.
17. Schats R, Bijker EM, van Gemert GJ, Graumans W, van de Vegte-Bolmer M, van 
Lieshout L, Haks MC, Hermsen CC, Scholzen A, Visser LG et al: Heterologous 
Protection against Malaria after Immunization with Plasmodium falciparum 
Sporozoites. Plos One 2015, 10(5).
18. Bijker EM, Schats R, Obiero JM, Behet MC, van Gemert GJ, van de Vegte-Bolmer M, 
Graumans W, van Lieshout L, Bastiaens GJ, Teelen K et al: Sporozoite immunization 
of human volunteers under mefloquine prophylaxis is safe, immunogenic and 
protective: a double-blind randomized controlled clinical trial. PloS one 2014, 
9(11):e112910.
19. Hermsen CC, Telgt DS, Linders EH, van de Locht LA, Eling WM, Mensink EJ, 
Sauerwein RW: Detection of Plasmodium falciparum malaria parasites in vivo 
by real-time quantitative PCR. Molecular and biochemical parasitology 2001, 
118(2):247-251.
20. Walk J, Schats R, Langenberg MC, Reuling IJ, Teelen K, Roestenberg M, Hermsen 
CC, Visser LG, Sauerwein RW: Diagnosis and treatment based on quantitative PCR 
after controlled human malaria infection. Malaria journal 2016, 15(1):398.
21. Delemarre BJ, van der Kaay HJ: [Tropical malaria contracted the natural way in the 
Netherlands]. Nederlands tijdschrift voor geneeskunde 1979, 123(46):1981-1982.
7
202 Bottlenecks of malaria transmission
22. Teirlinck AC, Roestenberg M, van de Vegte-Bolmer M, Scholzen A, Heinrichs MJ, 
Siebelink-Stoter R, Graumans W, van Gemert GJ, Teelen K, Vos MW et al: NF135.
C10: a new Plasmodium falciparum clone for controlled human malaria infections. 
The Journal of infectious diseases 2013, 207(4):656-660.
23. Ifediba T, Vanderberg JP: Complete in vitro maturation of Plasmodium falciparum 
gametocytes. Nature 1981, 294(5839):364-366.
24. Ponnudurai T, Lensen AH, Leeuwenberg AD, Meuwissen JH: Cultivation of fertile 
Plasmodium falciparum gametocytes in semi-automated systems. 1. Static cultures. 
Transactions of the Royal Society of Tropical Medicine and Hygiene 1982, 76(6):812-
818.
25. Ponnudurai T, Lensen AH, Meis JF, Meuwissen JH: Synchronization of Plasmodium 
falciparum gametocytes using an automated suspension culture system. Parasitology 
1986, 93 ( Pt 2):263-274.
26. Ponnudurai T, Lensen AH, Van Gemert GJ, Bensink MP, Bolmer M, Meuwissen 
JH: Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. 
Parasitology 1989, 98 Pt 2:165-173.
27. Campino S, Benavente ED, Assefa S, Thompson E, Drought LG, Taylor CJ, Gorvett 
Z, Carret CK, Flueck C, Ivens AC et al: Genomic variation in two gametocyte non-
producing Plasmodium falciparum clonal lines. Malaria journal 2016, 15:229.
28. Bijker EM, Bastiaens GJ, Teirlinck AC, van Gemert GJ, Graumans W, van de Vegte-
Bolmer M, Siebelink-Stoter R, Arens T, Teelen K, Nahrendorf W et al: Protection 
against malaria after immunization by chloroquine prophylaxis and sporozoites is 
mediated by preerythrocytic immunity. Proceedings of the National Academy of 
Sciences of the United States of America 2013, 110(19):7862-7867.
29. McCall MB, Sauerwein RW: Interferon-gamma--central mediator of protective 
immune responses against the pre-erythrocytic and blood stage of malaria. Journal 
of leukocyte biology 2010, 88(6):1131-1143.
30. Doolan DL, Dobano C, Baird JK: Acquired immunity to malaria. Clinical microbiology 
reviews 2009, 22(1):13-36, Table of Contents.
31. Neafsey DE, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, Lievens M, 
Abdulla S, Adjei S, Agbenyega T et al: Genetic Diversity and Protective Efficacy 
of the RTS,S/AS01 Malaria Vaccine. The New England journal of medicine 2015, 
373(21):2025-2037.
32. Takala SL, Coulibaly D, Thera MA, Dicko A, Smith DL, Guindo AB, Kone AK, Traore 
K, Ouattara A, Djimde AA et al: Dynamics of polymorphism in a malaria vaccine 
antigen at a vaccine-testing site in Mali. PLoS medicine 2007, 4(3):e93.
33. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, Guindo 
AB, Traore K, Traore I, Kouriba B et al: A field trial to assess a blood-stage malaria 
vaccine. The New England journal of medicine 2011, 365(11):1004-1013.
203modest heterologous Protection
34. Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, Chakravarty S, 
Stafford A, Ruck RC, Eappen AG et al: Protection against Plasmodium falciparum 
malaria by PfSPZ Vaccine. JCI insight 2017, 2(1):e89154.
35. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, 
Dowler M, Paul C et al: Protection of humans against malaria by immunization with 
radiation-attenuated Plasmodium falciparum sporozoites. The Journal of infectious 
diseases 2002, 185(8):1155-1164.
36. Nganou-Makamdop K, Sauerwein RW: Liver or blood-stage arrest during malaria 
sporozoite immunization: the later the better? Trends in parasitology 2013, 
29(6):304-310.
37. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, Gunasekera A, 
Chakravarty S, James ER, Sedegah M et al: Live attenuated malaria vaccine designed 
to protect through hepatic CD8(+) T cell immunity. Science 2011, 334(6055):475-
480.
38. Verhave JP, Leeuwenberg AD, Ponnudurai T, Meuwissen JH, van Druten JA: The 
biotin-streptavidin system in a two-site ELISA for the detection of plasmodial 








This thesis focuses on the transmission of malaria parasites from man to mosquito 
and back. 
These switches between hosts are critical moments for Plasmodium falciparum 
as it goes through narrow bottlenecks (Fig 1). Parasite numbers are most 
drastically reduced from a total of 106 to 1012 infected red blood cells to 1-1,000 
gametocytes that are taken up by the mosquito. Hence few gametocytes are 
available in the mosquito bloodmeal to establish an infection in the mosquito 
successfully. Similarly, of about 10,000 sporozoites in a mosquito’s salivary gland, 
only 10-200 sporozoites enter the human dermis at the site of an infectious 
Figure 1. Bottlenecks of Plasmodium falciparum transmission. Top: Key antigens that are 
under development as potential vaccine targets, and their expression at certain life stages of the 
parasite. Bottom: Development of P. falciparum in human and mosquito host, adapted from Fig 3 
of the introduction. TBV, transmission-blocking vaccine.
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mosquito bite that need to migrate through the bloodstream to establish an 
infection in the host’s liver.
Our findings have implications for the understanding of Plasmodium biology of 
these host switches, for diagnostics and for interventions. These aspects and use 
scenarios will be discussed separately, for each of them explaining aspects that 
matter for gametocytes and sporozoites.
Part 1: Biology
Metabolism in mitochondria and apicoplasts
Gametocytes and sporozoites are the life stages that rapidly need to establish 
malaria infection in the mosquito and human host, respectively. Despite the 
imminent demand for action, both life stages are in a state of relative inactivity 
while “waiting” for the host switch. From the results of the data integration for 
both life stages, it appears as if they are “prepared” for their next challenge. 
Sporozoites and gametocytes have one thing in common: translational repression. 
During both life stages, mRNA transcripts accumulate and are stored for rapid 
protein synthesis upon activation [1,2]. Furthermore, gametocytes are enriched 
in mitochondrial processes despite being metabolically inactive [Chapter 2]. This 
might be related to their single mitochondrion expanding and branching during 
gametocyte maturation [3]. The increased mitochondrial inner membrane surface 
with cristae [4], can provide sufficient ATP upon uptake by the mosquito - for the 
cell division and movement of male gametes and the formation of the female 
macrogamete. The gametocyte’s most life-stage specific proteins are already 
enriched in DNA elongation and DNA ligation despite DNA being replicated only 
upon activation. As this activation then happens so rapidly, the accumulation 
of the necessary proteins would give the parasite a head start. Consistent with 
phenotypic observations, highly enriched processes in gametocytes according to 
our analysis are “gamete generation”, “exit from host cell”, “microtubule-based 
movement” (male gametes) and “cellular respiration” [Chapter 2].
Notably, our approach of data integration cannot make distinctions between 
subpopulations of gametocytes. We did not define separate gold standards for 
female/male or immature/mature gametocytes. Male and female gametocytes 
await very different challenges and their biology is distinct (reviewed in [5]). 
Similarly, the sporozoite specific integration cannot distinguish between oocyst- 
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and salivary gland-derived sporozoites. While overall gene expression is highly 
correlated between oocyst-derived and salivary gland residing sporozoites, 
the sporozoites that successfully invaded the salivary glands have different 
characteristics [6]. To obtain a higher resolution, more data sets and more 
knowledge about exactly timed expression of benchmarking candidates would be 
required. However, also for sporozoites we confirmed previous findings like the 
importance of translational repression and added one potentially groundbreaking 
aspect: a clue to their inactivity.
Sporozoite-specific proteins are enriched for fatty acid synthesis-related 
processes [Chapter 6], which has shown to be important for liver stages in rodent 
malaria [7] and sporozoites through liver stages in P. falciparum [8]. The synthesis 
of fatty acids is mainly carried out in a specialized organelle called apicoplast 
[9]. This means – in contrast to gametocytes that show high mitochondrial 
activity – sporozoites rely on apicoplast-derived metabolites. Thus, in addition to 
mitochondria, another organelle of endosymbiontic origin plays an important role 
for malaria transmission. We added valuable information to proteins associated 
with both organelles by applying highly sensitive homology detection tools. Some 
of the many previously uncharacterized P. falciparum proteins are now annotated 
because we inferred their function from homologous proteins from other species.
In addition to this confirmation of previous findings, data “recycling” can also 
uncover potential new leads for biological peculiarities. The gene that was most 
specific to sporozoites in our analysis encodes for a previously uncharacterized 
protein (PF3D7_0104100) that has significant homology to the human stem cell 
marker prominin (CD133) [Chapter 6]. This transmembrane protein provides 
an interesting candidate for experimental research. Is it involved in keeping the 
sporozoites in an inactive state while they wait to be deposited in the human 
host’s skin, and if so, how? If this pathway is conserved across Plasmodium 
species, it might also be part of the dormant phenotypes in P. vivax parasites. 
The vivax-specific hypnozoites are a major stumbling block for vivax malaria 
elimination. To understand the mechanism that lets parasites rest in the liver and 
cause relapses years after the initial infection, is an important goal of vivax malaria 
research. Future work that might build upon the insights from this thesis, will aim 
to confirm the role of a prominin homolog in keeping cells in a resting state and 
examine how to disrupt their latency and thereby solve the problem of relapses.
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Part 2: Diagnostics
Gametocytes under the invisibility cloak
Theoretically, only one female and one male gametocyte are needed for sexual 
reproduction and the infection of a mosquito. If a mosquito takes up two to 
five microliters of blood, how do we know whether a malaria infected person 
carries enough gametocytes to contribute to transmission? Our understanding 
of transmission dynamics relied on the detection of infections (and specifically 
of gametocytes) by microscopy until the first molecular detection methods 
were introduced. In general, it is noteworthy that only half of the infections are 
detectable by microscopy as compared to PCR-based methods, as was shown in 
an analysis of 106 surveys [10]. Especially in low transmission settings (below 20% 
community parasite prevalence), the fraction of infections that is submicroscopic is 
considerable [10]. Further, it was shown that carriers of submicroscopic infections 
still infect mosquitoes and actually represent a large infectious reservoir [10–13]. 
Trained microscopists can quantify gametocytes and in a few expert labs even 
distinguish male and female gametocytes, but the scarcity of gametocytes in 
blood smears makes quantification of gametocytes in general and gametocyte 
sexing in particular prone to large errors [14,15][Chapter 4]. At low parasitemia, 
even the more abundant asexual parasites are mostly missed during the screening 
of a blood smear; light microscopy is not sensitive enough to detect the presence 
of asexual parasites or gametocytes. Gametocyte densities are loosely associated 
with asexual parasitemia and fluctuate substantially over time. It is hence critical 
to capture the transmission potential, expressed as gametocyte density, and 
potentially with a sex ratio indication, when microscopy is not sensitive enough.
Lifting the invisibility cloak
Measuring gametocyte density by molecular methods is superior to light microscopy 
because of a lower limit of detection and more accurate quantification. The 
quantification of abundant mRNA transcripts (in quantitative reverse transcription 
PCR, qRT-PCR) rather than of genomic DNA (regular or qPCR) gives a sensitivity 
advantage and makes it more specific to the life stage that needs to be detected, 
in this case gametocytes. The long-used gametocyte marker Pfs25 [4] is well-
established and widely used. Pfs25 transcript abundance is by now recognized as 
a female rather than total gametocyte marker, with 36- or 200-fold enrichment 
of transcripts in females over male gametocytes by RNA sequencing or qRT-PCR, 
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respectively [16][Chapter 3]. The density of female gametocytes is a good proxy 
for transmission potential in a blood sample, although the relationship between 
female gametocyte density and transmission intensity (measured as proportion of 
infected mosquitoes and number of oocysts per mosquito) is non-linear. We also 
observe unexpected outcomes of no infected mosquitoes at very high (female) 
gametocyte densities. Modeling efforts appreciate that very low gametocyte 
densities can still result in infected mosquitoes, with increasing probability 
at higher gametocyte densities [17,18]. There is a “jump” in infectivity when 
gametocytemia reaches 5-10 gametocytes per microliter [17] while no successful 
transmission occurred below 1 gametocyte per microliter in controlled human 
malaria infections [19,20] and field-observations of transmission of ultra-low 
gametocyte densities might also reflect challenges with mRNA integrity and thus 
unrealistically low quantitative estimates [21]. These studies indicate that we need 
to look hard, harder than we possibly can with a light microscope, to identify 
infectious individuals. However, highly sensitive markers as proposed by Essuman 
and others [22] might not be necessary and we discussed this in a comment 
to the editor [23]. We proposed that a new gametocyte marker should ideally 
reflect the transmission potential of the individual – not state the presence of 
gametocytes. In fact, one can argue that if markers are sufficiently sensitive, very 
low densities of gametocytes (reflective of stochastic commitment [24]), can be 
detected in all infections. Extremely low gametocyte densities, only detectable by 
ultrasensitive methods, play a negligible role in mosquito transmission [25]. The 
challenge is to capture those asymptomatic and submicroscopic infections with 
(slightly) higher gametocytemia, that actually do contribute to transmission and 
represent a public health burden [26,27].
Does sex matter?
One of the approaches to shed light on non-infectious gametocytes at high 
densities or highly infectious gametocytes at low densities is to examine the 
entirety of gametocytes rather than females only. Further, the sex ratio of male 
and female gametocytes is an important determinant of transmission success 
[Chapter 4]. The gametocyte sex ratio may vary during an infection, in response 
to treatment or due to the number of parasite strains present in one infected 
individual. As discussed above, microscopy is of little use in quantifying female 
and male gametocytes. To complement Pfs25 as female marker, male-specific 
markers, Pfs230p, pf13 and PfMGET (male gametocyte-enriched transcript) were 
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introduced in recent years [28–30]. Our ability to predict the probability of man 
to mosquito transmission improved: Using the combination of Pfs25 and PfMGET 
transcript quantification to estimate female and male gametocytes densities, 
Bradley and others modeled the mosquito infection rate in more detail [31]. 
Specifically, the authors could identify the role of male gametocytes at very low 
female gametocyte densities. In a cohort from Mali, there was a strong effect 
of low male densities (<10 males/µL blood) on transmission success, even if 
presumably sufficient female gametocytes were detected [31]. 
The discovery and validation of PfMGET as a potential male marker was directly 
based on a transcriptomics and proteomics study of sex-sorted gametocytes 
[16,30]. The RNAseq data is also part of our Bayesian data integration that led to 
the identification of more gametocyte-specific transcripts [Chapter 2], of which 
CCp4 was validated as female-specific [Chapter 3]. 
In our multiplex assay we combine intron-containing markers for male and female 
gametocytes in a potentially high-throughput method [Chapter 3]. The newly 
introduced female-specific transcript CCp4 is slightly more specific than Pfs25, 
reflected by more pronounced differences in transcript abundance compared to 
male gametocytes as well as to asexual parasites. Pfs25 is 100,000 fold higher in 
female gametocytes than in asexual blood stages [Chapter 3] which might have 
led to overestimated gametocyte densities at high parasitemia in the past. As 
such, the conclusion that nearly all clinical malaria cases carry gametocytes when 
presenting at clinics (with high asexual parasite densities), may need to be revisited. 
This is of relevance since if better estimates of gametocyte prevalence and density 
in clinical cases reveals that many do not harbor (transmissible) gametocyte 
densities upon clinical presentation, this offers a window of opportunity for early 
treatment of infections before onward transmission is possible. We tested several 
non-gametocyte producing lines for the abundance of gametocyte transcripts 
and provide a rationale for correcting for high asexual densities [Chapter 3] and 
make this re-examination possible. The sensitivity of CCp4 is lower than that of 
Pfs25, but still captures all transmissible gametocyte densities (limit of detection 
is 0.1 female gametocyte/µL).
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Infectiousness – not all are equal 
To complement knowledge of gametocyte density and sex ratio, a good marker 
for infectious gametocytes will be most useful and have a broad application. To 
find such a marker, or a set of markers, comparative studies are needed. Ideally, 
different gametocyte populations from culture or patient samples with varying 
infectivity to mosquitoes are scanned for differences in transcript and protein 
expression. We have conducted RNAseq analyses on time courses of developing 
gametocytes to capture the signature of peak infectivity and compare it to field 
samples with varying levels of infectivity to mosquitoes (manuscript in preparation). 
Gametocyte populations that result in higher oocyst prevalence cluster by principal 
component analysis (Fig 2). Candidate markers with high gametocyte specificity 
were detected by differential gene expression analysis. The respective genes still 
need to be validated in independent experiments. If successful, this work would 
build upon the findings in Chapters 2-4 and provide a useful additional tool to 
estimate transmission potential by molecular markers, potentially obviating the 
need for laborious mosquito infection assays. 
Detecting host signal: antibodies as markers of exposure
The major obstacle for the implementation of most molecular methods is their 
limited availability (specialized and expensive machines and consumables and 
specialized trained staff) in many malaria-affected areas. To overcome this, 
a point-of-care test like the rapid diagnostic test for general malaria infection 
could be developed specifically for gametocytes. A non-invasive saliva-based 
test that detects parasite proteins has been proposed recently [32]. This test 
still requires careful validation for the abundance and half-life of the detected 
proteins. Serological detection of antibodies in the human host’s blood is an 
indirect approach that uses the natural immune response against a current or 
recent malaria infection. For asexual blood stage exposure, such biomarkers 
have already been proposed by Helb and colleagues [33]. Depending on the 
measured responses to sets of three or six antigens, P. falciparum exposure in 
the past months or years could be predicted in Ugandan children, respectively. 
Can antibodies also identify gametocyte carriers? There is ample evidence for 
gametocyte-directed immunity, as reviewed by our group recently [34]. Functional, 
transmission-reducing responses will be discussed below, but even non-functional 
antibodies could serve as markers of (recent) gametocyte exposure. Currently, 
gametocytes are measured by transcript detection in cross-sectional surveys. We 
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Figure 2. Searching for infectiousness markers: mosquito prevalence after membrane 
feeding using synchronized gametocytes. Synchronized gametocyte cultures were split to 
infect mosquitoes in the standard membrane feeding assay and undergo bulk RNA sequencing 
analysis. The principal components (PC1 and PC2) on the left of the figure are based on global gene 
expression and cluster samples with (medium) high prevalence (blue dotted line). Differential gene 
expression analysis was carried out to compare this cluster with young (red samples, five days after 
synchronization) and old gametocytes (dark green samples, 16 days after synchronization). The 
right hand side lines out a possible validation strategy for marker candidates. Infectivity markers 
need to be associated with high mosquito infectivity across laboratory strains and field isolates and 
show a good correlation with infectivity over time of gametocyte development (ongoing work).
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begin to understand that especially in chronic infections, parasite and gametocyte 
densities fluctuate substantially over time. To get a full picture of gametocyte 
exposure rather than a single snapshot, we are working on a longitudinal screening 
for gametocyte-specific antibodies over the course of a transmission season. A 
recently printed protein microarray that was designed according to the results 
of this work [Chapter 2], will aid in capturing gametocyte-specific antibodies. 
Plasma samples from patients and asymptomatically infected individuals from 
multiple African sites will be examined to study antibody dynamics and detect 
candidate serological markers that can aid the identification of gametocyte 
carriers and better understand carriage dynamics across populations. This may 
help in identifying those individuals (disproportionally) responsible for onward 
transmission, the human infectious reservoir for malaria. 
For sporozoites, a similar approach can be envisioned. The exposure to infectious 
mosquito bites might be detectable through a serological test. We implemented 
a search algorithm to define a set of antibodies that covers all volunteers from 
controlled infections [Chapter 6].
Depending on the antibody half-life, either cumulative or recent exposure 
to sporozoites can be captured by such future application. In contrast to the 
immune response against the circumsporozoite protein (CSP) vaccine RTS,S, these 
antibodies do not need to prevent an infection. Functional antibody responses are 
discussed below.
Part 3: Interventions
Transmission bottlenecks as easy targets?
The host switches represent a vulnerable phase in the parasite’s life – it is present 
at extremely small numbers and transiently exposed to the hosts’ immune systems 
and other hostile elements in the environment. However, gametocytes and 
sporozoites are highly adapted to this task and transmission to mosquitos and 
humans is still surprisingly efficient. How can we use the newly gained insights 
to help in the fight against malaria? Strictly speaking, transmission-blocking 
interventions mean those measures that prevent a mosquito from getting infected 
after ingesting a bloodmeal with infectious gametocytes. Unlike conventional 
malaria treatment for clinical cases that acts on asexual blood stages and results 
8
216 Bottlenecks of malaria transmission
in quick recovery of the patient, transmission-blocking interventions give a smaller 
individual benefit. The community gain of reduced or halted disease transmission 
is non-disputable - transmission-blocking interventions thereby offer a delayed 
personal benefit – and several approaches are being researched. Recently, we 
reviewed the immune responses directed against sexual stages [34]. A careful 
distinction should be made between the gametocyte stages and what they 
become once they are activated in the mosquito midgut. The advantage of a 
vaccination strategy against gametocyte targets is the “natural” immune boost 
from each parasite that might expose the targeted antigen on the surface of the 
red blood cell. Eventually, gametocyte-infected cells are cleared by the spleen and 
might also trigger or “remind” the immune system when exposing intracellular 
antigens. Other targets of transmission-blocking interventions, like Pfs25, are only 
exposed after fertilization (in the mosquito midgut) and thus do not offer the 
natural boosting advantage. In general, sexual stage antigens are much more 
conserved than asexual antigens (Fig 1) and thus potentially represent a broader 
protection against a variety of strains. So far, however, recombinant antigen 
expression hampers vaccine development for some sexual antigens [reviewed 
in [34]] and immunizations with Pfs25 failed to elicit a functional, long-lasting 
immune response in humans [35]. To achieve a fast impact in near elimination 
settings, during short malaria seasons or outbreaks and when there is an acute 
threat of spreading drug-resistant parasites, a quick and broad application of 
monoclonal antibodies (mAbs) might be more beneficial than a vaccine. We 
showed that mAbs against pre- and post-fertilization antigens represent a potent 
measure against parasitic infections of mosquitoes in experimental feeding 
experiments. Importantly, genetic variability in the tested parasite strains or field 
isolates can demonstrate how vulnerable the efficacy of some mAbs is to inform 
further clinical development of those that function independent of antigen 
variation [Chapter 7].
No entry, trespassers will be neutralized
What if malaria parasites would not actually manage to get to the red blood cells 
and make anyone sick? In this ideal scenario, (man-to-mosquito) transmission-
blocking interventions are not needed. The same reasoning was underlying the 
development of the most advanced malaria vaccine. RTS,S is directed against a 
peptide derived from the abundant sporozoite surface protein CSP. Its genetic 
variability and the limited correlation of anti-CSP titers with sterile protection 
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are factors contributing to its low efficacy [36]. Immunizations using the whole 
organism can overcome dependency on the reaction to a single antigen. 
Fascinatingly, repeated exposure to malaria infections in endemic settings gives 
rise to natural immunity, but sterile protection is not achieved [37]. During 
controlled immunizations, however, live sporozoites (under chemoprophylaxis) 
or attenuated sporozoites elicit protective immune responses against sporozoite 
and liver stages [38–40]. We do not fully understand by which routes people 
achieve sterile protection, but a combination of B- and T-cell responses is most 
likely [41,42]. In some cases, strain-transcending immunity was observed after 
radiation-attenuated sporozoite application [43], but we have shown using 
other, heterologous strains, that protection is largely restricted to the strain 
that was used for immunization. Heterologous strains infected the immunized 
volunteers in about 80% of the cases while homologous challenges did not result 
in infections [Chapter 7]. One potential solution – immunization with a mix of 
strains – gives rise to logistical challenges. A simpler approach is to mix variants 
of the same (single) antigen, as it was done for AMA-1, an asexual-stage antigen 
[44]. For sporozoites, a number of non-CSP antibodies are under investigation. 
We have shown that some antibody responses are very specific to sporozoites 
and cover all immunized volunteers [Chapter 6]. The careful selection of antigens 
that show higher conservation than CSP and represent a variety of strains as 
now recognized by large sequencing consortia [malariaGEN Pf3k] promise more 
efficient approaches.
P. falciparum, a fascinating parasite, escaped earlier efforts of malaria elimination 
and a broad perspective targeting multiple life stages is warranted. This thesis 
takes a bioinformatics angled view and informs research efforts into biology, 
diagnostics and interventions of two critical life stages of the malaria parasites. 
By integrating data from multiple ‘omics disciplines, we took some steps forward 
to support interventions that should ultimately lead to malaria eradication. We 
need to develop and constantly optimize intervention strategies. The bottlenecks 
during the parasites development and critical transmission steps can serve as 
starting points.
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Malaria wordt door Plasmodium parasieten veroorzaakt. Deze parasieten verme-
nigvuldigen zich afwisselend in een menselijke gastheer en in een bloedzuigende 
mug. Dit proefschrift kijkt naar de overgangen van de ene gastheer naar de an-
der. Interessant is dat er maar weinig parasieten nodig zijn om een mug of een 
mens te besmetten. Tijdens acute ziekte dragen miljarden rode bloedcellen de 
malariaparasiet in zich. Hij vermeerdert zich en dat kan leiden tot bloedarmoede, 
koorts en zelfs de dood omdat de organen niet meer goed kunnen worden voor-
zien van bloed. De laatste 20 jaar sterven er wereldwijd steeds minder mensen 
aan malaria, maar sinds 2017 is die daling tot stilstand gekomen en gaan er in 
bepaalde gebieden zelfs weer meer mensen dood aan malaria. Problemen ont-
staan door resistentie van parasieten tegen medicatie en bij muggen tegen insec-
ticiden. De ontwikkeling van nieuwe strategieën is noodzakelijk om malaria de 
wereld uit te krijgen. De cirkel van infecties kan worden doorbroken als de mug 
tijdens het bloed zuigen op een malaria patiënt niet besmet raakt. Hoe precies 
werkt een besmetting bij malariamuggen? We weten dat de parasieten binnen 
de menselijke bloedcellen soms stoppen met vermenigvuldigen en zich ontwikke-
len tot de seksuele stadia, gametocyten. Het is belangrijk om erachter te komen 
welke mensen deze gametocyten bij zich dragen en de ziekte op muggen en via 
de mug op meer mensen in de omgeving kunnen overdragen. Middels een test 
in een laboratorium kunnen wij vrouwelijke en mannelijke gametocyten “tellen”. 
Beide seksen zijn belangrijk voor de besmetting van de mug. Voor de ontwikke-
ling van deze test waren meerdere stappen nodig. Ten eerste hebben wij data ver-
zameld van studies die onderzochten welke eiwitten en genen aanwezig waren 
bij malariaparasieten tijdens de verschillende ontwikkelingsstadia. In die stadia 
staan verschillende genen niet altijd “aan” en worden niet altijd dezelfde eiwitten 
geproduceerd voor de verschillende taken. We hebben onderzocht welke genen 
alleen bij gametocyten actief zijn [hoofdstuk 2] en deze met verschillende tests 
gevalideerd. Microscopie wordt het vaakst gebruikt bij verdenking van malaria, 
maar deze methode is niet gevoelig genoeg om de kleine aantallen gametocyten 
te identificeren die voor een besmetting voldoende zijn. Daarom hebben wij een 
PCR gebaseerde methode ontwikkeld om in één experiment zowel vrouwelijke 
als mannelijke gametocyten in bloed aan te kunnen tonen [hoofdstuk 3]. Als 
gametocyten aanwezig zijn, (soms zonder symptomen bij personen in malariage-
bieden) kunnen bepaalde medicijnen de gametocyten elimineren, om malariaver-
9
226 Bottlenecks of malaria transmission
spreiding te voorkomen. Onze nieuwe test kan dan ook laten zien of de behande-
ling succesvol was, en zowel mannetjes als vrouwtjes geëlimineerd werden. Hoe 
belangrijk de balans tussen vrouwelijke en mannelijke gametocyten voor versprei-
ding van malaria is, hebben wij in hoofdstuk 4 uitgelegd.
Stel dat er een lokale malaria uitbraak is of dat er weinig dragers van gameto-
cyten aanwezig zijn, dan kunnen antilichamen worden gebruikt om de ziekte te 
bestrijden. Deze antilichamen “plakken” aan de parasieten en voorkomen dat 
ze zich in de mug kunnen vermeerderen. We hebben drie antilichamen getest 
[hoofdstuk 5]. Als deze aan het bloed toegevoegd worden, ontwikkelen de pa-
rasieten zich minder vaak in de mug. Één van de drie antilichamen kan niet goed 
werken als zijn antigeen een klein beetje verandert op de plek waar het met 
het antilichaam contact maakt. Middels sequencing van DNA hebben wij veel 
van deze veranderingen kunnen vinden – zowel in de stammen uit het labora-
torium als bij de parasieten van mensen in Burkina Faso. Als het antigeen deze 
veranderingen heeft kan het antilichaam niet voorkomen dat de muggen besmet 
worden. Één andere van de drie antilichamen die we bestudeerd hebben kan de 
besmettingen bij alle patiënten verminderen en die wordt nader onderzocht in 
een vervolg klinische studie.
Als het de parasiet wel lukt om zich seksueel in de mug te vermeerderen, komt 
hij uiteindelijk in haar speekselklieren terecht. Tijdens het zuigen van bloed wor-
den de parasieten de menselijke huid ingespoten. De zogenoemde sporozoïten 
zijn ook een uitzonderlijk stadium van de Plasmodium parasieten, vrij levend en op 
zoek naar de lever. In een levercel gaan zij binnen een week vermenigvuldigen. Pas 
daarna, als rode bloedcellen worden gebruikt voor de vermenigvuldiging, komt het 
tot de typische symptomen die bij malaria horen. De enige vaccinatie tegen malaria 
die momenteel beschikbaar is bevat een eiwit van het oppervlak van de sporozo-
iten. Het immuunsysteem heeft weinig tijd om de sporozoïten op te sporen en te 
elimineren voordat zij de lever indringen. Het eiwit dat gebruikt wordt als vaccin 
om de immuunreactie te trainen heeft ook vaak veranderingen en sommige ma-
laria stammen kunnen zich dan alsnog ontwikkelen. We hebben een klein aantal 
eiwitten geïdentificeerd die weinig mutaties hebben en ook antilichamen opwek-
ken [hoofdstuk 6]. Immunisatie met levende sporozoïten leidt tot een uitgebreide 
immuunreactie, niet alleen tegen een enkel eiwit, maar tegen tientallen eiwitten. 
Helaas blijkt deze vorm om immuniteit op te bouwen ook kwetsbaar voor verschil-
len tussen parasiet stammen [hoofdstuk 7]. Het verslaan van stam A betekent niet 
voor alle proefpersonen dat zij ook tegen stam B immuun zijn.
227samenvatting
Met methoden uit moleculair biologie en bioinformatica heeft mijn proefschrift 
kunnen bijdragen aan malariaonderzoek. Om grote hoeveelheden data te kun-
nen integreren en het effect van mutaties op te kunnen sporen kan het niet meer 
zonder “computational power”. De experts in het lab, in de ziekenhuizen en in 
het veld zijn nodig om deze parasieten te kunnen temmen. Plasmodium is soms 
stilletjes op de achtergrond, en niet makkelijk te vinden, maar blijft dodelijk en 
met veel gezichten. Heel fascinerend! De besmetting van mens en mug zijn als 
ogen van naalden in het leven van de parasiet waar maar weinig parasieten door-
heen gaan. Met mijn proefschrift heb ik geprobeerd om aan te tonen waar ze 





Malaria wird durch Parasiten verursacht, die der Gattung Plasmodium angehören. 
Sie vermehren sich abwechselnd in einem menschlichen Wirt und einer Stech-
mücke. Dieses Werk behandelt die Übergänge von einem Wirt zum anderen. 
Interessanterweise sind immer nur einige wenige Parasiten nötig, um eine Mücke 
oder einen Menschen zu infizieren. Bei einer akuten Erkrankung hingegen sind 
Milliarden rote Blutzellen von sich vermehrenden Parasiten besetzt. Dies führt zu 
Blutarmut und Fieberschüben, im schlimmsten Fall zum Versagen innerer Organe 
und letztlich zum Tod. Die globalen Todesfälle konnten in den letzten 20 Jahren 
dramatisch reduziert werden, aber seit etwa 2017 stagnieren die Fortschritte und 
Fallzahlen steigen sogar in manchen Gebieten wieder an. Resistenzen bei den 
Parasiten gegen die geläufigen Medikamente bereiten ebenso Probleme wie Re-
sistenzen bei Mücken gegen Insektizide. Um dem Ziel einer malariafreien Welt 
näher zu kommen, werden neue Strategien zur Eindämmung entwickelt. Wenn 
wir verhindern könnten, dass eine Mücke sich „ansteckt“ während sie bei einem 
Malariapatienten Blut saugt, würde das einen Kreislauf durchbrechen. Sie kann 
bei weiterem Blutsaugen keine Parasiten übertragen. Wie genau steckt sich denn 
eine Mücke an? Wir verstehen recht gut, dass manche Parasiten im menschlichen 
Wirt aufhören sich zu teilen und stattdessen zu sexuellen Stadien heranreifen, 
den Gametozyten. Ein Ziel ist es, herauszufinden, wer Gametozyten trägt und 
somit Malaria auf Mücken übertragen und andere in seiner Umgebung mit Ma-
laria infizieren kann. Mit Hilfe eines Labortests können im Blut weibliche und 
männliche Gametozyten nachgewiesen werden, beide sind nötig für die Infekti-
on einer Mücke. Um diesen Test zu entwickeln, waren einige Schritte nötig. So 
haben wir zunächst Datensätze von Studien gesammelt, die Malariaparasiten auf 
ihren Gehalt an Eiweißen und Gentranskripten in verschiedenen Lebensstadien 
untersuchten. Da der Parasit in seinem Lebenszyklus unterschiedliche Phasen mit 
spezifischen Aufgaben durchläuft, sind auch unterschiedliche Gene „angeschal-
tet“ und wir haben untersucht, welche ausschließlich bei Gametozyten aktiv sind 
[Kapitel 2]. Lichtmikroskopie, die am häufigsten angewandte Nachweismethode 
bei Verdacht auf Malaria, ist nicht sensitiv genug um die geringe Zahl von Game-
tozyten zu identifizieren, die für erfolgreiche Übertragung auf Mücken nötig ist. 
Um in einem Experiment Männchen und Weibchen im Blut nachweisen zu kön-
nen, wurde eine PCR-basierte Methode entwickelt [Kapitel 3]. Wenn Gameto-
zyten nachgewiesen werden – häufig auch ohne Symptome – können spezielle 
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Medikamente verabreicht werden, um die Gametozyten zu eliminieren. Unser 
Test hilft auch dabei, zu überprüfen ob die Behandlung erfolgreich war und ob 
sowohl Weibchen als auch Männchen erfolgreich bekämpft wurden. Wie wichtig 
die Balance zwischen weiblichen und männlichen Gametozyten ist, haben wir in 
Kapitel 4 näher beleuchtet.
Bei einem lokal begrenzten Ausbruch von Malaria oder wenigen Trägern von 
Gametozyten kann man auch andere Mittel einsetzen: Antikörper, die an den 
Parasiten „haften“ und verhindern, dass sie sich in der Mücke fortpflanzen. Wir 
haben drei solcher Antikörper getestet [Kapitel 5]. Wenn sie dem Blut beige-
mischt werden, entwickeln sich in die Parasiten weniger oft in den Mücken. Es 
gibt Ausnahmen, denn einer der drei Antikörper verliert seine Wirkung, wenn 
sein Antigen (eine bestimmte Struktur in dem Eiweiß das er bindet) kleine Ände-
rungen aufweist. Mit DNA-Sequenzierung haben wir herausgefunden, dass die 
Parasitenstämme sowohl im Labor als auch bei den Patienten in Burkina Faso 
oft solche kleinen Mutationen tragen und dieser Antikörper dann keinen Schutz 
bietet. Einer der drei jedoch zeigt starken Rückgang der Übertragung auf Mücken 
bei allen getesteten Patienten und wird in weiteren klinischen Studien untersucht.
Wenn Parasiten es schaffen, sich in der Mücke sexuell fortzupflanzen, befallen 
sie zuletzt deren Speicheldrüsen. So gelangen sie beim nächsten Blutsaugen in 
die Blutbahn eines menschlichen Wirts. Diese sogenannten Sporozoiten sind ein 
weiteres hochspezialisiertes Stadium der Parasiten, sie können sich frei bewegen 
und Leberzellen befallen, in denen sie sich zunächst innerhalb einer Woche ver-
mehren. Erst danach, beim Befall der roten Blutzellen, setzen die oben beschrie-
benen Symptome ein. Die einzige Impfung, die derzeit gegen Malaria getestet 
wird, richtet sich gegen ein Eiweiß auf der Oberfläche eben jener Sporozoiten. Die 
Immunabwehr hat jedoch wenig Zeit, die Sporozoiten zu erkennen und zu elimi-
nieren, bevor sie die Leber befallen. Zudem weist das Eiweiß, auf das die Impfung 
das Immunsystem „trainiert“, oft Mutationen auf, und manche Parasitenstämme 
können sich ungehindert entwickeln. Wir haben einige weitere Eiweiße in Sporo-
zoiten identifiziert, die Antikörper bei infizierten Menschen hervorrufen können 
und weniger Mutationen tragen [Kapitel 6]. Mit einer Immunisierung gegen le-
bende Sporozoiten kann man eine breit gefächerte Immunantwort hervorrufen, 
die sich nicht auf ein einzelnes Eiweiß stützt. Leider scheint auch diese Art der 
Immunisierung noch anfällig für Unterschiede zwischen den Parasitenstämmen 
zu sein [Kapitel 7]. Eine erfolgreiche Abwehr von Stamm A heißt nur für wenige 
Probanden, dass sie auch von Stamm B nicht krank werden können.
231zusammenfassung
Mit molekularbiologischen und bioinformatischen Methoden hat dieses Werk zur 
Malariaforschung beigetragen. Um große Mengen an Daten zu integrieren und 
den Auswirkungen von Mutationen auf die Spur zu kommen, ist Bioinformatik 
nicht mehr wegzudenken. Expertise von Forschern im Labor, in der Klinik und im 
Feld ist nötig, um diesen Parasiten Einhalt zu gebieten. Plasmodium ist schwer zu 
bändigen, teilweise still im Hintergrund und schwierig nachzuweisen, aber noch 
immer tödlich, wandelbar und deswegen auch wirklich faszinierend. Die Über-
tragung von Mensch zu Mücke und zurück sind zwei Nadelöhre, durch die sich 
nur wenige Parasiten zwängen können. In dieser Arbeit habe ich untersucht, wie 
man sie nachweisen und eventuell dabei stören kann, wenn sie versuchen, den 
nächsten Wirt zu befallen.
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